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Abstract 
 
The globally distributed, ciprofloxacin resistant hospital associated methicillin resistant 
Staphylococcus aureus (MRSA) lineage epidemic (E)MRSA-15 (sequence type 22) 
continues to expand into new healthcare systems around the world. To further 
understand the evolution of EMRSA-15, which has been proposed to have emerged in 
the West Midlands, a large collection of contemporaneous and historical Birmingham 
isolates were studied alongside a collection of International genomes. Through 
generation of phylogenetic trees this study has been able to determine that EMRSA-15 
emerged in c1984 and that during this time a highly related healthcare associated 
ciprofloxacin sensitive ST22 population was present in Birmingham. A dominant, 
geographically restricted EMRSA-15 clone was also identified in Birmingham 
(designated the BHM clone). Analysis of the impact of fluoroquinolone use on the 
Birmingham EMRSA-15 phylogeny showed increasing use of fluoroquinolones (the 
introduction of ofloxacin) coincided with the emergence of the BHM clone. Further 
evidence of geographically restricted EMRSA-15 clones were found in Guernsey and 
Hong Kong; demonstrating localized evolution giving rise to distinct island populations. 
Comparison of the desiccation tolerance of geographically restricted and non-restricted 
EMRSA-15 clones indicated enhanced environmental survival as a possible reason for 
the spread and dominance of the restricted lineages.  
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1 Introduction 
 
1.1  Staphylococcus aureus  
 
Staphylococci are Gram positive, non-motile, non spore forming facultative anaerobic 
cocci that can be seen as pairs or clusters under a microscope which were first identified 
by Sir Alexander Ogston from a surgical wound abscess in 1881. Shortly following this 
identification Friedrich Rosenbach demonstrated the organism was responsible for 
wound infection and named it Staphylococcus aureus due to the golden colour of its 
bacterial colonies (Rosenbach, 1884). Today it is understood that S. aureus is a globally 
distributed opportunistic pathogen that can colonize a range of mammalian host species 
including humans (Ward et al., 2014, Fitzgerald, 2014).  Through the acquisition of 
resistance to antimicrobial drug classes such as beta-lactams, cephalosporins and 
fluoroquinolones it has gradually evolved into a pathogen that can cause a high degree 
of morbidity and mortality as well as becoming a significant economic burden to control. 
 
1.2 Colonization and carriage 
 
 
S. aureus colonization is distinct from infection, where colonization is the asymptomatic 
carriage of S.aureus in healthy individuals and infection is the invasion of sterile sites 
that leads to pathology and disease. 
The primary niche for human colonization is the anterior nares (Williams, 1963) but S. 
aureus is also carried on the skin in the axilla and perineum, throat and the uro-genital 
tract of women (Kluytmans et al., 1997, Mertz et al., 2009, Albrecht et al., 2015) with 
reports of high carriage rates in the throat  (Mertz et al., 2009). Human colonization by S. 
aureus has been well defined into persistent and intermittent carriage states with the 
use of longitudinal screening studies. Up to 20% of the population are persistently 
 
 
 
 
 
2 
colonized with S. aureus and an additional 60% are intermittent carriers who go through 
periods of being colonized over time. A third carriage state, non carriage, has been 
proposed previously however this is difficult to prove as screening studies would have 
to continuously screen individuals for extremely long periods of time or individuals may 
simply have S. aureus at levels below current detection methods (Miller et al., 2014, van 
Belkum et al., 2009).   
Carriage of S. aureus is a known risk factor for subsequent disease development (Bode et 
al., 2010, Edmond and Wenzel, 2013, Kluytmans et al., 1997) and infections are more 
common in carriers than non-carriers, however mortality risk is known to be higher in 
patients who  newly acquire S. aureus. Defined population groups are considered to be at 
a higher risk of developing disease due to high carriage rates. These include military 
recruits (Aiello et al., 2006, Zinderman et al., 2004), prison inmates (Aiello et al., 2006, 
Pan et al., 2003), injecting drug users (Huang et al., 2008, Atkinson et al., 2009, Cooke et 
al., 2010, Bassetti and Battegay, 2004), athletes (Champion et al., 2014, Karanika et al., 
2016) and the homeless (Cooke et al., 2008, Landers et al., 2009).  Underlying medical 
conditions also pre-dispose for S. aureus carriage such as human immunodeficiency 
virus (HIV), diabetes and heart diseases as well as individuals with continuing medical 
care such as haemodyalisis (Tong et al., 2015b).  
  
1.2.1 Infection 
 
 
S. aureus infection is the result of the invasion of bacteria into sterile sites that can cause 
pathology and disease leading to a wide range of infections that range in severity.  This 
process is multifactorial, involving both patient host and bacterial virulence factors to 
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establish infection such as the loss of the protective skin barrier in injured patients and 
the multitude of toxins and adhesins produced by S. aureus (Otto, 2014). Benign 
infections are largely superficial skin infection such as impetigo, folliculitis and 
furunculosis that are relatively common but can include more severe pathologies such 
as post-operative wound infection. Invasive infections are more severe and often 
associated with life threatening complications such as endocarditis, osteomyelitis and 
pneumonia that may require hospitalization for extended periods of time. In addition to 
specific site infections S. aureus is a leading cause of hospital associated bacteraemia, a 
life threatening condition that is often a sign of secondary site infections, such as 
infective endocarditis, and can cause a high degree of morbidity and mortality (Tong et 
al., 2015b). The combination of carriage and scope of disease burden that is coupled 
with the continued development of antimicrobial resistance has led S. aureus to become 
a significant nosocomial pathogen and a leading cause of hospital acquired infection 
around the globe.  
 
1.3 Methicillin resistant Staphylococcus aureus (MRSA) 
 
The evolution of antimicrobial drug resistance in S. aureus has led to the emergence and 
subsequent global spread of Methicillin Resistant Staphylococcus aureus (MRSA); a 
hospital-associated pathogen that causes a similar array of infections to methicillin 
sensitive Staphylococcus aureus (MSSA) but has resistance to an extended range of 
antibiotics. This not only reduces the possible treatment options available for serious 
MRSA infection but infection with MRSA has been shown to have poorer therapeutic 
outcomes compared to MSSA infection (Cosgrove et al., 2003) leading to increased 
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morbidity and mortality in the hospital inpatient population and an increased length of 
hospitalization (Cosgrove et al., 2005, Grundmann et al., 2006).  
 
1.3.1 The evolution of MRSA  
 
 
In the early 1940s, shortly after the discovery of antibiotics, the first beta lactam 
antibiotic called penicillin was introduced as a treatment for severe staphylococcal 
infections which at the time had a mortality rate of approximately 80% (Skinner and 
Keefer, 1941). In the same year as the first clinical success, penicillinase producing S. 
aureus bacteria were described shortly followed by increasing clinical failures to 
penicillin (Jevons et al., 1963).  
 In order to combat this antimicrobial resistance the first and second generation beta 
lactam penicillins were developed, including methicillin and oxacillin, which were semi 
synthetic penicillins that were stable to penicillinase (Simon, 1962). Methicillin was 
introduced into clinical practice in 1959 and two years after this introduction the first 
clinical failure of methicillin for S. aureus treatment was described (Jevons et al., 1963). 
Subsequent work identified resistance to be due to the presence of a modified penicillin 
binding protein (PBP2) that was not inhibited by methicillin and was encoded by the 
resistance gene mecA (Enright, 2003) which was carried on the mobile genetic element 
(MGE) staphylococcal cassette chromosome mecA (SCCmec) (Katayama et al., 2000). 
MRSA was seen to cause a similar range of infections as MSSA and remained relatively 
uncommon after it was first reported (Jevons et al., 1963) and was not seen as a major 
public health threat. 
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By 1967 evidence of increasing numbers of multidrug resistant MRSA were being 
reported across Europe, Australia and India (Jessen et al., 1969, Benner and Kayser, 
1968, Jevons et al., 1963, Grundmann et al., 2006). These outbreaks belonged to a single 
phage type 80A complex that had been widely disseminated. Shortly following this rapid 
spreading event, MRSA rates began to decline again. The MRSA isolation rate in 
Switzerland dropped from 20% to 3% between 1971 and 1975 while the frequency of 
MRSA in Denmark dropped to 0.2% by 1984 (Kayser, 1975, Rosendal et al., 1976). These 
drastic reductions are thought to have been mediated by changes in antibiotic 
prescribing and infection control policy being implemented at this time.  
 In the 1980s MRSA began to develop as a public health concern again as gentamicin 
resistant clones began to be reported from several countries including the USA (Boyce et 
al., 1983) and the UK (Duckworth et al., 1988). During this time the first epidemic MRSA 
(EMRSA) strains were being reported (Kerr et al., 1990, Duckworth et al., 1988) which 
are defined as a strain that has been identified in two or more patients in two or more 
hospitals. The first EMRSA strain, EMRSA-1, was identified in London and the South East 
of England in the 1980s (Duckworth et al., 1988). Since then an additional sixteen 
EMRSA strains have emerged, with the latest strain being EMRSA-17 however this 
classification system of MRSA has since been superseded by spa and MLST 
nomenclature (section 1.4) (Mackintosh et al., 1991, Kerr et al., 1990).  
From the early 1990s onwards there was a rapid increase in MRSA hospital associated 
infections in the UK where MRSA isolation rate increased from 1-3% to 40% (Lowy, 
1998, Reacher et al., 2000) but also in Europe and the Americas (Diekema et al., 2001), 
causing MRSA to become a significant global public health threat requiring immediate 
intervention to reduce the increasing MRSA infection rate.  
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Currently the global MRSA rate is on the rise however endemic MRSA prevalence varies 
between countries (Grundmann et al., 2006, Stefani et al., 2012). As a general rule, the 
prevalence of MRSA has decline in European countries over the past 10 years, with the 
Scandanavian countries having the lowest rates of MRSA (Grundmann et al., 2010).  The 
majority of the global burden of MRSA is currently found across Asia, Africa and South 
American continents which encompass many developing countries. Unfortunately 
limited data on MRSA prevalence and endemic lineages are available for these countries 
due to lack of resources to fund extensive public health networks. Varying reports of 
MRSA rate from different regions have been published however high MRSA rates have 
been reported in Sri Lanka, South Korea, Vietnam, Taiwan and Hong Kong in Asia (Song 
et al., 2011, Chen and Huang, 2014) and from Argentina, Chile, Colombia, Guatemala, 
Mexico, Peru and Uruguay in South America (Guzmán-Blanco et al., 2009). 
 
1.3.2 Infection prevention and control of MRSA 
 
 In order to combat the public health threat posed by the increasing rate of MRSA 
related deaths in hospitals in the late 1990s and early 2000s many countries began to 
implement infection prevention and control (IPC) policies in hospitals. These policies 
vary between countries and relate to the background MRSA prevalence and healthcare 
funding for each country. Countries that have a low MRSA prevalence, The Netherlands 
and Scandinavian countries (Stefani et al., 2012), tend to adopt “Search and Destroy” 
methods were MRSA carriers and high risk patients are isolated and barrier nursed by 
healthcare workers followed by disinfection of rooms after patient discharge. This has 
been deemed to be successful in reducing both financial costs and patient morbidity 
(van Rijen and Kluytmans, 2014, Souverein et al., 2016).  In higher prevalence countries, 
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such as Greece or Portugal (Stefani et al., 2012), surveillance policies are employed to 
suppress MRSA rates to manageable levels (Coia et al., Calfee et al., 2014).   
 The UK has introduced a stream of IPC policies since 2001, starting with the 
mandatory reporting of MRSA bacteraemias in 2001 (Error! Reference source not 
found.), which have been extremely successful in continually reducing the MRSA 
bacteraemia rate. Record low rates of annual MRSA bacteraemia have been achieved 
annually from 2001 to 2015 with the lowest rate of 750 bacteriaemias per year being 
reported (Figure 1) (Public Health England, 2016). These policies include 
recommendations to manage MRSA transmission such as active surveillance, isolation 
and cohorting colonized or infected patients, decolonization of admitted patients, 
environmental decolonization and antimicrobial stewardship. These protocols can be 
employed to different effect however hand hygiene remains the most important 
measure for preventing all HA infections including MRSA (World Healthcare 
Organisation, 2009).  
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Year Intervention Methodology 
2001 
Mandatory MRSA bacteraemia 
reporting All MRSA bacteraemias in hospitals reported to UK government  
2004 "Clean your hands" 
Surveillance of orthopaedic surgical site infections. Mandated placement of 
bedside alcohol rub. NHS trusts appoint DIPC (director of infection prevention 
and control) 
2004 Targets introduced 
Hospitals must aim to meet specific targets (for each hospital) in reduction of 
MRSA bacteraemias 
2005 
Cleanliness improvement  - Saving 
lives document 
National target reduction for number of MRSA BS infections by 50% over 3 
years (Apr 2005 to March 2008) compared to the 2003/4 baseline.  
2006 Revised national guidelines  
Department of Health (DoH) visits to acute hospitals implemented. CEOs 
personally responsible for accuracy of infection data for their trusts.  
2007 Deep clean Introduction of bare below the elbow guidance.   
2007 Antimicrobial prescribing guidelines 
Reduction in use of fluoroquinolones and 3rd generation cephalosporins 
(3GCs) 
2008 Screening elective admission  
"Patient safety first". High risk patients screened on admission to selective 
wards  
2010 Universal screening All patients admitted to a ward are screened for MRSA (nasal/perinneal) 
2011 MSSA surveillance Surveillance and reporting of MSSA blood stream infections 
2011 Antimicrobial Stewardship 
Hospitals to introduce antimicrobial stewardship policy to control 
antimicrobial use 
2013 PIRs introduced Post infection reviews of all MRSA blood stream infections 
Table 1: Overview of UK national infection prevention and control policy by date of introduction. 
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Figure 1: Annual MRSA bacteraemias  in England and Wales (UK) from 1993 
to 2015. Data before 2001 are from voluntary reports (blue) and after 2001 
from mandatory reports (red). 
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1.3.3 Community associated MRSA 
  
 
In 1993 a novel MRSA strain from indigenous Australian individuals who had not been 
exposed to the Australian health care system was identified as the first true community 
associated MRSA (CA-MRSA) strain (Udo et al.). CA-MRSA strains are transmitted in the 
community, outside the hospital setting in individuals who have no hospital admission or 
associated risk factors, and differ from HA-MRSA lineages in several ways. Firstly CA-
MRSA strains are more susceptible to beta lactam antibiotics compared to HA-MRSA 
strains; secondly CA-MRSA strains are genotypically different from HA-MRSA strains due 
to their differing SCCmec cassettes and clonal complex (CC) lineages (Section 1.4.3). 
Finally community isolates are more likely to encode the Panton Valentine leukocidin 
(PVL) virulence determinant which is often lacking in HA-MRSA strains (Vandenesch et 
al., 2003, Okuma et al., 2002, Ito et al., 2004). CA-MRSA lineages have also started to be 
implicated in hospital outbreaks, adding more public health implications to infection 
control procedures (David et al., 2014).  
 
1.4 Epidemiological typing of MRSA; investigating evolution and transmission  
 
Understanding the genetic relatedness, clonal spread and evolution of MRSA is necessary 
to facilitate the control of outbreaks and monitor the spread of drug resistant organisms 
in both local and global settings. Both phenotypic and genotypic methods can be 
employed to determine the epidemiology of MRSA, however genotypic methods are now 
largely favored over phenotypic methods due to the higher level of discriminatory power 
they provide. A variety of genotyping methods are used for delineating MRSA 
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transmission and epidemiology; many of which exploit genetic polymorphisms in the 
bacterial genome (Ochman and Davalos, 2006).  These techniques have been developed 
over the past three decades and vary in cost, analysis time and discriminatory power 
(Table 2), with a general trend of increasing levels of discrimination as new techniques 
are developed. As these techniques have been developed over time the nomenclature 
defining MRSA lineages has also with the implementation of new typing methods. MLST 
is currently the preferred system for categorizing MRSA strains and is described in 
section 1.4.3. 
1.4.1 Phenotypic typing 
 
Phenotypic methods used for typing of S. aureus are antibiotic resistance profiles, or 
antibiograms, and phage typing.  Antibiograms consist of a profile of an organism’s 
susceptibility or resistance to a panel of antibiotics (Andrews, 2001) and are 
standardized (EUCAST guidelines 2016 (European Comittee on Antimicrobial 
Susceptibility Testing (EUCAST), 2016)), easy to perform and can be automated with the 
use of robot technology such as the VITEK system (BioMerieux, Marcy-L’Etoile, France).   
Phage typing was first developed in the 1940s and involves interpreting the lytic 
reactions of bacteria to lysis inducing bacteriophage (Wentworth, 1963).This technique 
has been used in hospitals since the 1960s and is still carried out in healthcare resource 
poor countries (Williams and Dean, 1974, Wiśniewska et al., 2012, Kali et al., 2013) but is 
now highly dated and is both time consuming and technically demanding, with limited 
standardization (Marples and Rosdahl, 1997) and no portability of results. Due to the 
limited discriminatory power of phenotypic typing methods, genotyping methods are 
preferred for epidemiological investigation in developed countries.  
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Typing 
technique 
Equipment and 
reagent cost 
Average cost 
per isolate 
Routine clinical use 
Time to 
results 
(days)* 
Analsis 
demand 
Data 
portability  
Resolution detail 
PFGE Moderate £4-7 Yes  2-3 Low Low 
Moderate (within 
lineages) 
MLST High £20 Yes (reference lab)  2-3 Moderate High Low (lineage) 
spa High £3-5 Yes (reference lab) 1.5 Moderate High Low (lineage) 
VNTR Low £10 Yes (reference lab) 1.5 Low High 
Moderate (within 
lineages) 
WGS High ~£50α Noβ  2-5γ High High High (SNP level) 
 
Table 2: Comparison of Staphylococcus aureus genotyping techniques. * Time inclusive of 24 hour culture, α = Includes 
culture and DNA extraction costs, β = Used for public health investigations. γ = Dependent on sequencing platform and 
level of analysis. 
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1.4.2 Pulsed field gel electrophoresis (PFGE)  
 
 
PFGE is a discriminatory method for determining if MRSA isolates are clonal and is often 
considered to be the gold standard in hospital outbreak and transmission investigation. 
Chromosomal DNA is digested with the enzyme smaI to produce 12 or more high 
molecular weight fragments which are then separated on an agarose gel by 
electrophoresis using an alternating voltage gradient. Banding patterns produced from 
the electrophoresis are then interpreted to determine how related isolates are; a process 
which can be enhanced with the use of software packages such as BioNumberics 
(Applied Maths, Sint-Martens Latem, Belgium) that can apply unweighted pair group 
matching or Dice comparisons to improve validity (Golding et al., 2015, Reed et al., 
2007). PFGE has several limitations and is both labour intensive and time consuming. All 
DNA extraction, protein removal and restriction digestion processes involved in PFGE 
have to be performed in agarose plugs due to PFGE results relying on accurate sizing of 
high molecular weight DNA fragments which are cleaved easily. Gel electrophoresis 
requires a minimum of 24 hours for size separation and the use of oscillating frequency 
gel tanks with pH and temperature controlled buffers (Golding et al., 2015, Reed et al., 
2007). Results are reliant on human interpretation and banding patterns can vary 
between different protocols and laboratory technicians. Furthermore changes in a single 
restriction site can cause more than one band change, reducing the accuracy of results. 
This makes PFGE largely un-portable due to results being entirely reliant on banding 
pattern interpretation that can vary between different diagnostic laboratories (Murchan 
et al., 2003). Efforts to improve Interpretation have been implemented and validated 
(Tenover et al., 1995) as well as to standardize PFGE on national and international levels. 
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The USA and the Netherlands have had success at standardizing PFGE results and 
reporting on national scales, however there is still no successful programmes for 
international standardization of PFGE protocols and results.  
 
1.4.3 Multi locus sequence typing (MLST) 
 
 
MLST is currently the most widely used genotypic method for assigning MRSA into 
lineages or sequence types (ST) based on single nucleotide polymorphisms (SNPs) 
occurring in seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi and yqi) each of 
which are approximately 500 base pairs (bp) in length.  These housekeeping genes are 
amplified by PCR and then Sanger sequenced, the results of which are compared on an 
online database. Sequences are compared to all known deposited sequences in a 
database and assigned a numerical allelic profile that corresponds to a designated 
sequence type number (Enright et al., 2000). For example the allelic profile 7 6 1 5 8 8 6 
corresponds to ST22, profile 3 3 1 1 4 4 3 corresponds to ST8 and profile 2 2 2 2 3 3 2 
corresponds to ST36.   
Current MRSA nomenclature and population structure definition is based on MLST 
profiling and often in conjunction with SCCmec typing, for example EMRSA-15 is defined 
as a ST22-SCCmecIV lineage. Highly related MLST lineages are assigned to clonal 
complexes (CCs) using the Based Upon Related Sequence Types (BURST) algorithm 
which groups MLST types to a single CC when five of the seven housekeeping genes are 
identical, therefore creating a group or complex of related lineages. Examples of this 
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hierarchical structuring of MRSA lineages are detailed in Table 3. 
MLST is a useful technique for looking at the global phylogeny of isolates or determining 
shifts in MRSA populations but has limited use in defining microevolution within 
hospitals and cannot distinguish between closely related isolates. MLST is also often 
considered to be labour intensive and time consuming, due to the need for high quality 
DNA extraction, several rounds of PCR amplification and clean up along with sequencing 
and post sequencing analysis. The application of next generation sequencing (NGS) 
methodologies for determining MLST has now reduced both financial and time costs and 
is discussed in section 1.5. 
 
1.4.4 spa locus typing 
 
spa typing is the single locus sequencing of the polymorphic X region of the highly 
diverse spa gene (Protein A) that was developed by Frénay et al in 1996 (Frénay et al., 
1996). The diversity of the spa gene is due to variation in a number of 24bp repeats 
within the gene that arise through point mutations, duplications and deletions which 
changes the number of repeats within the polymorphic X region. Counting the number of 
repeats can be used to infer a digital profile which can allow different S. aureus strains to 
be determined and compared to each other (Shopsin et al., 1999).  
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Clonal 
complex 
MLST spa* EMRSA SCCmec Additional Names 
CC1 
ST1 t128 - IV USA400, Canadian MRSA-7 
ST772 t657 - V Bengal Bay clone, WA MRSA-60 
CC5 
ST5 t001 EMRSA-3 II USA100, New York-Japan Clone, Canadian MRSA-2 
ST228 t041 - I South German Epidemic Strain, Italian Clone 
CC8 
ST8 t008 - IV USA300, WA MRSA-12, Canadian MRSA-10 
ST8 t190 
EMRSA-2, -6, -12, -13, -
14 
IV Lyon Clone 
ST239± t037 EMRSA-1, -4, -7, -9, -11 III 
Czech/Vienna/Hungarian/Portguese/Brazilian Clone, 
Canadian MRSA-3,-6 
CC22 ST22 t032 EMRSA-15 IV Barnim Epidemic Clone, Canadian MRSA-8 
CC30 
ST30 t019 - IV USA1100, Southwest Pacific Clone 
ST36 t018 EMRSA-16 II Canadian MRSA-4 
Table 3: Example nomenclature of globally distributed MRSA lineages. * = Represents most common spa type. ± = ST239 
has 80% homology with ST8 and 20% with ST30. 
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 Single locus sequencing is cheaper than MLST and spa typing is highly concordant 
with MLST. Furthermore publically available centralized spa data servers 
(http://spaserver.ridom.de) (www.seqnet.org) allow spa types from over 51 countries to 
be compared and comprise of over 3900 unique spa types and remain one of the largest 
typing databases for S. aureus (Deurenberg and Stobberingh, 2008). WGS methodologies 
have now been employed to attempt to gain spa typing data from next generation 
sequencing analysis, with a good backwards compatibility being achieved between the 
traditional Sanger methodology and NGS (Bartels et al., 2014, Bletz et al., 2015).  
spa-typing has been used to determine hospital outbreaks and the molecular evolution of 
MRSA over time (Garvey et al., 2016) and remains the typing method of choice for the UK 
staphylococcal reference unit (Colindale, Public Health England, UK) however the 
technique has several limitations. Firstly it cannot differentiate between closely related 
isolates within the same lineage, a caveat of many typing techniques, and secondly it may 
not infer evolutionary relationships appropriately due to only analyzing a single locus.  
 
1.4.5 Variable Number Tandem Repeat (VNTR) analysis 
 
Staphylococcal Interspersed Repeating Unit (SIRU) (Hardy et al., 2004) is a S. aureus 
specific VNTR typing scheme that provides high levels of discrimination between two or 
more isolates by determining the number of consecutively arranged, near identical 
repeated DNA sequences occurring at seven mini-satellite regions around the genome. 
These repeat regions are flanked by conserved sequences that are targets for primers 
and can allow the repeat regions to be amplified by PCR. Amplified products are then 
separated and sized by gel electrophoresis, which in turn allows a number of repeats to 
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be calculated for each locus. This generates a digital profile for each isolate, creating a 
highly portable and high level differentiating typing method (Hardy et al., 2006b, Hardy 
et al., 2004).   
VNTR has been successfully applied to hospital outbreaks (Hardy et al., 2006b), is a 
cheap and effective method for studying the micro-evolutionary dynamics of hospital 
MRSA strains and provides a greater level of discrimination than both PFGE and MLST.  
 
1.5 Whole Genome Sequencing (WGS)  
 
 
Whole genome sequencing (WGS) is the construction of the complete nucleotide 
sequence of an organisms genome. In 1995 the genome of Haemophilus influenzae, the 
smallest known genome at the time, was fully sequenced and annotated; making it the 
first bacteria to be whole genome sequenced using Sanger sequencing (Fleischmann et 
al., 1995). This huge effort took years to undertake and required a six figure budget to 
complete and is often considered to be “First Generation” whole genome sequencing. In 
the subsequent 20 years next generation sequencing (NGS), often simply called WGS, has 
advanced rapidly to become the most appropriate tool for whole genome studies. NGS is 
the high throughput massively parallelized DNA sequencing of millions of DNA strands to 
give read sequences, small strands of sequenced DNA, which can be combined to give the 
nucleotide sequence of the entire genome, therefore drastically increases sequencing 
capacity to reduce time and cost to sequence multiple genomes (in contrast to capillary 
electrophoresis Sanger sequencing). NGS technology has rapidly advanced in the past 
decade in terms of reduced cost and turnaround time, where NGS sequencing capacity 
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has doubled every 6 to 9 months and now outstrips Moore’s law of computer technology 
whereby computer processor speeds double approximately every 18 months (Loman et 
al., 2012, Metzker, 2005).   
These advances in technology combined with reducing costs have allowed WGS to 
become a much more accessible tool for investigating all facets of microbiology. In 
particular WGS has been demonstrated as a highly accurate and discriminatory 
molecular typing tool for several clinical pathogens due to the ability to provide detail at 
the single nucleotide polymorphism (SNP) level across an entire genome (Price et al., 
2014, Price et al., 2013, Walker et al., 2013, Gardy et al., 2011, Gardy et al., 2015, Koser et 
al., 2012b, Koser et al., 2012a, Eyre et al., 2012) (Fitzpatrick et al., 2016). Many 
genotyping techniques such as PFGE and VNTR have been demonstrated to show a 
reduced ability to discriminate within HA-MRSA lineages, however WGS can scrutinize a 
considerably larger proportion of the genome than these methodologies. This provides 
WGS with a much higher discriminatory power than any previous typing scheme which 
is investigated in this thesis.  
 WGS has now been used to infer the genetic relatedness of isolates not only in 
localized hospital settings but also on global population scale (Harris et al., 2010, Price et 
al., 2013, Fitzpatrick et al., 2016). Furthermore, MLST, spa and antibiotic resistance data 
can all be acquired from the WGS data, providing additional depth of detail being derived 
from a single technique.  
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1.5.1 Next generation sequencing platforms 
 
As mentioned above NGS and WGS are terms used for a group of several different NGS 
sequencing technologies and platforms that are marketed by different industries, each 
with differing costs and completion times as well as different sequencing chemistry and 
read lengths produced (Table 4). Of the differing characteristics that define each 
sequencing platform read length is considered the most important due to smaller reads 
being more likely to be reproduced in a sequencing run and being more difficult to map 
to a reference. Increasing read length provides more genetic information, therefore 
allowing greater overlap between reads and more accurate mapping to the reference 
genome and a greater reliability of the correct nucleotide at each position. Longer reads 
also allow sequencing across repetitive regions of the genome which are particularly 
difficult to map to due to smaller reads mapping in the middle of a repetitive region 
giving no information on the repetitive region length of position in the genome.  
 Of the nine currently most used sequencing platforms the Illumina MiSeq and Life 
Technologies IonTorrent are the first to be used for clinical applications. However, the 
recently developed Oxford Nanopore minION has significant potential in primary and 
secondary care as well as field deployment in military hospitals due to it being highly 
portable with limited power requirements (powered by a laptop) and rapid production 
of interpretable data.   
 Currently WGS is still hampered by relatively high costs combined with the 
requirement for intensive bioinformatics input to make the data understandable and 
relevant. However continuing reduction in cost and increased automation of analysis, 
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reducing the need for extensive bioinformatics analysis, will improve the usability of 
WGS in the clinical setting where it is likely to become a key technique in the future.  
It is also prudent to assess prepared libraries for quality and quantity before being 
applied to sequencers. Several platforms are available including fluorometers 
(Qubit [Life Technologies]), Fragment size analysers (Bioanalyzer [Agilent 
Technologies]) or real time quantitative PCR using commercially available kits. 
qPCR is the most sensitive method for quantifying presence of adaptor tagged 
fragments due to the specificity of the PCR probes to the adaptor tags on the DNA 
fragment, while the Bioanalyzer system is most effective at assessing the quality of 
libraries by determining the range of library fragment sizes.  
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Table 4: Next generation sequencing technologies and platforms. Bench top sequencing platforms are coloured blue. α = 
mode dependent (regular versus rapid mode). * Technologies continually improving. Increasing read length and reduced 
run time being developed. 
Manufacturer Sequencer name Chemistry 
Read 
Length 
(base)* 
Run 
time* 
Advantages Disadvantages 
Roche 
454 GS FLX Pyrosequencing 700-800 23h 
Long read lengths, short run 
time 
Labour intensive, high reagent 
costs 
GS Junior system Pyrosequencing 500 8h 
Long read lengths, short run 
time 
Labour intensive, high reagent 
costs 
Illumina 
HiSeq 2000  Reversible terminator 2x150 11d/2dα 
Cost effective, high 
throughput, increeasing read 
length 
Very long run time, short read 
lengths 
MiSeq  Reversible terminator 2 x159 27h 
Cost effective, short run times, 
widely used.  Shorter read lengths 
Life 
Technologies 
ABI/5500xl SOLiD Ligation 75+35 8d 
Low error and high 
throughput 
Very short read lengths, long 
run times 
IonTorrent Proton detection 200-400 4h 
Short run times. Simple 
machinery 
High error rate, high cost per 
Mb 
Proton Proton detection 125 4h Low cost instrumentation. 
High error rate. Increased hands 
on time. 
Pacific 
Biosciences  
PacBio RS 
Single molecule 
synthesis >10kb 2d 
Long read lengths. Simple 
sample preparation, low 
reagent cost 
High error rate. Very expensive. 
Difficult installation. 
Oxford 
Nanopore 
minION Solid state nanopore >510kb Real-time 
Extremely long read length, 
can sequence across difficult 
regions. Simple library prep. 
Highly portable. 
Not fully validated at time of 
writing, high error rate. 
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1.5.1.1 llumina sequencing and solexa chemistry  
 
Each of the different available sequencing platforms use different processes to 
generate NGS read data. Illumina technology employs sequencing by synthesis (SBS) 
using Solexa chemistry to determine single bases as they are incorporated into a 
growing sequence read across a large number of DNA template molecules 
simultaneously. This process is outlined below as an example due the Illumina MiSeq 
(Illumina, San Diego, USA) being one of the most frequently used technologies which 
has also been employed in this thesis.  
 
Prepared libraries are denatured to single strand DNA molecules then immobilized on 
a solid surface flow cell by having one of the sequencing adaptors on the end of the 
DNA fragment bind to complimentary oligonucleotides bound to the surface of the 
Illumina flow cell. These oligonucleotides are used as primers to form an initial copy of 
the bound DNA which is then denatured and the original bound (and now copied) DNA 
is washed away. The unbound adaptor at the opposite end of the fixed DNA molecule 
then hybridizes with a bound complementary oligonucleotide on the flow cell to create 
a bridge structure in a process known as bridge amplification or simultaneous solid 
phase amplification. Polymerases then form a complementary strand to create a double 
stranded bridge that is denatured to result in two single stranded copies of the original 
tagged DNA molecule. This process is repeated simultaneously with other bound DNA 
fragments to generate clusters of up to 1000 identical copies of each DNA template 
fragment in highly dense regions across the flow cell. 
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Sequencing begins with the extension of the first sequencing primer and in each 
sequencing cycle a mixture of fluorescently labeled deoxynucleoside triphosphates 
(dNTPs), that have different emission wavelengths for each nucleotide (A C T G), are 
perfused over the flow cell. A single labeled nucleotide is added to the sequencing read, 
which is complementary to the template, and after the addition of each nucleotide the 
fluorescent label is imaged to identify the base. The label is then enzymatically cleaved 
to allow incorporation of the next nucleotide and the process continues which is 
known as sequencing by synthesis. This process occurs hundreds of thousands of times 
in parallel across all clusters on the flow cell, thereby allowing a large amount of DNA 
material to be sequenced in a relatively short space of time (Illumina Incorporate, 
2015a, Illumina Incorporate, 2015b, Loman et al., 2012, Bentley et al., 2008).  
 
1.6 Analyzing WGS data and the need for Bioinformatics  
 
Whole genome sequencing produces millions to billions of reads per run, increasing 
considerably if high throughput sequencers are being employed, which can take 
approximately 1GB per S. aureus sequence to store (but is dependent on sequencing 
platform). Therefore any sequencing project requires a good information technology 
infrastructure to track, analyze and store the WGS data. In addition to high 
computational demand a significant level of bioinformatics analysis is required to turn 
raw WGS data into high quality, relevant and interpretable data.  
 Bioinformatics technology has advanced at a similar speed to sequencing and 
there is now a multitude of programmes, pipelines and analysis software to manipulate 
WGS data for a variety of functions. The high number of programmes available from 
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the Wellcome Trust Sanger Institute, Galaxy Project and Broad Institute alone offer 
hundreds of different software product options each with differing functionalities 
meaning the selection of programmes to analyse data can be a daunting task. The exact 
methodology used to analyze sequencing data is dependent on the length of reads 
obtained from sequencing, the availability of good reference genomes and the intended 
application of the data.  
 For epidemiology and phylogenetic studies an alignment and mapping approach 
is the most suitable as it allows sequenced reads to be mapped to an annotated 
reference genome in order to determine SNPs occurring across the genome. These 
SNPs can in turn be used to infer the relatedness of organisms to each other and 
generate phylogenetic trees.  
 
1.6.1 Data quality, reference mapping and SNP determination 
 
The quality of WGS produced reads need to be examined as a first step of any WGS 
analysis. Erroneously identified bases, poor quality sequences or contamination from 
adaptors can all poorly affect results generated downstream (such as SNP 
determination) (Bolger et al., 2014, Patel and Jain, 2012). Standard procedures of 
cleaning data involve adaptor removal and trimming of low quality bases at the end of 
reads or removing reads from unwanted species (Bao et al., 2014).   
 
Following trimming reads are mapped to a reference genome. Careful consideration 
should be given when choosing an appropriate reference genome. For example 
investigating an ST22 MRSA set of isolates one should map to the ST22 reference 
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genome (HO 5096 0412) as this will give good mapping across the reference genome, 
therefore maximizing data to determine SNPs from.  
 Different methods for mapping should be employed depending on the length of 
read produced by sequencers. For short reads (below 1000bp) programmes that use 
Burrows-Wheeler Transformation methods are appropriate for rapidly mapping reads 
to references genomes with limited error (Bao et al., 2014, Li and Durbin, 2010).  
 
Having suitably mapped reads to a reference genome, single nucleotide 
polymorphisms (SNPs) and insertions or deletions (indels) can now be determined. 
This is achieved by comparing mapped reads to the reference sequence, with SNPs 
being identified where bases in mapped reads do not have the same nucleotide as the 
reference. For bacterial epidemiological analysis this involves determining and 
comparing the presence or absence of SNPs across all genomes being investigated. 
SAMtools is one of the most commonly used variant callers which examines every 
position in the mapped genome and calculates the likelihood that each of these 
genotypes is truly present in the analysed genome. This can be combined with bcftools 
which can call SNPs from the genotype likelihoods generated by SAMtools using a 
defined set of cut-offs to call or reject SNPs (Li et al., 2009, Bao et al., 2014).  
 Mapped genomes can be viewed with the reference genome in visualization 
software such as Artemis (Rutherford et al., 2000). This highly useful tool allows users 
to see where reads are mapping to the genome, review quality of reads, identify gaps in 
the mapping and see positions of any SNPs that may have been identified.  
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1.6.2 Phylogenetics and Bayesian Inference  
 
Phylogenetics is the study of evolutionary relationships between biological organisms.  
As bacteria evolve away from a common ancestor over time they accumulate genetic 
differences in their genomes in the form of SNPs, insertions or deletions (indels) or the 
acquisition of mobile genetic elements (MGEs). By comparing genomic data of these 
phenomenon it is possible to infer the phylogenetic relationship of organisms to each 
other, usually in the form of a phylogenetic tree (Croucher et al., 2013, Pearson et al., 
2009).   
 WGS provides extensive genomic data for application to phylogenetics, however 
what specific data to include or exclude can affect the topology and structuring of 
phylogenetic trees. The “core genome” of bacteria has been defined as the conserved 
genes that are present in all members of bacterial species. The core genome is 
interspersed with genes from the “accessory genome” which may be present or absent 
in individual strains or isolates. The core genome comprises approximately 80% of the 
S. aureus genome with the remaining 20% being the accessory genome which 
comprises of MGEs such as the SCCmec element, phages, plasmids or pathogenicity 
islands (Lindsay, 2014). SNPs occurring in the core genome are most often separated 
and retained from those in the accessory genome in order to obtain a reliable scaffold 
of SNPs to generate phylogenetic trees from. This is because inclusion of SNPs from 
MGEs can result in misleading phylogenetic interpretations. A caveat of removing 
MGEs is that it omits parts of the genome that can distinguish isolates and may be 
influencing micro-evolutionary events (Planet et al., 2016), however the repertoire of 
MGEs in a population can be determined using de novo assembly.  
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Reliable SNP information can be use to display the relatedness of isolates to each other 
in the form of a phylogenetic tree. This tree contains nodes connected by branches, 
with each node representing the divergence of isolates away from a common ancestor 
(Yang and Rannala, 2012). Different methods for phylogenetic reconstruction are 
available, the most commonly published of which are neighbor joining (NJ), maximum 
likelihood (ML) or Bayesian maximum clade credibility trees (MCC). Neighbor joining 
is the most basic algorithm for tree generation and uses a distance method to construct 
trees based on pairwise distance (SNP distance) between isolates. Maximum likelihood 
is the estimation of unknown parameters in a model (Felsenstein, 1981) and compares 
all sequence sites in an alignment to build trees with more evolutionary relevant 
branch lengths. Bayesian inference is a method of statistical inference where 
parameters in a model are considered to be random variables with statistical 
distributions. This methodology was applied to phylogenetics (Bayesian phylogenetics) 
in the late 1990s (Yang and Rannala, 2012) and has the benefit of allowing variable 
mutation rate across branches in the phylogenetic tree  (Drummond and Rambaut, 
2007). Bayesian phylogenetics is however considerably more complex to perform than 
ML or NJ techniques but allows time-linked MCC trees and can demonstrate at what 
point in time isolates diverged from each other.  
 The choice of which type of tree to produce is therefore dependent on the 
question being asked. For example NJ tree is appropriate for determining number of 
SNP relating isolates in an outbreak where MCC trees can identify when a new strain or 
clone emerged. The differing models of tree construction also have differing process 
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times, with NJ trees being more rapid to construct compared to ML trees and is also 
dependent on the number of genomes in the analyses.  
 
 
1.6.3 Application of WGS in MRSA epidemiological studies 
 
1.6.3.1 Hospital transmission and infection control 
 
 
WGS is highly applicable for hospital transmission investigation and infection 
prevention control for several key nosocomial pathogens. This is due to the high level 
of discriminatory power provided from determining SNPs across the core genome that 
cannot be achieved with other typing techniques. This high discriminatory power can 
however become difficult to interpret when used to determine transmission between 
patients. If a large number of SNPs distinguish two isolates (over 100 SNPs) from 
different patients it is clear that there is significant genetic distance between the 
isolates, indicating they are unrelated and a transmission event can be reliably 
excluded. However when a smaller number of SNPs distinguish isolates a transmission 
event is less easy to exclude. Defined cut offs for excluding transmission events have 
been suggested at 2.5 SNPs (Fitzpatrick et al., 2016) or 3 SNPs (Salipante et al., 2015) 
in Acinetobacter baumanii, 2 SNPs in Clostridium difficile  (Eyre et al., 2013, Didelot et 
al., 2012) or 12 SNPs for recent transmission of M. tuberculosis (Walker et al., 2013). In 
S. aureus cut offs have been suggested at greater than 23 SNPs to exclude a 
transmission event (Uhlemann et al., 2014) while other authors suggest <40 SNPs 
(Golubchik et al., 2013). This is due to the cloud of variation that has been 
demonstrated in MRSA carriers, where different colonies from a single nasal swab 
from an individual have differed from each other by up to 40 SNPs (Young et al., 2012, 
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Golubchik et al., 2013) (Harris et al., 2013). This phenomenon has been demonstrated 
in A. baumanii and C. difficile (Eyre et al., 2013, Fitzpatrick et al., 2016) suggesting 
caution should be used when using SNPs to identify transmission events and ought to 
be used in conjunction with epidemiological data where possible.  
 
Despite uncertainty around defining transmission WGS has been used in real time 
MRSA outbreak situations. Harris et al (2013) were able to link two outbreaks across 
space and time in a neonatal intensive care unit that could not be confirmed by 
conventional typing methods. WGS was able to determine transmission within the unit, 
between mothers and to the community and confirm MRSA carriage by a staff member 
was the reservoir for linking the two outbreak periods.  
 
1.6.3.2 Global epidemiology 
 
 
WGS has also been used to further understand the global epidemiology and evolution 
of MRSA. Harris et al conducted the first application of WGS for global MRSA 
epidemiological analysis in 2010 (Harris et al., 2010). The authors were able to show 
strong evidence of intercontinental spread of ST239 between Asia and the UK as well 
as endemic sub-clones of the lineage in Thai hospitals. More recent studies have used 
both MCC and ML trees to date the emergence and global transmission of EMRSA-15.  
Holden et al (2013) used an MCC tree to show the evolution of the ciprofloxacin 
resistant ST22 strain EMRSA-15 emerged in the West Midlands of the UK in the late 
1980s before spreading across the UK and to Europe (Holden et al., 2013) (Section 
1.8.1). Further evidence of EMRSA-15 transmission from the UK to Portugal and 
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Germany has been demonstrated by Aanensen and colleagues who used ML trees with 
a snapshot population of ST22 across Europe to show single importations to Portugal 
and Germany from the UK (Aanensen et al., 2016). Hsu et al and colleagues also 
showed the importation of ST22 into the Singaporean healthcare system and tracked 
its evolution over time in comparison to the previously dominant ST239. Data showed 
multiple sub-clades of ST239 isolates but a single highly related clade of ST22 isolates, 
suggesting multiple introductions of ST239 from the surrounding regions, but only a 
single introduction of ST22 at the turn of the millennium, which was consistent with 
previous literature (Hsu et al., 2015, Holden et al., 2013).  
 
1.6.3.3 Evolutionary rate 
 
 
A key factor in understanding phylogenetics is the rate at which mutations occur to 
accumulate SNPs in the genome which is known as the molecular clock rate. This rate 
varies between bacteria, with Mycobacterium tuberculosis evolving very slowly at 0.5 
mutations per genome per year (1.1x10-7 mutations per site per year) (Ford et al., 
2011) compared to Helicobacter pylori at 30.4 mutations per genome per year (1.9 x10-
5 mutations per site per year) (Kennemann et al., 2011).  
 There is current debate as to how the molecular clock changes in different 
environments such as in nasal carriage versus clinical infection or the hospital 
environment. The clock rate is also unlikely to be fixed and how differing selection 
pressures that are likely to change with time and therefore affect the evolutionary rate 
of mutation.  
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1.7 Global Epidemiology of MRSA 
 
1.7.1 Globally distributed lineages of MRSA  
 
Over the past 30 years the methodologies outlined in section 1.4 have been used to 
understand the localized, national and global epidemiology of MRSA. It is now 
established that different lineages are endemic to various regions around the globe. 
  ST239 is the most widely distributed MRSA lineage and is dominant throughout 
most of Asia, accounting for regions where 60% of the world’s population are resident 
and MRSA rates are high (Feil et al., 2008, Chongtrakool et al., 2006, Ko et al., 2005). 
MRSA lineages vary across Europe with different lineages predominating in different 
countries. ST228 and ST5 are endemic in many European countries such as France, 
Germany and Italy, however the dominant UK lineage ST22 (see section 1.8.1) has 
steadily replaced the dominant lineages in these countries and is now the fastest 
growing HA-MRSA lineage in Europe (Grundmann et al., 2014). 
 In contrast in the USA the clinical landscape is currently dominated by the CA-
MRSA lineage USA300 (ST8, CC8). Studies in healthcare facilities in the USA have 
shown varying reports of the prevalence of USA300; ranging from 60% to 98% of 
MRSA isolates being related to USA300 (Deurenberg and Stobberingh, 2008). 
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Figure 2: The global prevalence of MRSA. Countries are coloured by MRSA prevalence. Coloured circles represent 
distribution of three of the most dominant MRSA lineages where data available. =Estimates are based on a study from a 
single hospital. ‡=Prevalence estimates are based on studies between 1993 and 1997. Adapted from Grundmann et al 
(2006). 
Review
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designs, diff erent inclusion criteria for health-care 
institutions, the selection of clinical and surveillance 
specimens, and diff erent antimicrobial testing and 
reporting routines, which makes international 
comparisons diffi  cult.73 Despite these drawbacks and the 
scarcity of data for many countries, especially for 
developing ones, an impression of the present MRSA 
pandemic begins to emerge (ﬁ gure 1). Of the 
expected 2 billion individuals carrying S aureus worldwide, 
conservative estimates based on either Dutch or US 
prevalence ﬁ gures would predict that between 2 million 
and 53 million carry MRSA.87,88 
Evolutionary biology and resistance 
determinants 
The understanding of the evolution of MRSA has beneﬁ ted 
from the development of molecular methods that provide 
characterisation of both the strain phylogeny (evolutionary 
history) and the meticillin-resistance determinant. Strain 
phylogenies can be resolved by multilocus sequence 
typing, which unambiguously identiﬁ es a strain on the 
basis of its sequence at seven housekeeping genes.89 
Consistent molecular epidemiological evidence supports 
the view that the evolution of MRSA and of S aureus as a 
species is predominantly clonal.90–92 Nevertheless, 
horizontal transfer of DNA from other strains or species 
occurs and plays an important part in resistance acquisition 
in S aureus and is brought about mainly by insertion of 
insertion sequences (IS), transposons, prophages, and 
incompletely understood events.2,92
Staphylococcal cassette chromosome mec
MRSA originates from the introduction of a large mobile 
genetic element called staphylococcal cassette 
chromosome mec (SCCmec) into a meticillin-susceptible 
S aureus strain. The meticillin-resistance determinant 
mecA, which encodes an additional penicillin-binding 
protein (PBP2A) with reduced affi  nity for β-lactam 
antibiotics,93 is carried on the SCCmec element. PBP2A is 
a transpeptidase that, assisted by the transglycosylase 
domain of the native PBP2 of S aureus, takes over the 
function of biosynthesis of cell-walls, which is otherwise 
blocked in the presence of β-lactam antibiotics.94 SCCmec 
is inserted into the chromosome at a speciﬁ c site (attBSCC) 
at the 3 prime end of an open reading frame of unknown 
function (orfX) located near the origin of replication of 
S aureus95 and therefore will be replicated at an earlier 
stage, which might have strategic importance for 
immediate transcription of imported antibiotic resistance 
genes. For its mobilisation—ie, excision and integration 
into the host chromosome—SCCmec carries speciﬁ c 
genes designated cassette chromosome recombinases 
(ccrA/ccrB96 or ccrC40). 
Up to now, ﬁ ve types of SCCmec (SCCmec I to V)40,97,98 
and several variants2,99,100 have been described according to 
the combination of the mec and ccr gene complexes they 
Figure 1: Worldwide prevalence of MRSA displayed by country* 
*All presented MRSA proportions are from peer -reviewed studies undertaken since 1998.32,74–85 Prevalence estimates for Morocco, Algeria, Tunisia, Egypt, Jordan, 
Lebanon, and Turkey are from the antimicrobial resistance in the Mediterranean region website86 at www.slh.gov.mt/armed/earss.asp. Studies providing most recent 
estimate of the MRSA proportion taken into account. If more than one study reported over same period, study including diff erent types of clinical isolates was 
preferred over studies including only one speciﬁ c type of specimen. †=Prevalence estimates are based on a study that included only one hospital. ‡=Prevalence 
estimates are based on studies between 1993 and 1997.
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1.8 MRSA in the UK  
 
1.8.1 Epidemic methicillin resistant Staphylococcus aureus 15 (EMRSA-15); the 
dominant UK clone. 
 
 
The current UK MRSA landscape is dominated by the ST22 HA-MRSA strain EMRSA-15. 
The strain is classically identified by being urease negative, produces enterotoxin C, 
has weak lysis with phage 80/81 and is resistant to ciprofloxacin. EMRSA-15 isolates 
are usually PVL negative, as are all UK HA-MRSA isolates, with less than 2% of UK 
clinical isolates being PVL positive (Teare et al., 2010). 
 
The evolutionary origin of EMRSA-15 was recently described by Holden and colleagues 
who hypothesized that the strain emerged in the West Midlands (UK) in the late 1980s 
(Holden et al., 2013). Using a collection of globally sampled ST22 isolates the authors 
proposed that a ciprofloxacin sensitive ST22 population present in the West Midlands 
in the 1980s acquired resistance to ciprofloxacin via mutations in the DNA 
topisomerase genes gyrA and grlA (Holden et al., 2013, Griggs et al., 2003) (discussed 
in section 1.9). This ciprofloxacin resistant strain (EMRSA-15) spread rapidly 
throughout the UK, during which time the national MRSA bacteraemia rate also rapidly 
increased (Figure 1). In 2001, EMRSA-15 accounted for greater than 60% of UK MRSA 
bacteraemias (Johnson et al., 2001), the height of the MRSA epidemic in the UK, and 
rose to 85% in 2007 (Ellington et al., 2010).  
The rapid expansion of EMRSA-15 across the UK has been suggested to be facilitated by 
EMRSA-15 having inherent resistance to ciprofloxacin. This resistance is thought to have 
provided a fitness advantage allowing the resistant strain to spread rapidly around the 
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country as ciprofloxacin use increased in hospitals, increasing from 18.9% of total 
antibiotic usage in 1992 to 31.5% in 1999 (Livermore et al., 2002). Further evidence of 
the rapid dissemination of EMRSA-15 demonstrated by Reuter et al who investigating 
the phylogeny of MRSA in the UK on a national scale. Using over 700 EMRSA-15 
bacteraemia isolates sampled over 10 years the authors were able to show geographical 
population structuring across the UK which they attribute to the rapid emergence, 
spread and subsequent local diversification of the clone (Reuter et al., 2015).  Evidence 
for the evolution of EMRSA-15 in the Birmingham region remains somewhat debatable. 
Limited isolates from the West Midlands or any isolates pre-dating 1990 have been 
included in previous evolutionary studies. Additionally no study has extensively 
examined the longitudinal phylogenetic evolution of EMRSA-15 in the region it emerged 
in, which is addressed in this thesis.  
 
EMRSA-15 is currently a globally disseminated clone, having been exported from the UK 
to Europe, Australia and localized regions in Asia where it has been shown to repeatedly 
replace established dominant lineages in both high and low resource healthcare systems 
(Witte et al., 2001, Knight et al., 2012, Hsu et al., 2007a, Hsu et al., 2015, Dhawan et al., 
2015, Coombs et al., 2014, Coombs et al., 2004, Aanensen et al., 2016, Dailey et al., 2005). 
A recent WGS study by Aanensen et al (2016) has shown that EMRSA-15 was exported 
to Berlin from the UK before spreading outwards throughout Germany and similarly 
with an importation to Lisbon in Portugal (Aanensen et al., 2016), replacing the 
dominant clones CC5 (Albrecht et al., 2011) and ST239 (Amorim et al., 2007) 
respectively. In Singapore ST239 was the dominant MRSA lineage (Ko et al., 2005, Feil et 
al., 2008) however between 2003 and 2015 there was a notable increase in ST22 MRSA 
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strains being isolates from clinical specimens in Singapore where EMRSA-15 is now the 
dominant lineage (Hsu et al., 2005, Hsu et al., 2015, Hsu et al., 2007b). Furthermore 
other globally dominant lineages such as ST239 have caused sporadic outbreaks in UK 
hospitals however they repeatedly fail to become established as the dominant clone, 
suggesting EMRSA-15 is highly adapted to the UK hospital system. The reason for the 
dominant and highly adaptable nature of EMRSA-15 is not fully understood, however 
improved stress responses compared to other MRSA lineages and the inherent 
resistance to fluoroquinolones (Baldan et al., 2015, Baldan et al., 2012, Knight et al., 
2012) are thought to play an important role (discussed in section 1.10).  
 
 
1.9 Resistance to Fluoroquinolone antibiotics in MRSA 
1.9.1 Fluoroquinolone antibiotics  
 
 
Quinolones, and subsequent fluoroquinolones, are a class of synthetic broad-spectrum 
antimicrobial agents first discovered in the early 1960s that fulfill many of the criteria 
defining a “good antibiotic drug”.  Qualities such as high potency, broad spectrum of 
activity (Gram positive and negative bacteria), high serum levels and availability of oral 
and intravenous formulations have given strength to the benefits of using quinolone 
antibiotics to treat infections (Andersson and MacGowan, 2003, Redgrave et al., 2014). 
  The first quinolones were derived from the naturally occurring quinine and 
acted by directly inhibiting DNA replication via binding and creating drug-protein 
complexes with DNA gyrase and topoisomerase IV; two highly conserved proteins that 
are essential in the supercoiling of bacteria DNA (Drlica, 1990). DNA gyrase is required 
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for the relief of torsional stress that accumulates in front of DNA replication forks by 
introducing negative supercoils and is the only known enzyme capable of actively 
unwinding nucleic acids. Topoisomerase IV is involved in decatenating newly replicated 
daughter chromosomes. Both proteins achieve their function by covalently binding to 
DNA to introducing double strand DNA breaks and form enzyme-DNA complexes. These 
complexes are altered with the addition of a fluoroquinolone which creates a drug-
enzyme-DNA complex by forming a water metal ion bridge between oxygen molecules in 
the amine group of the drug and the hydroxyl group of the enzyme. The enzymes are 
then no longer able to re-ligate the cleaved DNA causing a build up of cleaved DNA 
complexes and triggering the SOS response, ultimately leading to cell death (Baranello et 
al., 2012, Anderson et al., 1999, Redgrave et al., 2014, Aldred et al., 2013).  
  
 Fluoroquinolone antibiotics were created to increase the potency of quinolone 
drugs by replacing the eighth carbon of the molecule “backbone” with a nitrogen atom 
and the addition of a fluorine molecule at position 6 (Figure 3) (Ball, 2000).  This initial 
modification caused a 10 fold increase in DNA gyrase inhibition and a 100 fold 
improvement in MIC (Andersson and MacGowan, 2003). Over the years the 
fluoroquinolone drugs have been further modified in accordance with clinical need; with 
structural changes resulting in increasing in potency and spectrum of activity (Table 5) 
and subsequent increasing global widespread use of the drug class.   
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Figure 3: Chemical structure of quinolone and fluoroquinolone drugs: (A) 
Nalidixic acid, (B) Ciprofloxacin, (C) Levofloxacin hemihydrate and (D) 
Moxifloxacin. Chemical structures were obtained from the Sigma Aldrich website 
(www.sigmaaldrich.com).
A.	
C.	 D.	
B.	
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Table 5: Fluoroquinolones licensed for clinical use in the UK by year of FDA approval. MIC values obtained from 
Andersson and McGowan (2003). 
 
 
 
 
 
Year of FDA 
approval Drug Generation MIC90 (E. coli) Primary use/treatment Note 
1967 Nalidixic acid 1st 8 UTI  - 
1986 Norfloxacin 2nd 0.12 UTI, Gonorrhoea  - 
1987 Ciprofloxacin 2nd 0.03  UTI, tissue infection  - 
1990 Ofloxacin 2nd 0.12 Occular infection - 
1995 Sparfloxacin 3rd 0.06 
Pneumonia, abdominal 
infection 
Withdrawn from UK 
Market 
1996 Levofloxacin 3rd 0.12 SSTI, UTI, pneumonia  - 
1997 Trovafloxacin 4th 0.06 
Pneumonia, abdominal 
infection 
Withdrawn from UK 
Market 
1999 Moxifloxacin 4th 0.06 
Pneumonia, abdominal 
infection 
Withdrawn from UK 
Market 
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1.9.2 Mechanism of fluoroquinolone resistance in Staphylococcus aureus  
 
As with many antimicrobial agents, increasing use of fluoroquinolones over the past 30 
years had led to increases in antimicrobial resistance and highly resistant isolates of S. 
aureus are now prevalent. Unlike many other resistance mechanisms, resistance to 
fluoroquinolones is primarily mediated by point mutations in one or more of the genes 
encoding for DNA gyrase ,gyrA and gyrB, or topoisomerase IV, grlA and grlB (in S. 
aureus). Non-synonymous point mutations arising in short DNA sequences known at the 
quinolone resistance determining region (QRDR) are known to cause changes in 
fluoroquinolone drug susceptibility. If these mutations cause amino acid changes that 
alter the structure of either subunit of the two enzymes, the drug target site of the 
fluoroquinolone can be changed. This reduces the drug binding affinity and can lead to 
drug resistance (Hooper, 2000, Piddock, 1999, Hooper, 1999, Hooper, 2001).  Many of 
these mutations have been well described in S. aureus (Table 6) with some mutations 
having greater decrease in drug susceptibility than others. In Gram negative bacteria 
mutations in gyrA are thought to be most influential in generating resistance (Takahashi 
et al., 1998), however the primary drug target in S. aureus, and other Gram positive 
bacteria, is topoisomerase IV (Anderson et al., 1999) and mutations in gyrA, gyrB and 
grlA genes are associated with clinical resistance. In resistant strains mutations in gyrA 
are always preceded by mutations in grlA and mutations in gyrA and gyrB alone have 
been seen to not cause resistance. Conversely mutations in the grlA gene with or without 
gyrA mutations have been described in fluoroquinolone resistant strains. Combinations 
of mutations in gyrA and grlA have been shown to give increased minimum inhibitory 
concentrations (MIC) compared to mutations in grlA alone. An example of this is the 
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combination of an S80F mutation in GrlA and a S84L mutation in gyrA giving a 128-fold 
increase in ciprofloxacin resistance compared to wild type strains (Griggs et al., 2003, 
Horii et al., 2003).  Interestingly mutations in grlB are less widely reported than 
mutations in grlA or gyrA but appear to have a minimal impact on fluoroquinolone 
resistance in combination with mutations in grlA and gyrA (Takahashi et al., 1998).  
 
In addition to the alteration in drug target described above, fluoroquinolone resistance 
can also arise from drug efflux. The membrane efflux pump NorA, encoded by the gene 
norA, has been shown to cause increased resistance to hydrophilic fluroquinolones 
including norfloxacin by actively pumping the drug out of the bacterial cell and 
decreasing intracellular concentration. Increased expression or mutations arising in the 
coding region of the norA gene have been shown to increase resistance to 
fluoroquinolones (Kaatz et al., 1993, Kaatz et al., 1999, Yoshida et al., 1990).  
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Enzyme Gene Mutation Reference 
Gyrase 
gyrA Ser-84-Lys  (Griggs et al., 2003) 
gyrA Gly-88-Leu  (Takahashi et al., 1998) 
gyrB Asp-437-Asn  (Ito et al., 1994) 
gyrB Arg-458-Gln  (Ito et al., 1994) 
Topoisomerase  
grlA Ser-80-Phe  (Griggs et al., 2003) 
grlA Ala-116-Glu  (Hooper, 2000) 
grlB Arg-470-Asp  (Fournier and Hooper, 1998) 
grlB Pro-451-Ser 
 (Hannachi-M’Zali et al., 2002, Horii 
et al., 2003) 
 
Table 6: Characterized mutations in fluoroquinolone target genes.
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1.9.3 Fluoroquinolone use and MRSA evolution  
 
As mentioned previously fluoroquinolone drugs are used across the globe in human and 
veterinary medicine due to their high potency and spectrum of activity. This frequent 
use over the past 25 years has led to an increase in fluoroquinolone resistance in species 
such as Escherichia coli, Klebsiella pneumoniae and S. aureus across Europe, with clinical 
MRSA isolates resistant to fluoroquinolones now being widespread (Livermore et al., 
2002).  
 In the UK, changes in prescription policy have been implemented to reduce the 
use of fluoroquinolones in primary and secondary care, partially due to the link between 
fluoroquinolone use and Clostridium difficile infection (Deshpande et al., 2015). Recent 
data from the English surveillance programme for antimicrobial usage and resistance 
(ESPAUR) report has shown that there has been a slight reduction in the use of 
fluoroquinolnes in England and Wales between 2010 and 2013, however this trend has 
been reversed with an increase in use from 2014 (Public Health England, 2015).  
 
 While not a first line drug for staphylococcal infections fluoroquinolone 
resistance is thought to be a biomarker for successful lineages, with major successful 
HA-MRSA clones being resistant. These include EMRSA-15 (Richardson and Watson, 
2013) (detailed in section 1.8.1), EMRSA-16 (McAdam et al., 2012), ST 239 (Lindsay, 
2013) and the CA-MRSA strain USA 300 (Alam et al., 2015).  The widespread 
fluoroquinolone resistance in MRSA likely due to fluoroquinolones being readily 
secreted in sweat through body regions such as the axilla and perineum which are 
colonization sites for MRSA (Hawkey, 1997). Furthermore the selective advantage 
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resistance would provide in the hospital environment where fluoroquinolone drugs 
would be frequently used provides reasoning for resistance in HA-MRSA lineages. 
 Due to the large number of fluoroquinolone resistant isolates emerging in a range 
of bacterial species, the evolutionary fitness advantage of fluoroquinolone resistance has 
been widely debated.  Alterations in supercoiling genes are thought to have global 
cellular responses, with changes to supercoiling shown to increase expression of over 
100 genes and decrease expression of 200 genes in E. coli (Peter et al., 2004). 
Evolutionary experiments with E. coli have suggested mutations within supercoiling 
genes are also under selection for fitness in the absence of antibiotic pressures (Crozat 
et al., 2005). Studies determining the relative fitness of mutations in supercoiling genes 
in E. coli and S. pneumoniae have shown mutations to result in a fitness cost; with 
mutant strains having poorer survival in co-culture and growth rate experiments (Rozen 
et al., 2007, Marcusson et al., 2009).  On the other hand mutations in gyrA in 
Campylobacter jejuni (Han et al., 2012) and Salmonella enterica (Baker et al., 2013) have 
been shown to give a fitness gain, allowing strains to become fluoroquinolone resistant 
and out compete wild type strains in drug free competition experiments.  
 It has previously been demonstrated that a fitness advantage is required for 
dissemination of MRSA clones in hospitals (Thouverez et al., 2003) however 
experiments directly relating to flouroquinolone resistance and fitness in S. aureus are 
limited. Horvath et al have shown that different MRSA lineages suffer different fitness 
costs upon developing resistance to fluoroquinolones (Horváth et al., 2012). For 
example an ST239 isolate had reduced fitness compared to an ST5 isolate when both 
isolates had the same MIC value; which the authors attribute to the change in dominant 
lineage in their region over time (the replacement of ST239 with ST5). The authors also 
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demonstrated that higher MIC values cause a greater loss of fitness, with isolates with 
increasing MIC values have reduced fitness. Interestingly the data also showed that 
EMRSA-15 isolates had the highest fitness, with an EMRSA-15 isolate having comparable 
fitness to an ST5 isolate with a two fold lower MIC to ciprofloxacin and an ST239 isolate 
with a 64 fold lower MIC to ciprofloxacin (section 1.8.1).  
 
While limited molecular studies have investigated fitness advantage of fluoroquinolone 
use in MRSA, several studies have investigated the impact of fluoroquinolone use on the 
MRSA isolation rate in hospitals. Exposure to fluoroquinolones has been shown give an 
increase in MRSA isolation rate (Weber et al., 2003) and a systematic review has 
implicated fluoroquinolones are the antibiotic class having most impact on MRSA 
infection incidence in hospitals (Tacconelli et al., 2008).  Data has shown that increasing 
use of fluoroquinolones in hospitals has been linked with increasing MRSA rate 
(Lafaurie et al., 2012, Knight et al., 2012, Weber et al., 2003) and decreasing use has 
induced a decrease in MRSA rate (Lafaurie et al., 2012). Re-introduction of 
fluoroquinolones into a hospital after period of restricted use has also been shown to 
cause a significant increase in MRSA isolation rate to pre-restricted use (Parienti et al., 
2011). 
 A caveat of studies linking fluoroquinolone use to MRSA prevalence is they often 
fail to include factors other than antimicrobial prescription in their MRSA impact 
analyses. Several studies have investigated the usage of alcohol based hand rubs (ABHR) 
in litres per year and have shown that increasing use of ABHRs led to a decreasing trend 
of MRSA isolation (Lafaurie et al., 2012, Parienti et al., 2011).  However most studies fail 
to account for important infection prevention and control (IPC) interventions such as 
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elective or universal screening of inpatients, decolonization procedures or patient 
isolation. A recent and unique study by Lawes et al (Lawes et al., 2015) has attempted to 
address these issues by assessing the impact of both antibiotic stewardship and IPC 
policies on MRSA prevalence across a health board in Scotland over a period of 16 years. 
In 2008 Scotland developed it’s first national antibiotic stewardship plan (Nathwani et 
al., 2011) to reduce use of the 4C antibiotics (clindamycin, ciprofloxacin [and other 
fluoroquinolones], cephalosporins and co-amoxiclav) and macrolide antibiotics. 
Comparisons of antibiotic prescribing data, MRSA rate and IPC interventions showed 
restricted use of antibiotics reduced hospital MRSA prevalence by 46% but that IPC 
procedures also had important contributions to recent reductions in MRSA burden.  
However co-linearities in associations between the different classes of antimicrobials 
analysed meant that the MRSA reduction could not be directly linked to reduction in 
fluoroquinolone drug use and the exclusion of data for staffing levels, patient transfer 
rates and compliance with isolation and decolonization protocols due to inconsistency 
further demonstrates the difficulty of quasi-experimental studies.  
 Fluoroquinolone use has therefore been implicated in the continuing evolution of 
MRSA. While there is evidence of the impact fluoroquinolone use has in generating 
resistance and how it can affect hospital MRSA isolation rate, no study has investigated 
the impact clinical fluoroquinolone use has on detailed MRSA phylogenetic evolutionary 
structures which is investigated in this thesis. 
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1.10 Desiccation Tolerance in Staphylococcus aureus 
 
The environment plays an important role in MRSA outbreaks and control due to it being 
a potential MRSA contamination reservoir and can therefore transmit to patients and 
lead to infection (Hardy et al., 2006a, Boyce, 2007). Several hospital surfaces or 
inanimate objects are readily colonized by S. aureus including mattresses, curtains, door 
handles, beds, telephones, patient notes and medical equipment (Boyce, 2016). In order 
for an environmental surface to act as a reservoir the bacteria must be able to survive on 
that surface or media. Several hospital pathogens are capable of surviving in the hospital 
environment, most notably Clostridium difficile, Acinetobacter baumanii (Jawad et al., 
1996) and S. aureus (Boyce, 2007).  
 
 In the natural environment bacteria are exposed to many stresses such as 
starvation, exposure to UV or short chain fatty acids for those that colonize skin. One of 
the major stresses bacteria face is desiccation; the process of extreme drying where 
bacteria lose cellular water causing them to become damaged and die. The loss of water 
causes the cell capsular layer to shrink, increases intracellular salt and macromolecule 
concentrations (Nocker et al., 2012, Potts, 1994) and further damage is caused, 
particularly to DNA and proteins, by the increase in concentration of cellular oxygen 
radicals. These radicals are produced from the Fenton reaction where hydrogen 
peroxide is reduced to form highly reactive hydroxyl species that increase in the 
desiccated cell. Gram positive bacteria are considered to be more resistant to 
desiccation, partially due to their lack of LPS or flagella and thicker peptidoglycan walls 
which reduce net loss of water (Nocker et al., 2012). 
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1.10.1 Experimental methods for desiccation assays/tolerance 
 
Noble (Noble, 1962) and Rountree (Rountree, 1963) were two of the first authors to 
investigate the desiccation tolerance of S. aureus in the early 1960s. Their findings 
showed S. aureus to be able to survive for an extended period time on hospital fabrics 
and that different S. aureus strains had different tolerances to desiccation. Since then 
many other studies have been performed on the desiccation tolerance of S. aureus and 
MRSA that are detailed in Table 7. These studies are difficult to compare directly due to 
the variability in their methodology, with studies using different strains, inoculum 
concentrations, substrate growth materials or recovery media. The duration of study is 
also highly variable between studies and to date the longest duration MRSA strains have 
been analysed is 3 years, with 0.001% of bacteria being able to survive for this duration 
(Chaibenjawong and Foster, 2010). Furthermore it is almost impossible to measure 
desiccation tolerance without including other stress factors such as starvation and UV 
exposure. Despite these variable parameters most studies come to similar conclusions 
regarding several key aspects to desiccation tolerance which are outlined in the sections 
below.  
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Table 7:Desiccation survival studies of methicillin sensitive and resistant Stapylococcus aureus. Studies that have 
controlled relative humidity are denoted by a * in the relative humidity column. 
Author (reference) 
Publish 
date 
Strains (number) 
Innoculum 
concentration 
Relative 
Humidity 
(%)* 
Temperature  
(oC) 
Protectants  Test Material 
Max duration 
of 
experiment 
Survival 
time  
Noble  (Noble, 1962) 1962 MSSA (5+) - - - - Cotton blanket - >203d 
Rountree  (Rountree, 
1963) 
1963 
MSSA, MSSA clinical 
and screening (19 
total) 
1.0 x107 to 2.0 
x107 
42-50 19-27 None. Cotton 90d >15d 
Pettit and Lowbury 
(Pettit and Lowbury, 
1968) 
1968 MSSA (3)  2 x107 35-50 25 None Glass 24h >24h 
Lacey  (Lacey et al., 
1970) 
1970 MSSA (38) 
1.0x103 to 
1.0x104 
40-60 25, 37 None Glass 12h >12h 
Lacey  (Lacey, 1972) 1972 MRSA (10)  Not stated - 30, 36 none Glass 6h >6h 
Beard-Pegler 
(Beard-Pegler et al., 
1988)  
1988 
MRSA (16), MSSA (9), 
CNS (12) 
5.0x107 50-67 22-29 None Cotton  - <9w 
Duckworth and 
Jordens  (Duckworth 
and Jordens, 1990) 
1990 
EMRSA-1 (5), MSSA 
(13) 
7.0 x107 - 37 None Formica 14d >14d 
Hirai et al  (Hirai, 
1991) 
1991 MRSA, MSSA  1.5 x105 50 21  None Cotton 25d  >25d 
Farrington et al   1992 MRSA, MSSA  - 42-54 22-25 - Cotton - > 79d 
Jawad et al (Jawad et 
al., 1996) 
1996 MSSA (3) 2x107 
10, 31 and 
93* 
22 BSA Glass 35d >18d 
Wagenvoort 
(Wagenvoort et al., 
2000) 
2000 MRSA (5) 1.0x109  20 - 49 - - 
Hospital 
dust/plastic 
409d >315d 
Chaibenjawong et al 
(Chaibenjawong and 
Foster, 2010) 
2011 
MRSA, MSSA, E-16, 
COL, S. aureus 
mutants (22 total) 
Not stated - 20, 25, 37 
BSA, inert 
proteins, 
catalases, 
sugar 
protectants  
Plastic 3y >3y 
Knight et al (Knight 
et al., 2012) 
2012 
ST22 [EMRSA-15], 
ST36 [EMRSA-16] 
1.0x106 - - - Plastic 5d > 5d 
Baldan et al (Baldan 
et al., 2015) 
2015 
ST22 [EMRSA-15] 
(10), ST228 (10) 
Not stated - - - plastic 7d > 7d 
Domon et al (Domon 
et al., 2016) 
2016 MRSA (5), MSSA (4) 
2-5x106 and 2-
5x104 
- - - Plastic 8d >8d 
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1.10.2 Test environment factors  
 
In 1950 Lidwell and Lowbury first noticed that the daily death rate of S. aureus changed 
with the relative humidity of the environment (Lidwell and Lowbury, 1950), showing 
that different environmental humidity affected how bacteria survived over time. Since 
then relatively few studies have actively controlled the relative humidity that test 
bacteria are exposed to (Jawad et al., 1996), however two have demonstrated natural 
changes in room temperature and humidity changed the number of bacteria recovered 
in their experiments (Rountree, 1963, Beard-Pegler et al., 1988).  
 
1.10.3 Test material and suspension media 
 
The material S. aureus is inoculated onto determine its desiccation tolerance and 
therefore has strong implications as to how long it survives. Variable survival rates have 
been demonstrated on glass (Lacey et al., 1970, Pettit and Lowbury, 1968, Lacey et al., 
1986, McDade and Hall, 1964, Jawad et al., 1996), cotton or other hospital fabrics 
(Rountree, 1963, Beard-Pegler et al., 1988, Hirai, 1991, Noble, 1962) and inert plastics 
(Duckworth and Jordens, 1990, Knight et al., 2012, Baldan et al., 2015, Wagenvoort et al., 
2000, Domon et al., 2016).  These test materials reflect the various materials found in 
the hospital environment, suggesting some hospital surfaces can harbor viable bacteria 
longer than others. MRSA appears to survive for longer on cotton fabrics compared to 
glass however to date the longest record of MRSA survival has been three years on dry 
plastic (Chaibenjawong and Foster, 2010, Neely and Maley, 2000). Interestingly bacteria 
inoculated onto cotton fabric in experiments by Rountree (Rountree, 1963) and Beard-
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pegler et al (Beard-Pegler et al., 1988) showed bacterial counts to have increased 
between primary inoculation and day one (24 hour timepoint).  This may be due to the 
environmental temperature and humidity in the laboratory setting of these experiments 
in which humidity and temperature were not controlled. 
 
The addition of protectants in the form of inert protein has also shown to increase the 
long term survival of MRSA. Chaibenjawong et al noted a 15 fold increase in survival of 
MRSA strains suspended in 3% bovine serum albumin (BSA), the concentration of 
protein in “dirty hospital conditions” and a 5 fold increase with the addition of boiled 
catalase (Kawamura-Sato et al., 2008, Tuladhar et al., 2012), compared to those 
suspended in water (Chaibenjawong and Foster, 2010) with similar findings being seen 
in Acinetobacter species (Jawad et al., 1996).  
 
1.10.4 Methicillin resistant and desiccation tolerance 
 
Lacey et al in 1972 (Lacey, 1972) were the first authors to include MRSA strains in their 
analysis; finding no difference in survival between methicillin resistant and sensitive 
strains. This finding has been supported by some literature (Lacey et al., 1986, Hirai, 
1991, Chaibenjawong and Foster, 2010) but refuted by others (Duckworth and Jordens, 
1990, Domon et al., 2016). Beard-pegler et al (Beard-Pegler et al., 1988) and Lacey 
(Lacey, 1972) showed no relationship between antibiotic resistance to various 
antimicrobial agents and the desiccation tolerance of different strains based on phage 
typing and the acquisition and loss of resistance determinants respectively.  On the 
other hand Duckworth et al (Duckworth and Jordens, 1990) showed multi-drug 
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resistant EMRSA-1 was able to survive better than both MSSA and MRSA strains with 
fewer drug resistances, however this greater survivability may have been due to 
inherent features of the EMRSA strain rather than it’s antimicrobial resistant properties. 
Finally a recently published article by Domon et al (Domon et al., 2016) showed that 
methicillin sensitive strains survived longer than resistant strains; perhaps due to the 
lack of the SCCmec element in the MSSA strains.  
 
1.10.5 Inoculum concentration  
 
The concentration of bacteria inoculated onto test material has been shown to be 
important in their length of survival. The majority of MRSA desiccation studies use 
inoculum concentrations ranging from 1.0x107 to 1.0x109 cfu per ml however Domon et 
al (Domon et al., 2016) showed bacteria inoculated onto propylene tubes at lower 
concentrations, 1.0x104  cfu per ml compared to 1.0x106 cfu per ml, had poorer survival 
and faster cell death. The established infective dose for MRSA is 1.0x105 cfu per ml 
(Schmid-Hempel and Frank, 2007) and the total aerobic bacteria count on human hands 
is approximately 2.0 to 3.0x106 cfu per ml (McGinley et al., 1988), suggesting lower 
inoculum concentrations may more accurately represent MRSA transmission by human 
contact.  
 
1.10.6 MRSA lineages with different desiccation tolerance  
 
Different MRSA lineages have different inherent properties associated with them 
including their tolerance to desiccation.  Sequence type 22 (ST22) has been repeatedly 
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shown to outcompete other lineages such as ST36 (EMRSA-16) (Knight et al., 2012), 
which evolved at a similar time to EMRSA-15, or ST228 (Baldan et al., 2015) that is 
endemic across several countries in Europe. In both cases ST22 had a significantly 
higher number of bacteria surviving at 120h and 168h post inoculation respectively. 
EMRSA-15 was also able to outcompete both strains in co-culture, had greater acid and 
alkali tolerance as well as thermo-tolerance and osmostic stress resistance (Baldan et 
al., 2015, Baldan et al., 2012). EMRSA-1 strains have also been shown to survive longer 
than non-epidemic strains, surviving twice as long (14 days) as the MSSA strain “oxford 
staph” (NCTC 6571) (Duckworth and Jordens, 1990).  Studies that have investigated 
different strains have selected isolates based on antibiotic profiles or phage typing 
however due to the study pre-dating the MLST typing scheme it is difficult to relate 
these data to current nomenclature and MRSA lineages.  
 Only a limited number of studies have examined the differences in desiccation 
tolerance between well defined MRSA lineages and none have examined desiccation 
tolerance within an MRSA lineage. As most HA MRSA clones are pandemic, individual 
STs are likely being exposed to different environmental stresses in different 
geographical locations. Therefore evolutionary adaptation to these specific 
environments may have occurred between different clones of a specific ST. To date no 
study has investigated desiccation tolerance between EMRSA-15 clones from different 
geographical niches which has been investigated in the work described here.  
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1.11 Cellular mechanisms for desiccation tolerance in S. aureus 
 
S. aureus has several regulation factors that contribute to it’s ability to tolerate 
desiccation. Sigma factor B (σB) is an RNA polymerase global regulator that is known to 
control over 250 genes (Bischoff et al., 2004) and has been identified in many Gram 
positive and negative bacteria. Unlike other bacteria, S. aureus has a limited repertoire of 
sigma factors to regulate many different cellular mechanisms (Chaibenjawong and 
Foster, 2010, Shaw et al., 2008) and σB has been demonstrated to be important in stress 
responses, particularly in the stationary phase, (Clements and Foster, 1999) including 
desiccation tolerance. σB mutants have been shown to have reduced tolerance to 
desiccation (Chaibenjawong and Foster, 2010) which is mediated through a number of 
mechanisms. Sigma B has also been demonstrated to control katA production (Cosgrove 
et al., 2007) and staphyloxanthin biosynthesis (Pelz et al., 2005, Clauditz et al., 2006) 
both of which are involved in desiccation stress tolerance.   
 The only catalase gene in S. aureus is katA which produces catalase that is 
required for tolerance to oxidative stress by reacting with oxygen radical species and 
desiccation tolerance is increased 12 fold when media is supplemented with catalase 
(Chaibenjawong and Foster, 2010). Furthermore mutants lacking the catalase 
production gene katA (Cosgrove et al., 2007) have shown reduced survivability over 
time.  
 Staphyloxanthin is an orange-red triterpenoid carotenoid pigment that was first 
described by Marshall and Wilmoth (Marshall and Wilmoth, 1981) which gives S. aureus 
it’s golden colour and is coded by the five gene operon ctrNOPQM (Pelz et al., 2005). 
Staphyloxanthin plays important role in desiccation tolerance by absorbing energy from 
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oxygen radicals (Pelz et al., 2005) and greater killing of bacteria is seen in mutants 
lacking functional staphyloxanthin (Liu and Nizet, 2009). Furthermore the pigmentation 
properties of the carotenoid are thought to protect the cell from UV damage in the 
environment (Potts, 1994).  
 
 Recently an additional sigma factor, σS, has been suggested as an alternate factor 
for regulation and desiccation tolerance. σS mutants showed reduced long term survival, 
due to desiccation and other environmental stresses, however transcription profiling 
showed the factor is not expressed under normal growth conditions (Shaw et al., 2008), 
indicating a secondary role of σS in stress tolerance.  
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1.12 Hypotheses 
 
 EMRSA-15 emerged in the Birmingham region in the mid 1980s. 
 The Evolution of EMRSA-15 in Birmingham has been influenced by the clinical use of 
fluoroquinolone antibiotics. 
 Geographically restricted EMRSA-15 populations will exhibit limited diversity 
 EMRSA-15 clones or sub-lineages exhibit differences desiccation tolerance.  
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1.13 Aims 
 
 Develop a bioinformatics pipeline that will analyse WGS data to determine SNPs 
occurring in the core genome and construction of phylogenetic trees of EMRSA-15 
genomes.   
 
 Use clinical and screening isolates collected between 1985 and 2015 from 
Birmingham in conjunction with an international collection of genomes to further 
elucidate the evolutionary origins of EMRSA-15. 
 
 Investigate the phylogenetic structure of EMRSA-15 from geographically restricted 
regions, its transmission around the globe and its continuing evolution in 
Birmingham and using the isolate collection from aim 2.  
 
 To apply comprehensive antimicrobial prescription data from a single hospital trust 
to a phylogenetic tree of Birmingham genomes in order to determine the impact of 
antimicrobial prescription on the phylogenetic evolution of EMRSA-15.  
 
 Compare the discriminatory power of VNTR and WGS SNP typing methodologies to 
discriminate isolates and identify transmission events within the Birmingham 
EMRSA-15 population.  
 
 To establish if desiccation tolerance has contributed to the success of different 
geographically restricted EMRSA-15 clones by investigating their desiccation 
resistance in a controlled environment.    
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2 Materials and Methods 
 
2.1 Media 
 
All Staphylococcus aureus isolates used in this study were cultured on pre-poured ISO 
sensitest agar or Columbia blood agar (CBA) plates provided by Oxoid (Basingstoke, 
UK).  
 
2.2 Storage of Isolates  
All bacterial isolates in this study were stored long term in “Protect microorganism 
preservation tubes (Technical service consultants Ltd, Heywood, UK) tubes. Each isolate 
was grown at 37oC for 24 hours on ISO sensitest agar (Oxoid, Basingstoke, UK) and then 
suspended in the cryotube liquid using a sterile cotton swab. Each preserve tube was 
labeled with the strain ID and storage date and stored at -80oC. When required, strains 
were sub-cultured directly from frozen stock onto CBA or ISO sensitest agar and 
incubated at 37oC.  
 
2.3 Isolate Collections 
In order to study the evolution of EMRSA-15 in Birmingham over time a total of 317 
isolates from retrospective and prospective sample collections that were sampled from 
circa 1985 to 2015 were sourced (Table 8).  These collections were then screened for 
EMRSA-15 isolates using VNTR typing (detailed in section 2.5). VNTR typing was used to 
identify EMRSA-15 isolates is currently the most appropriate tool available, being 
cheaper, faster and more discriminatory than spa typing. 
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Collection Date Range Location (Country) 
Number of Isolates 
VNTR typed 
Number of 
ST22 Isolates* 
Number of 
isolates WGS 
Clinical  Screening 
HEFT ITU 2002-2004 Birmingham (UK) 36 36 36 0 36 
HEFT Surgical 2005-2007 Birmingham (UK) 33 33 33 0 33 
HEFT Contemporary 2012-2015 Birmingham (UK) 64 54 54 15 39 
QEHB 
Contemporary 
2013-2015 Birmingham (UK) 55 36 36 14 22 
CHB Contemporary 2013-2015 Birmingham (UK) 48 18 18 4 14 
CHB Historical 1985 Birmingham (UK) 14 1 1 1 0 
Guernsey (PEH) 2005-2010 
Guernsey (British 
Channel) 
54 21 21 8 13α 
Hong Kong 2010-2014 Hong Kong (China) 13 13 13 4 9 
Total - - 317 212 212 46 153 
 
Table 8: Isolate collections used in the study. * Isolates classified as ST22 from VNTR typing result comparison to NCTC 
EMRSA-15 control. α eight unknown screening or clinical isolates.  
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Example 
Strain 
Locus 
Profile 
L1 L13 L15 L16 L21 L5 L7 
EMRSA-15 1 5 0 3 16 - 2 1 5 0 3 16 - 2 
EMRSA-16 1 2 2 2 5 3 2 1 2 2 2 5 3 2  
MSSA-476  1 6   2  2  11 3   2 1 6 2 2 3 2 2  
 
Table 9: Examples of the seven digit VNTR profile patterns where the number of repeats at each locus is displayed as an 
integer. Throughout this thesis VNTR profiles are displayed in the order L1, L13, L15, L16, L21, L5 and L7.  
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Isolates with one, zero and three repeats at VNTR loci L1, L15 and L7 were considered to 
be ST22 or EMRSA-15 due to previous work identifying EMRSA-15 isolates to 
demonstrate this profile (Table 9).  
 
2.3.1 Historical Isolate collection  
 
A collection of 14 clinical isolates that had been sampled from City hospital Birmingham 
(CHB) in circa 1985 were grown on cysteine lactose electrolyte deficient (CLED) media 
(Oxoid, Basingstoke, UK) to select for S. aureus by presence of bright yellow colonies 
which were confirmed as S. aureus by latex agglutination test (Thermo Scientific, 
Waltham, USA).  Only a single isolate from this collection was identified as ST22 by 
VNTR typing.   
 
 
2.3.2 Retrospective screening isolate collection 
 
 
Thirty six isolates from 36 patients were selected from a collection of 477 screening 
isolates sampled from 117 MRSA positive patients admitted to an intensive treatment 
unit (ITU) at the Heart of England Foundation Trust (HEFT) between February 2001 and 
December 2003. During the study period 412 patients were admitted to ITU each 
patient admitted to ITU was screened on admission and every three days for the 
duration of their stay in ITU as well as having any infected wounds swabbed.  
 
Thirty three isolates from 33 patients were selected from a second inpatient nasal 
screening collection sampled between November 2005 and April 2007 from surgical 
 62 
 
wards at HEFT. All patients admitted to seven surgical wards (two general surgery 
wards, trauma and orthopaedics, vascular, ear nose and throat (ENT), thoracic and 
urology wards) were screened on admission and then every four days until discharge.  
 
For both retrospective collections isolates were selected on matching specific criteria.  
Due to the collections having been previously VNTR typed, isolates were primarily 
selected on VNTR typing data. Only isolates corresponding to an EMRSA-15 VNTR 
profile (number of repeats at each locus) (Table 9) were included, leaving a pool of 198 
isolates from 95 patients in the ITU screening collection and to 1098 isolates from 714 
patients in the surgical screening collection. 
  Isolates were then selected to maximize sampling across time (as required for 
BEAST analysis) with at least one isolate per month being included where possible. Due 
to ITU study design there were no isolates sampled between October 2002 and June 
2006 for this collection.  
 
Isolates selected from the ITU screening study between 2001 and 2003 are hereby 
designated as the “HEFT ITU” collection and those from surgical wards between 2006 
and 2008 are designated as “HEFT surgical” collection (Table 8).  
 
2.3.3 Contemporaneous Birmingham Isolate collections  
 
 
One hundred and sixty seven contemporaneous isolates from three hospitals in 
Birmingham (HEFT, City Hospital Birmingham (CHB) and the Queen Elizabeth Hospital 
Birmingham (QEHB) were collected (Table 8, Figure 4) from routinely saved collections 
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(Table 8). These comprised of 64, 55 and 48 isolates from HEFT, QEHB and CHB 
respectively and were all sampled from individual inpatients from surgical, trauma and 
ITU wards at each of the hospitals.   
 
VNTR typing identified 54, 36 and 18 EMRSA-15 isolates from HEFT, QEHB and CHB 
respectively to give a total of 108 (33 clinical and 75 screening) isolates.  
 
 
2.3.4 Isolates from around the World 
 
 Fifty four isolates from the only acute hospital on Guernsey (UK) were sourced, 
21 of which were designated as EMRSA-15 by VNTR typing. Of these 21 isolates, eight 
were sampled from an ITU ward over a period of four years between 2006 and 2010. 
The remaining 13 isolates were sampled from sterile sites across five inpatient wards 
between 2013 and 2015.  
 Thirteen previously identified as ST22 isolates from four district general 
hospitals in Hong Kong (China) were also included. These comprised of eight nasal 
screening isolates from neonatal and pediatric wards across two hospitals sampled in 
2014 and five blood culture isolates from three hospitals sampled between 2010 and 
2011.  
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Figure 4: location of sampling hospitals in the Birmingham conurbation.
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%
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2.4 Downloaded genomes  
 
In order to contextualize the Birmingham phylogeny on a national and global scale 227 
publically available EMRSA-15 genomes were downloaded in fastq format from the 
European Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena/) (Table 10).  
One hundred and twenty three genomes from the Holden et al global ST22 population 
study (Holden et al., 2013) consisting of 13 ciprofloxacin sensitive ST22 isolates and 110 
ciprofloxacin resistance ST22 (EMRSA-15) isolates were downloaded. This collection 
included the first three reported EMRSA-15 genomes from the West Midlands that were 
sampled between 1991 and 1992 as well as genomes from Germany, Portugal, the Czech 
republic, Australasia and Singapore.   
An additional one hundred and six EMRSA-15 bacteraemia genomes sampled over a 
period of 10 years from the UK national Reuter et al (2016) study were also included. 
This study collected and sequenced a total of 783 EMRSA-15 genomes from 46 
laboratories (across 16 UK regions) that submitted MRSA bacteraemia isolates to the 
British Society for Antimicrobial Chemotherapy (BSAC), collecting between 58 and 92 
EMRSA-15 isolates per year.  
 My selection of isolates from this study included all 73 genomes that were 
collected from three hospitals (33 from Coventry and Warwickshire, 24 from Royal 
Shrewsbury and 16 from CHB) across the West Midlands and a single genome from each 
English submitting region (11 regions excluding the West Midlands) in 2001, 2005 and 
2010.  Only a single isolate was available from one English region therefore giving 31 
genomes selected for analysis. Delineation of submitting hospital was requested from 
BSAC for the West Midlands hospitals only.  
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Collection Locations  Date range Number of Genomes 
Holden 
(International) 
UK 1990-2008 49 
Europe 1997-2008 58 
Australia 1999-2006 10 
Singapore 2004-2007 7 
Reuter (UK) 
UK (West Midlands) 2001-2010 73* 
UK (England Regions) 2001-2010 30 
Total - - 227 
 
Table 10: Downloaded genomes included in the study. * Includes 13 isolates from 
CHB. 
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2.5 Variable Number Tandem Repeat (VNTR) Staphylococcal interspersed Repeating Unit 
(SIRU) analysis 
 
DNA was extracted from overnight cultures of MRSA at 37°C on ISO sensitest agar for 
use as a DNA template in PCR reactions. Three colony picks were suspended in 25μl of 
100μg/ml lysostaphin (Sigma Aldrich, St Louis, USA), vortexed and incubated at 37°C for 
10 minutes to lyse the cellular membrane. Lysate was then incubated in 25μl of 
100μg/ml proteinase K (Sigma Aldrich, St Louis, USA) and 75 μl 0.1M pH 8.0 Tris (Sigma 
Aldrich, St Louis, USA) at 37oC for 10 minutes followed by 95°C for an addition 10 
minutes. Solutions were then centrifuged at 13000 rpm for two minutes to pellet any 
cell debris and leave DNA extract in solution. DNA extracts were stored at 4°C or at -
20°C long term. 
PCR mastermixes were prepared in a laminar flow cabinet under PCR clean conditions. 
Each PCR reaction contained 15.9ml of molecular grade water (Thermo Scientific, 
Waltham, USA), 1 X PCR buffer (Thermo Scientific, Waltham, USA), 1μM left and right 
flanking primer (Eurofins, Luxembourg), 200μM of each deoxynucleoside triphosphate 
(dNTP) (BioGene, Huntingdon, UK), 2mM MgCl2 (Thermo Scientific, Waltham, USA), 0.5U 
AmpliTaq Gold (Thermo Scientific, Waltham, USA) and two μl DNA extract to give a total 
volume of 25μl per reaction. Amplification was performed in a block system on a 
Mastercycler Pro (Eppendorf, Hamburg, Germany). PCR reaction had a pre- 
denaturation step at 94°C for 2 min, denaturation at 94°C for 30s followed by 35 cycles 
of annealing at 55°C and extension at 72°C for one minute. A final extension phase at 
72°C for two minutes was also included. 
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PCR amplicons were analysed by capillary gel electrophoresis using the QIAGEN QIAxcel 
E gene (QIAGEN, Hilden, Germany). A separation programme of OL500 for each of the 
VNTR loci with the exception of locus 21 which has the separation programmme 
OM1100. All runs were analysed with a 50bp ladder (Promega, Madison, USA). The 
number of repeats was calculated from the amplicon size using the repeat unit and 
flanking region base pair sizes as outlined by Hardy and colleagues 2004 (Hardy et al., 
2004). 
EMRSA-16 DNA extract was used as a positive control for all VNTR tests due to its 
amplifying across all loci and a negative control of one μl water instead of DNA extract 
was also included. Isolates were considered unique if they varied at any of the seven loci. 
 
2.6 Whole Genome Sequencing (WGS)  
2.6.1 Qiagen DNA extraction  
 
 
MRSA isolates were inoculated onto ISO senstiest agar (Oxoid, Basingstoke, UK) from -
80oC stored cultures and incubated for 24 hours at 37oC before DNA was extracted from 
single colony picks using QiaAmp DNA mini kits (QIAGEN, Hilden, Germany).  
 Three colony picks were suspended in 180µl lysis solution (135µl 0.1M tris-HCl 
and 45µl of 200µg/ml lysostaphin) in a 1ml sterile Eppendorf tube (Eppendorf, 
Hamburg, Germany) and incubated at 37°C for 60 minutes to denature the bacterial cell 
wall. The nuclear envelope was then denatured by adding 20µl proteinase K (Qiagen 
Hilden, Germany) and 200µl buffer AL(Qiagen Hilden, Germany). Tubes were vortexed 
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and incubated at 56°C for 30 minutes followed by incubation at 95°C for 15 minutes to 
denature the proteinase K. Two hundred microliters of absolute ethanol was added to 
the tube, to elute DNA, which were vortexed for 15 seconds followed by short spin 
centrifugation to collect droplets. The 600µl volume from the tube was transposed to a 
Qiagen DNA spin column (Qiagen, Hilden, Germany) and centrifuged at 8000rpm for one 
minute and collected supernatant was discarded. Five hundred microlites of buffer AW1 
(Qiagen, Hilden, Germany), which contains guanidinium chloride for denaturing 
proteins, was applied to the column which was centrifuged at 8000rpm for one minute 
and collected supernatant was discarded.  Five hundred microlites of buffer AW2 
(Qiagen, Hilden, Germany), which contains ethanol and removes salts to purify DNA, was 
applied to the column which was centrifuged at 14000rpm for three minutes and 
collected supernatant was discarded. Clean collection tubes were applied to each of the 
columns and 200µl of buffer AE (10 mM Tris-Cl, 0.5 mM EDTA; pH 9.0) was applied to 
the column which was then incubated at room temperature for 15 minutes. The column 
was then centrifuged at 8000rpm for 3 minutes to collect purified DNA which was 
transferred to a 0.5ml PCR clean Eppendorf and stored at -20°C.  
DNA concentrations were verified by fluorometry using the Qubit dsDNA high spec 
assay kit (Invitrogen, Carlsbad, USA) and the Qubit 2.0 flourometer (Invitrogen, 
Carlsbad, USA). Quantification of a single DNA sample is as follows: Qubit working stock 
was made by adding 3μl Qubit dsDNA high spec reagent to 597μl Qubit dsDNA high spec 
buffer in a 1ml PCR clean Eppendorf to give a volume of 600μl. One hundred and ninety 
microlitres of working stock was added to each of two PCR clean thin-walled, clear, 
0.5ml PCR tubes along with 10μl of each Qubit quantification standard. One hundred and 
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ninety eight microlitres of working stock solution was then added to PCR clean thin-
walled, clear, 0.5ml PCR tube to which 2μl of purified DNA were added. All PCR tubes 
were vortexed for 10 seconds and incubated at room temperature for two minutes. 
Tubes containing standards were applied to the fluorometer first, in order of size, to 
create a standard curve that DNA concentrations could be quantified against before 
applying the tube with DNA.  
Extracted DNA was then diluted to 0.2ng per μl in molecular grade water for Nextera XT 
sample preparation.  
 
2.6.2 Sample library preparation and MiSeq instrumentation  
 
Samples were prepared for sequencing using Nextera XT DNA Sample Preparation Kit 
(Illumina, San Diego, USA). For each sample five microliters of DNA at 0.2ng/ul was 
mixed with 10μl of tagment DNA buffer (Illumina, San Diego, USA) and 5μl of amplicon 
tagment mix (Illumina, San Diego, USA) in a 96 well PCR clean plate and heated at 55oC 
for 10 minutes using a thermocycler (Eppendorf, Hamburg, Germany). A separate well in 
the plate was used for each MRSA isolate DNA extract. Five microliters of neutralize 
tagment buffer (Illumina, San Diego, Germany) was added to each well and incubated at 
room temperature for five minutes.   
Each tagmented DNA sample was then amplified by a limited cycle PCR reaction and 
given a unique barcode index to allow sample pooling and cluster formation when being 
sequencing on the MiSeq. Five microlitres of index 1 and five microlitres of index 2 along 
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with 15μl of Nextera PCR mastermix were added to each well of the PCR plate. The PCR 
plate was then put in a thermocycler (Eppendorf, Hamburg, Germany) and run with the 
following conditions:  pre- denaturation step at 72°C for 3 min, denaturation at 95°C for 
30s followed by 12 cycles of 95°C for 10 seconds, 55°C for 30 seconds and 72°C for 30 
seconds, and a final step of 75°C for five minutes.  
DNA libraries were purified using AMPure XP beads (Beckman Coulter, California, USA) 
to remove short library fragments. Fifty microlitres of each PCR product was transferred 
to a 96 deep well midi plate (Thermo Scientific, Waltham, USA) containing 30μl of 
AMPure XP beads. Midi plates were then sealed and shaken at 1800rpm for two minutes 
using a plate shaker. Following shaking the midi plate was placed on a magnetic stand 
for two minutes until the liquid in each well had become clear and a visible pellet of 
beads was evident in each well. Supernatant material was collected and discarded using 
a 200μl pipette. The midi plate was removed from the magnetic stand and each well was 
washed with 200μl of 80% ethanol before being placed back on the magnetic stand for 
30 seconds and removing the supernatant with a 200μl pipette. This wash procedure 
was repeated twice then wells were allowed to air dry for 15 minutes while on the 
magnetic stand. After 15 minutes the plate was removed from the magnetic stand and 
52.5μl of re-suspension buffer (Illumina, San Diego, USA) was added to each well and 
shaken on a plate shaker at 1800rpm for two minutes. Plates were left to incubate at 
room temperature for two minutes before being placed on a magnetic stand for two 
minutes or until the liquid was clear with an evident pellet at the bottom of the well. 
Fifty microlitres of supernatant from each well was aliquoted into in a new PCR clean 
midi plate using a 200μl multichannel pipette.  
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Libraries were then normalized to allow equal library representation in pulled samples 
for sequencing. Library normalization buffer was prepared by mixing library 
normalization additives LNA1 (Illumina, San Diego, USA) with library normalization 
beads LNB1 (Illumina, San Diego, USA). Forty five microlitres of this normalization 
buffer was then added to each well of the PCR 96 well plate containing the PCR cleaned 
libraries. The plate was shaken at 1800rpm for 30 minutes then placed on a magnetic 
stand until the liquid was clear and a pellet was seen at the bottom of each well. 
Supernatant was discarded using a 20μl pipette and the beads were washed twice by 
adding 45μl of library normalization wash buffer NLW1 (Illumina, San Diego, USA) to 
each well and shaking for five minutes at 1800rpm. After shaking the plates were placed 
on a magnetic stand until the liquid was clear and the supernatant was discarded with a 
20μl pipette. This was process was then repeated. Following washing 30μl of 0.1M 
sodium hydroxide was added to each well, to elute the DNA from the normalization 
beads, and the plate was shaken at 1800rpm for five minutes. Following shaking the 
plate was placed on a magnetic stand for two minutes to allow liquid to clear. 
Supernatant liquid was transferred from the midi plate to a PCR clean 96 well plate.  
Prepared libraries were then pooled by aliquoting 5μl of liquid from each well of the 96 
well plate into a 1.5ml sterile Eppendorf. The pooled library was then diluted to 6-8pM 
in hybridization buffer HT1 (Illumina, San Diego, USA) as described by the Illumina 
protocol. Samples were loaded into the sample well of a MiSeq reagent cartridge 
(Illumina, San Diego, USA) and loaded onto the MiSeq sequencer (Illumina, San Diego, 
USA) for 2x150bp paired end reads to obtain a minimum coverage of 20x for each 
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genome. A negative control of no DNA was included in all sample preparation and 
sequencing runs.  
 
2.7 Analysis of WGS data  
 
A bioinformatics pipeline was constructed to determine SNP occurring in the core 
genome from the raw Illumina data and produce maximum likelihood (ML) phylogenetic 
trees from the derived SNPs. The pipeline was set up to exclude SNPs occurring in highly 
repetitive regions of the genome, MGEs as well as SNPs that may have arisen by 
homologous recombination.  
 
In order to undertake Bayesian analyses, SNP alignments produced by the pipeline were 
applied to a Bayesian analysis platform to generate maximum clade credibility (MCC) 
trees.  
 
 
2.7.1 Development of Bioinformatics pipeline 
 
2.7.1.1 Pipeline production and implementation 
 
 
Published literature and public bioinformatics forums were searched to find the most 
suitable programmes to construct a WGS pipeline that would check raw Illumina 
sequenced data for quality, align data to a reference genome, call SNPs and create 
phylogenetic trees. Literature and bioinformatics forums were further investigated for 
specific programmes and previously published pipelines to determine appropriate 
sources and how best to implement them into a custom pipeline. Programmes were 
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selected on their performance, speed, accuracy and ability to produce desirable output 
files and data.  
 All 437 genomes were applied to a finalized pipeline consisting of twelve 
programmes (fastQC, trimmomatic ,BWA, samtools, qualimap, bcftools, VarScan, vcfutils, 
seqtk, bedtools, gubbins and RAxML) and a single script to create dendrograms from 
raw sequencing data (Table 11)(Error! Reference source not found.).   
Default parameters were used for FastQC, Trimmomatic, BWA, qualimap which quality 
checked, trimmed raw reads then mapped reads to the EMRSA-15 reference genome HO 
5096 0412 (Koser et al., 2012b); a representative isolate of EMRSA-15 that was isolated 
from a fatal neonatal infection in Suffolk, UK in February 2005.  This reference genome 
was chosen for all bioinformatics mapping analysis of EMRSA-15 isolates as it is the only 
fully annotated ST22 genome available on GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) and has been used extensively in previous 
literature (Holden et al., 2013, Hsu et al., 2015, Harris et al., 2013, Harrison et al., 2014, 
Nubel et al., 2013, Paterson et al., 2015, Price et al., 2014).  
 Samtools was used to generate pileup data to identify Genomic variants. SNPs 
and indels were identified with VarScan using separate commands (pileup2snp and 
pileup2indel) with minimum ten read coverage, two minimum supporting reads and 
minimum base quality of 30 parameters for both commands.  
 Bcftools “view” command was used to generate consensus vcf files for each 
genome and was piped with vcfutils (vcf2fq command), seqtk (seq command) and 
bedtools (maskfasta command) to create consensus fastas with repeat and MGE regions 
removed for each of the 437 genomes. Removed regions from each genome are detailed 
in Table 12. These 437 consensus fastas were merged to a single multi fasta file and 
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applied to gubbins for recombination region determination using default parameters. 
Identified recombinant, repeat region and MGE SNPs were removed from the SNP VCF 
file which was converted to a multi-fasta using the script “vcf2phyloviz” 
(https://github.com/nickloman/misc-genomics-tools/tree/master/scripts). 
 Phylogenetic reconstruction was achieved by applying the multi-fasta file to 
RAxML using a generalized time reversible (GTR) model and gamma distribution for 
among site variation. One thousand bootstrap replicates were conducted and applied to 
dendrograms.  
 
 
2.7.1.2 Mobile Genetic Element analysis with Nullarbor 
 
 
All 210 sequenced genomes were applied to the pipeline “Nullarbor” (Github 
https://github.com/tseemann/nullarbor) to determine MGEs occurring in each of the 
genomes.  Untrimmed Illumina fastq files for each genome were applied to the pipeline 
which used Prokka (Seemann, 2014) for genome assembly and annotation and Roary 
(Page et al., 2015) to determine the pan genome.
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Table 11: Programmes implemented in the bioinformatics pipeline and their function.
Programme Version Function Reason for choice Reference  
FastQC 0.10.1 Sequencing quality control and 
validation 
Fast analysis of raw data. Visual output of 
quality of data.  
http://www.bioinformatics.ba
braham.ac.uk/projects/fastqc/ 
Trimmomatic 0.32 Nextera sequencing adaptor trimming 
and read quality control 
Fast and accurate analysis for Illumina data. 
Pre-loaded files for removal of Nextera 
adaptors 
Bolger et al 2014 
BWA 0.7.5 Read mapping to reference  Fast and accurate analysis for Illumina data Li and Durbin 2009 
Samtools 0.1.19 File manipulation and variant analysis Standard programme.  Li et al 2009 
Qualimap  2.1 Mapping quality and genome coverage 
analysis 
Accurate values for mapping. Visual output 
for coverage. 
Garcia-alcalde et al 2012 
Varscan  2.4.0 Variant detection Accuracy and determining SNP thresholds Koboldt et al 2012 
Bcftools 0.1.19 File manipulation, variant detection and 
analysis 
Versatility of programme. Can produce bcf 
files and consensus sequences.  
Li 2011 
Vcfutils 0.1.19 File manipulation Ease of use. Part of bcftools package.  https://github.com/lh3/samto
ols/blob/master/bcftools/vcfu
tils.pl 
Seqtk 1.0 File manipulation Ease of use https://github.com/lh3/seqtk 
Vcftools 0.1.12b Removal of SNPs from vcf files Ease of use http://vcftools.sourceforge.ne
t/ 
Bedtools 2.18.2 File manipulation. Removal of repeat 
regions from analysis.  
Ease of use  Quinlan and Hall 2010 
Gubbins 1.0.2 Homologous recombination detection 
and removal 
Fast and automated recombination 
detection. Visual output for regions of 
recombination.  
Croucher et al 2015 
RAxML 8.0 Maximum likelihood phylogenetic tree 
construction  
Robust programme for tree construction. 
Can generate bootstrap values to be added 
to trees. 
Stamitakis 2014 
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Element/Region (gene) Genomic coordinates 
SCCmec 34163..51525 
IS element 80765..83026 
Repeat region (Spa)  98547..98768 
Transposase 137322..138041 
Transposase 141474..142274 
Repeat region (Staphylocoagulase) 236662..237098 
IstB-like ATP-binding protein and transposases 315945..318143 
Repeat region 633963..634193 
IS element transposase 818385..820574 
IS element 935317..936294 
Transposase 938088..938798 
IS element 977393..979583 
IstB-like ATP-binding protein 1104852..1107038 
IS element 1252874..1254311 
IstB-like ATP-binding protein 1283817..1288790 
putative transposase, putative insertion element protein 1328804..1330543 
Repeat region 1361018..1375548 
phiSLT and phi PVL like phage 1520143..1566314 
IS element 1567574..1569770 
IS element 1852864..1853851 
Duplication 861820..1863920 
IS element 1874756..1876610 
IS element  1895353..1896040 
IS element 1890687..1892984 
Repeat region 1894737..1895351 
IS element 1902192..1903454 
Repeat region 1936053..1936070 
IS element 1936131..1936301 
IS element 1943176..1944547 
IS element 1944548..1945123 
IS element 1945380..1945465 
Repeat region 1990382..1990425 
Tn552-like 2021753..2029411 
IS element 2006700..2008180 
Prophage (PhiSa3) 2042948..2087965 
Phage terminase 2098645..2099998 
Repeat region 2103706..2103983 
Transposase 2136387..2138610 
 
Table 12: Regions of the EMRSA-15 genome removed from SNP analyses. 
Continued on page 78. 
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Element/Region (gene) Genomic coordinates 
Repeat region 2407740..2408448 
IS element 2509256..2510560 
Transposase 2568107..2570285 
IS element 2585866..2586861 
Intergenic 2631410..2633180 
Transposase 2700680..2701410 
IS element 2774816..2778254 
IS element transposase 2825393..2826315 
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Figure 5: Pipeline of DNA extraction, sequencing and Bioinformatics processing. 
Bench work stages are coloured green, sequencing purple, quality control blue 
and bioinformatics black. 
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2.7.2 Bayesian Inference 
 
 
 The Bayesian analysis package BEAST (Bayesian evolutionary analysis sampling trees) 
1.8.1 (Drummond et al., 2012) was used to determine the spatiotemporal evolution of 
the SNP dataset produced by the pipeline.  BEAST is a platform of six programmes 
(Table 13) that are implemented in a stepwise process to produce an annotated 
maximum clade credibility (MCC). 
  
2.7.2.1 File generation and BEAST implementation  
 
The ML tree produced with RAxML was uploaded to the programme Path-O-Gen 1.4 to 
determine the molecular clock rate of the dataset. Each isolate in the tree was tagged 
with a sampling date to allow the evolutionary rate to be calculated.  
A graph of root to tip distances of each isolate against time and a dendrogram 
identifying isolates that do not adhere to the strict molecular clock rate of isolates was 
produced. Evolutionary rate values were automatically calculated by Path-o-Gen which 
are required for input in BEAST. 
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Stage/Step Programme Version Function 
1 Path-O-Gen 1.4 Testing clock rate of phylogenetic trees. Estimation of evolutionary rate. 
2 BEAUTi 1.8.1 
Preparation of XML files for BEAST input. Setting of evolutionary rate 
model, tree model and priors for BEAST implementation. 
3 BEAST 1.8.1 Bayesian analysis of XML files 
4 Tracer 1.6 Analysis of log files from BEAST 
5 Tree Annotator 1.8.1 Construction of maximum clade credibility (MCC) trees 
6 FigTree 1.4.0 Visualisation and annotation of MCC trees 
Table 13: Programmes implemented within the BEAST software package. 
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An aligned multi fasta file of SNPs from all isolates was uploaded to the programme 
BEAUTi 1.8.1 in order to set parameters for the main BEAST programme and generate 
appropriate XML files for BEAST input. These included selecting of site substitution 
models, clock rate models, population models and priors that affect how the BEAST 
Bayesian inference is run.  
  In order to determine the best model for the dataset all combinations of strict, 
relaxed lognormal and relaxed exponential clock models with constant, exponential, 
expansion and Bayesian skyline population models were evaluated in triplicate runs. All 
combination pairs of clock and population models used a GTR model with gamma 
correction for among site variation site model and included the sampling dates of 
isolates in the analysis. Priors were set to default with the exception of the “ucld.mean” 
prior, which was set to a normal distribution using the rate value obtained from Path-o-
gen as the initial and mean input values. XML files generated by BEUTI were applied to 
the BEAST programme and each replicate was run for 100,000,000 chains and sampled 
every 10000 generations.  
 
2.7.2.2 Quality analysis and interpretation  
 
 
BEAST runs were confirmed for convergence and checked for quality using Tracer 1.6. 
Convergence was confirmed by having effective sample size (ESS) values equal to or 
greater than 200 for key parameters including posterior, prior and likelihood statistics. 
Convergence was further confirmed by a “hairy caterpillar” trace.  
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The Tracer model comparison tool Bayes factor test was used to determine the best 
model to fit the ST22 population dataset using an aimc model and 1000 bootstrap 
replications.  
 
Once the best model had been selected a burn in of 10 million chains was removed from 
each replicate run before all three triplicate runs for each clock/population model were 
combined with the LogCombiner V1.8.1 programme.  The resulting combined trees file 
was used to create MCC trees with TreeAnnotator V1.8.1. MCC trees were viewed and 
edited with FigTree V1.4.0 to colour branches by sampling origin, show divergence 
dates and apply scaled axes to the trees. 
 
 
2.7.3 MLST typing  
 
All sequenced genomes were confirmed as ST22 by multi locus sequence typing (MLST) 
via submission of fastq files to the center for genomic epidemiology (CGE) server 
(https://cge.cbs.dtu.dk/services/MLST/).   
 
2.8 VNTR and WGS comparison  
 
 
VNTR and WGS methodologies were compared in two ways. Firstly the number of 
tandem repeats at VNTR loci L13 and L21, the two most variable loci in EMRSA-15, were 
applied at the tips of a BEAST constructed MCC tree using the Interactive Tree of Life 
(ITOL) website (http://itol.embl.de/). 
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 Secondly differences in SNP and VNTR typing methods were compared. Each of 
the 210 WGS sequenced EMRSA-15 isolates were compared to each other isolate for the 
number of SNP differences, number of VNTR locus variants (LV) and summed tandem 
repeat difference (STRD). Multi-fasta files produced from the bioinformatics pipeline 
detailed in section 2.7.1 were applied to MEGA 5.2.2 to generate a pairwise SNP distance 
matrix of the 210 isolates which had also been VNTR typed. This matrix calculated the 
SNP distance of each of the 210 isolates to every other isolate in the multi fasta file. The 
matrix was converted to a list of “isolate x” versus “isolate y” SNP distances in an excel 
format output from MEGA. All versus all pairwise LVs and STRDs were calculated using 
Microsoft Excel. LV was defined as the number of loci each isolate varied at (relative to 
every other isolate). STRD for each isolate was calculated by the sum of the absolute 
difference in tandem repeat copy number at each locus. Pairwise values were then 
calculated as the difference in STRD between isolates. Data for LV, STRD and SNP 
differences were concatenated using Microsoft Excel to give a table of the SNP distance, 
LV and STRD of every isolate to each other. Data was applied to STATA 14.2 to generate 
SNP versus LV and SNP versus STRD graphs with increasing data point size representing 
increasing number of isolates.  
 
 
 
2.9 Antimicrobial sensitivity testing  
 
Eleven isolates were tested for sensitivity to ciprofloxacin, levofloxacin and ofloxacin 
using Etests (Biomerieux, Marcy-l’Etoile, France). Isolates were selected from their 
positioning in the EMRSA-15 global phylogeny described in  section 3.2. These consisted 
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of three randomly selected BHM clade isolates, three of the isolates basal to the BHM 
clade, three randomly selected isolates out with the BHM clade and single isolates from 
Guernsey and Hong Kong.  
 MRSA from overnight cultures grown on Muller Hinton agar at 37oC were 
suspended in 5ml of ISO broth to match a 0.5 McFarland standard followed by 
suspensions being diluted in a ratio of 1:10 with sterile water. Adjusted suspensions 
were used to create a bacterial lawn on ISO sensitest agar and sterile forceps were used 
to place an Etest strip (range 0.002 to 32 μl per ml for all three antibiotics) onto the 
dried lawn. One Etest strip per bacterial lawn/agar plate was applied. S. aureus control 
strains ATCC 29213 and NCTC 1066 were used as sensitive and resistant controls 
respectively. All plates were incubated at 37oC for 24 hours before the diameter of zones 
of inhibition were measured against the Etest strip markings. MIC values above one 
mg/L were considered resistant and below one mg/L were considered sensitive 
(European Comittee on Antimicrobial Susceptibility Testing (EUCAST), 2016). S. aureus 
strains ATCC 29213 and NCTC 1066 were used as sensitive and resistant controls 
respectively.  
 
 
2.10 Metadata acquisition and analysis 
2.10.1 Bacteraeamia and occupied bed days (OBD) data 
 
Voluntary and mandatory annual MRSA bacteraemia data for HEFT between 1993 and 
2015 was retrieved from Public Health England (PHE) 
(https://www.gov.uk/government/statistics/mrsa-bacteraemia-annual-data). 
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Occupied bed days for HEFT between 2001 and 2015 were retrieved from the HEFT 
hospital record system. 
 
2.10.2 Antibiotic consumption data 
 
Annual in-patient antibiotic prescribing data for fluoroquinolones, macrolides and third 
generation cephalosporins (3GCs) between the years 1990 and 2015 were obtained 
from the pharmacy record system at HEFT. Quantities of each drug were converted to 
number of defined daily doses (DDD) as defined by the World Health Organization 
(WHO) collaborating Centre for Drug Statistics Methodology (http://www.whocc.no).  
 
 
2.11 Desiccation assay 
 
Isolates of S. aureus were tested for their tolerance to desiccation under constant 
relative humidity (RH) and temperature in a sealed environment. Glass coverslips were 
inoculated with bacteria and enumerated at set time points of 0, 12 hours and 1, 2, 3, 5, 
7, 10, 14, 21, 28 and 35 days post inoculation and enumeration counts used to 
determine the survival of each S. aureus strain over time.  
 
2.11.1 Bacterial strain selection 
 
 
Nine isolates were selected for inclusion in the desiccation assay based on phylogenetic 
results from chapter 3.2 along with the NCTC EMRSA-15 and MSSA-476 control strains 
as detailed Table 14. Isolates were selected to include clinical and screening isolates and 
 87 
 
comprised three isolates from a localized, dominant Birmingham strain, three isolates 
that were sporadically distributed with other UK and two single isolates from Hong 
Kong and Kuwait that were chosen to determine the desiccation tolerance of EMRSA-15 
from non-UK sampling regions. The EMRSA-15 NCTC control strain (NCTC 13142) was 
included to act as an EMRSA-15 control and the NCTC MSSA-476 strain (NCTC 13297) 
was included to act as an MRSA and MSSA comparator.  
 
 
2.11.2 Desiccation protocol validation  
 
2.11.2.1 Sterilization of glass coverslips  
 
Five glass coverslips were placed in an open petri dish in a PCR clean hood and 
irradiated with UV light at 450nm for 15 minutes and another five glass coverslips were 
immersed in 98-99% ethanol for two minutes then left to dry in a sterile petri dish in a 
PCR clean hood. The five UV irradiated coverslips were placed into individual brain 
heart infusion (BHI) (Oxoid, Basingstoke, UK) broth and vortexed for 30 seconds. 100μl 
of broth was inoculated onto a Colombia blood agar (CBA) (Oxoid, Basingstoke, UK) 
plates and both BHI broth and CBA were incubated at 37oC for 24 hours. This was 
repeated for the five ethanol washed coverslips and again for five coverslips that had 
undergone no sterilization procedure. A negative control of BHI broth with no coverslips 
and a positive control of the NCTC EMRSA-15 strain (NCTC 13142) inoculated BHI were 
included. After incubation plates and broths were inspected manually for growth and 
any broths showing no growth were incubated again for 24 hours at 37oC and inspected 
after incubation.  
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2.11.2.2 Maintenance of relative humidity (RH) and temperature 
 
The maintenance of a stable RH in a sealed environment was verified. A digital thermo-
hygrometer (Fischer Scientific, Hampton, USA) was placed in a large sterilized plastic 
box (height 23cm, width 44cm, depth 71cm) that was sealed and humidity and 
temperature readings were taken every hour for 8 hours and then again at 24 hours to 
establish the baseline temperature and RH. To establish if a saturated salt solution could 
maintain a relative humidity, the thermo-hygrometer was sealed in the box with a 
saturated solution of calcium chloride (Sigma-Aldrich, St Louis, USA) (5g of calcium 
chloride in 5mls of water) in a 100ml beaker and temperature and humidity readings 
were taken every hour for 8 hours and then again at 24 hours.  
 
 
 
2.11.3 Inoculation of glass coverslips with bacteria 
 
A single colony pick from an overnight growth of each strain that was grown on ISO-
Sensitest agar (Oxoid, Basingstoke, UK) at 37OC was mixed with 10ml BHI broth (Oxoid, 
Basingstoke, UK) and incubated at 37OC overnight. Overnight broth cultures were 
quantified using the Nanodrop (Thermo Scientific, Waltham, USA) for optical density 
(OD) at a wavelength of 600 nm and then diluted to an OD of 0.1. A 1ml aliquot of each 
diluted culture was pipetted into a sterile 1.5ml Eppendorf tube (Eppendorf, Hamburg, 
Germany) and centrifuged at 13,000rpm for five minutes to pellet cells. Supernatant was 
collected and discarded then replaced with 1ml of either water or 3% bovine serum 
albumin (BSA) and re-suspended by vortexing for 30 seconds. BSA was used as 
comparator menstrua to water as it acts as a protective media that has been used 
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previously to represent dirty biological conditions at 3% w/v solution (Kawamura-Sato 
et al., 2008, Tuladhar et al., 2012).   
 
Three UV irradiated glass coverslips per time point were inoculated with 20μl of either 
water or BSA suspended bacteria, giving a total of 36 inoculated coverslips per strain 
that were placed inside a sterile petri dish which was in turn placed in the desiccation 
chamber.  
 
A saturated salt solution of 5g of calcium chloride in 5mls of water was placed in the 
desiccation box and left overnight to establish a controlled RH. Petri dishes containing 
the inoculated coverslips, one petri dish per S. auerus strain, were placed inside the box 
and the calcium chloride solution was replaced with fresh solution. A digital thermo-
hygrometer (Fischer Scientific, Hampton, USA) was placed in the box to monitor 
temperature and RH then the box was sealed. The box was opened at each designated 
time point to remove coverslips for enumeration. Saturated salt solutions were replaced 
each time the box was opened.  
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ISOLATE Sampling Location 
Ciprofloxacin 
sensitivity 
Clinical or screening BHM clade 
CT124 Birmingham  Sensitive Unknown no 
HK_N5 Hong Kong Resistant Screen no 
KW64± Kuwait Sensitive Unknown no 
A120 Birmingham Resistant Screen yes 
ECMM195 Birmingham Resistant Screen yes 
CT147 Birmingham Resistant Clinical yes 
A901 Birmingham Resistant Screen no 
EMM513 Birmingham Resistant Screen no 
CT300 Birmingham Resistant Clinical no 
EMRSA-15 control - Resistant - no 
MSSA-476  control - Sensitive - no 
Table 14: Isolates included in the desiccation assay. 
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2.11.4 Enumeration of viable bacterial counts 
 
At each time point three inoculated glass coverslips from each strain were removed 
from the desiccation box and were each eluted in separate 2ml volumes of phosphate 
buffered saline (PBS) in a 15ml polystyrene universal (Thermo Fischer Scientific, 
Madrid, Spain) and vortexed for 15 seconds.  
 
Eluents were then appropriately diluted in PBS to allow suitable growth on agar plates 
for enumeration and applied to a spiral plater (Don Whitley Scientific, Shipley, UK) 
which deposited bacterial solutions onto ISO sensitest agar using a 50μl log deposition 
in a concentric spiral from the centre of a round agar dish outwards. The methodology 
was altered over time to accommodate the reducing number of viable bacteria being 
enumerated. Day 0 to day 14 water suspension viable counts were determined by 
washing each glass coverslip in 2ml (PBS) and application to the spiral plater. This was 
reduced to 1ml eluent with flood plate methodology from day 21 onwards. Flood plates 
had 100μl volumes of eluent deposited directly onto ISO sensitest agar plates and 
spread with a sterile plastic spreader. Due to the slower reduction in bacteria surviving 
in BSA this methodology change occurred at day 35 in the BSA suspension assay with 
time points 0 to 28 being applied to the spiral plater.  
Three replicate plates were spiral plated or flood plated for each coverslip to give a total 
of nine replicates per time point. Agar plates were incubated at 37oC for 24 hours before 
being enumerated using a spiral plate counting grid or total colony counts on flood 
plates. Colony counts for each replicate were recorded and then used to calculate the 
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number of bacteria surviving on each glass coverslip by averaging the values for each of 
the nine replicates.  
 
 
2.11.5 Analysis  
 
 
Standard deviation and standard error were calculated for each time point in water and 
BSA using the respective functions in Microsoft Excel.  
Percentage survival values for each time point were generated by dividing the 
average colony count of nine replicates at each time point by the average colony count 
for time point 0. Area under the curve values were calculated using Microsoft Excel 
using the trapezoidal equation y = f(x).   
P-values were calculated for each time point by comparing the nine colony count 
values of isolates suspended in water to the nine colony counts of isolates suspended in 
BSA using a two-tailed Student’s T test.    
Exponential linear regression graphs were constructed with Microsoft excel and 
had error bars for each time point applied.  
 
Whole genome sequencing data for each isolate was scrutinized for SNPs or indels 
occurring in the core genome that may be linked to desiccation tolerance. A vcf file was 
generated for the eleven genomes investigated using the bioinformatics pipeline 
described in section 2.7.1.1. Fourteen key genes with known stress response or 
desiccation tolerance activity (Table 15) were scrutinized. Validation of SNP position 
and coverage was accomplished by uploading sorted bam files to Artemis comparison 
tool V15.0 and comparison with the EMRSA-15 reference genome annotated GenBank 
file.  
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Gene 
Genomic location in EMRSA-15 
reference genome 
Start Finish 
sodM 124261 124860 
ahpC 397470 398039 
SigH 548176 548745 
spx 937591 937935 
KatE 1309029 1310483 
sodA 1627085 1627684 
clpX 1738081 1739343 
perR 1953517 1953963 
agr 2109592 2109861 
SigB 2148019 2148789 
rsbU 2149691 2150692 
SarR 2366747 2367094 
crtN 2661629 2663137 
crtM 2663149 2664012 
 
Table 15: Genes linked to desiccation tolerance that were investigated for 
mutation at each of the eleven isolate genomes investigated. 
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3 Results 
 
 
3.1 Whole genome sequencing and bioinformatics pipeline validation 
 
 
A total of 317 MRSA isolates sampled across five hospital trusts from the UK, Guernsey 
and Hong Kong were successfully cultured and VNTR typed (Table 8). Two hundred and 
ten of these isolates were determined to be EMRSA-15 with a VNTR profile highly 
related to the EMRSA-15 control strain, with one, zero and two repeats at VNTR loci L1, 
L13 and L7 respectively (Appendix [Table 25]).  
 
 In addition to these sequenced isolates, 227 previously sequenced and published 
genomes from isolates that had been sampled across the UK and around the world 
(Table 10) were downloaded in fastq format and included in all bioinformatics analyses 
(Holden et al., 2013, Reuter et al., 2016).   
 
 
 
3.1.1 Whole genome sequencing results  
 
The two hundred and ten isolates were successfully sequenced to an average coverage 
of 60.10x (range 15.0.x to 428.7x). All isolate DNA sequences were confirmed to have 
sufficient quality for bioinformatics analysis, with quality score of 28 or above using 
FastQC.  
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All sequenced genomes were confirmed as ST22 by being applied to the CGE MLST 
typing server and produced the allelic profile of 7 6 1 5 8 8 6 for the arcC, aroE, glpF, 
gmk, pta, tpi, and yqiL genes respectively.  
 
3.1.2 Bioinformatics pipeline outputs 
 
 
 
The raw fastq files of the 210 sequenced isolates along with the 227 downloaded fastq 
format genomes were applied to the bioinformatics pipeline to give a total of 437 
analysed genomes. Automation of the pipeline was achieved for over 75% of command 
inputs, reducing the chance of error for manual command input and reducing user 
interface time. Twenty five percent of commands could not be automated due to 
programmes not being compatible for piping (linking together).  
 
 Qualimap demonstrated complete read mapping across the reference strain for each 
genome and was used to confirm read coverage. After SNPs arising in MGEs and 
repetitive regions were removed a total of 13293 SNPs were determined from the pileup 
file of the 437 genomes in a vcf.  
 
Consensus sequences for each genome were successfully generated and combined into a 
single multi-fasta and applied to gubbins to determine regions of homologous 
recombination across the dataset. Gubbins converged on a recombination removed 
phylogeny after five iterations and identified 50 recombination blocks of between four 
and 18 SNPs that gave a total of 419 recombinant SNPs in the dataset (3.15% of all 
SNPs). This would indicate homologous recombination across the 437 isolates was low.  
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These recombinant SNPs were removed from the MGE and repetitive region clean vcf 
(containing 13293 SNPs) to give a total of 12874 core SNPs across 437 genomes.  
 
 The 12874 SNPs in the vcf file were concatenated to a multi-fasta file and applied to 
RAxML which successfully generated a ML tree with 500 bootstrap iteration values 
applied to it (Figure 6). Bootstrap values ranged from 0 to 100, with over 80% of values 
ranging from 50 to 100 (mode 100).  These high ranges of bootstrap values are 
indicative of a robust phylogenetic reconstruction, meaning the tree produced by the 
pipeline would be appropriate for application to path-o-gen for determination of 
molecular clock rate (Section 3.1.3.1).  
 
The pipeline developed was compared to five pipelines that have been recently used to 
analyse MRSA WGS (Holden et al., 2013, Reuter et al., 2016, Hsu et al., 2015, Aanensen et 
al., 2016, Harris et al., 2010). Different programmes and methodologies were used for all 
key steps with the exception of phylogenetic tree reconstruction (Table 16). The 
application of Bayesian phylogenetics to generate time linked phylogenetic trees was 
also only applied in two other studies (Holden et al., 2010, Hsu et al., 2015) investigating 
ST22 epidemiology in the past five years but also used different models for tree 
construction compared to this study.  
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Figure 6: Maximum likelihood (ML) phylogenetic tree of the 437 genomes 
included in the study. Bootstrap values are displayed at each node of the tree in 
blue.
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Table 16: Comparison of programmes and parameters used in bioinformatics pipelines applied to MRSA WGS studies. Harris et 
al 2010 did not analyse EMRSA-15 genomes but is included as Holden, Aanensen and Reuter papers use SNP calling parameters 
outlined in this study. *Publications included non ST22 isolates. Information displayed is relevant to ST22 isolate analysis.
Process This Thesis 
Reuter et al 
2016* 
Aaenensen et 
al 2016* 
Hsu et al 2015* 
Holden et al 
2013  
Harris et al 2010 
Isolates/Genomes 
Number  437 783 41 87 193 43 
Locations Global UK Europe Singapore Global Global 
Sequencing 
Platform Illumina MiSeq Illumina HiSeq 
Illumina 
Genome 
Analyser GAII, 
Illumina HiSeq 
Illumina 
Genome 
Analyser GAII, 
Illumina HiSeq 
Illumina 
Genome 
Analyser GAII, 
Illumina HiSeq 
Illumina Genome 
Analyser GAII 
Reads (bp) 2x 150bp 100bp 54bp, 75bp Not stated. 54bp, 75bp 54bp 
Mapping 
Programme  BWA SSAHA SSAHA SMALT SSAHA SSAHA 
Reference 
genome 
HO 5096 0412 HO 5096 0412 HO 5096 0412 HO 5096 0412 HO 5096 0412 TW20 
Variant calling 
Programme  
VarScan, 
bcftools 
SSAHA SSAHA Samtools SSAHA SSAHA 
SNP threshold 
 10x coverage, 
min 2 supp. 
reads.  
Quality score 
>30 
Quality score 
>30 
Read depth 5, 
SNP score >60 
Quality score 
>30 
Quality score >30 
Recombination 
removal 
- Gubbins N/A N/A Gubbins 
Manually 
removed. 
N/A 
Phylogenetics 
Programme RAxML RAxML 
FastTree, 
RAxML 
RAxML RAxML RAxML 
Method GTR GTR Not stated. GTR GTR GTR 
Bayesian 
Inference 
- BEAST N/A N/A BEAST BEAST N/A 
Model 
Relaxed clock 
constant 
population 
- - 
Relaxed clock 
skyline 
population  
Relaxed clock  - 
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3.1.3 Bayesian analysis results  
3.1.3.1 Path-o-gen results 
 
The phylogenetic tree produced in section 3.1.2 was applied to the BEAST platform 
programme Path-o-gen to determine the molecular clock rate of the dataset, Figure 7 
shows each isolate in the tree’s root to tip divergence against time. A scatter plot of each 
of the 437 isolates distance from the strict molecular clock (Appendix [Figure 30]) was 
used to determine cut offs for isolates displaying fast or slow evolutionary rate relative 
to a strict clock. Isolates falling out with a normal distribution (beyond residual values of 
plus or minus 2.0E-3) from the strict molecular clock line were considered outliers. 
These cut off points were applied to Figure 7 as dotted lines above and below the solid 
strict molecular clock line.  Figure 7 shows eighteen isolates above the upper dotted line 
(displaying a fast rate of evolution) and fourteen isolates below the lower dotted line 
(displaying a slower rate of evolution) compared to the strict molecular clock line. None 
of these outlier isolates showed poor mapping or irregular sequences and did not cluster 
together but were randomly distributed throughout the tree as displayed in figure 8. 
The remaining 411 isolates were within acceptable distance of the clock rate line to be 
considered to have a stable evolutionary rate. Due to a low number of outlier isolates 
(n= 26, 5.9% of isolates) the rate value of 3.11628E-4 produced by Path-o-gen was 
considered acceptable as a rate input value for BEAST and that a relaxed molecular clock 
would be appropriate for BEAST analyses.  
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Figure 7: Plot of root to tip divergence values for each isolates in the tree against time. The solid black line represents a strict 
molecular clock rate. Isolates above the line have a faster divergence rate that the fixed molecular clock and isolates below the 
line have a slower divergence rate. Dotted lines indicate the normal distribution cut off points, with isolates between the 
dotted lines being within the normal distribution. 
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Figure 8: ML phylogenetic tree identifying outlier isolates with fast or slow evolutionary rate. Branches in black fit to a strict 
clock model. Branches coloured red have evolved slower than the fixed clock rate and branches colored blue have evolved 
faster than the fixed clock rate.
  
102 
 
 
3.1.3.2 Bayesian Inference  
 
 
An aligned fasta file of 12874 SNP sites that excluded SNPs in MGEs and 
repetitive regions or those arising by homologous recombination was applied to BEAST 
to generate .tree and .log files for MCC tree generation and quality analysis.  
 
Run combinations including exponential clock models or Bayesian skyline population 
models failed to converge and were discarded, therefore leaving runs consisting of strict 
and relaxed lognormal clock models with constant, exponential or expansion population 
models. All model combinations were confirmed to have converged by having effective 
sampling size (ESS) values greater than 200 and demonstrating “hairy caterpillar” traces 
(Figure 9).  
 
Bayes factor test was used to determine the model that best fit the dataset (Table 17). 
The model combination with the best fit was a relaxed clock model with a constant 
population model due to it having the lowest aimc value, and was subsequently chosen 
for all further analyses.  
 
.tree files for the three independent runs of the lognormal relaxed clock with a constant 
size population model were successfully combined and applied to the Tree Annotator 
1.8.1 programme to produce an MCC tree for phylogenetic analysis. 
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Figure 9: Example "hairy caterpillar” trace from one of the triplicate 
relaxed clock with constant population size models. White shaded area at 
the beginning of trace shows a 10% burn in at the beginning of the MCMC.
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Table 17: Table of Bayes factor test results comparing each convergent BEAST run to each other. Lower AIMC values indicate a 
better fit of the model to the dataset. Positive values indicate better relative fit of the rows model compared to the columns 
model. 
Run AIMC 
Relaxed 
constant 
Relaxed 
expansion 
Relaxed 
exponential 
Strict 
constant 
Strict 
expansion 
Strict 
exponential 
Relaxed constant 172204.523 - -8.755 -8.252 495.971 475.469 469.602 
Relaxed expansion 172213.278 8.755 - 0.503 504.726 484.224 478.357 
Relaxed exponential 172205.026 8.252 -0.503 - 504.223 483.721 477.854 
Strict constant 172709.249 -495.971 -504.726 -504.223 - -20.502 -26.369 
Strict expansion 172688.748 -475.469 -484.224 -483.721 20.502 - -5.868 
Strict exponential 172682.88 -469.602 -478.357 -477.854 26.369 5.868 - 
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3.1.3.2.1 Birmingham isolate MCC tree generation  
 
To examine the phylogeny of EMRSA-15 in Birmingham in more detail, an additional 
MCC tree consisting of only isolates sampled from Birmingham (n = 181) was generated 
using BEAST. A fasta file of 5082 SNP sites was applied to BEAST and as with the BEAST 
run of the international collection in section 3.1.3.2 run combinations using exponential 
clock models or Bayesian skyline population models failed to converge. A lognormal 
relaxed clock with a constant size population model was also the best fit model using 
Bayes factor test.  
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3.2 The phylogeny of EMRSA-15  
 
3.2.1 Evolutionary rate of EMRSA-15  
 
 
The mean evolutionary rate for the core genome was determined to be 1.38 x 10-6 (95% 
Bayesian credibility intervals 1. 29x10-6 to 1.49 x10-6) substitutions per nucleotide site 
per year.  
 
3.2.2 The phylogeny of EMRSA-15 
 
An MCC phylogenetic tree of 437 EMRSA-15 isolates was successfully generated by 
BEAST (section 3.1.3) and is displayed in Figure 10.  
 
3.2.2.1 Evolution of ciprofloxacin resistance  
 
 
A distinct phylogeny in respect to ciprofloxacin susceptibility was evident. The single 
ciprofloxacin sensitive historical CHB isolate clustered with the nine other ciprofloxacin 
sensitive genomes (from Holden et al 2013) at the base of the MCC tree (dotted box in 
Figure 10) and were separate from the 427 ciprofloxacin resistant genomes. This is 
highly consistent with the previous study that the ciprofloxacin sensitive genomes were 
sourced from (Holden et al., 2013) despite using a different bioinformatics pipeline to 
determine SNPs in the core genome and a different Bayesian analysis model for MCC 
tree generation (Table 14).  
 The historical CHB isolate from c1985 (isolate CT124 [Table 25]) was the second 
most basal isolate on the tree and sat on a single branch that emerged in 1975 (95% 
Bayesian credibility intervals 1971.12 to 1978.9), two years before the larger cluster of 
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eight UK sampled ciprofloxacin sensitive isolate branches (diverged in 1977 [95% 
Bayesian credibility intervals 1974.47 to1981.57]) and nine years before the evolution 
of ciprofloxacin resistance. The CHB isolate was 43 SNPs from the nearest common 
ciprofloxacin sensitive ancestor node and 52 SNPs from the first reported EMRSA-15 
genomes that were sampled from Birmingham six years after the historical CHB isolate.  
 
Both the CHB historical isolate and the isolate directly basal to it lacked the deletion in 
the ureC gene that causes non-production of urease. This was determined indel 
identification with VarScan (position 2362301 G to GT indel) and manual inspection 
with Artemis. 
 
 All of the 427 ciprofloxacin resistant isolates clustered to a single large clade that 
emerged from the ciprofloxacin sensitive cluster on a single branch in approximately 
1984 (95% Bayesian credibility intervals 1979.14 to 1985.14). The three isolates 
sampled from East Birmingham, where HEFT is located, between 1991 to 1992 
(Richardson and Reith, 1993) were most basal isolates within the large ciprofloxacin 
resistant clade (Figure 10). This is again consistent with data from Holden and 
colleagues (Holden et al., 2013).  Considerable diversity was evident within the 
ciprofloxacin resistant clade. Four hundred and twenty isolates were distributed across 
two branches that that emerged in 1985 (95% Bayesian credibility intervals 1983.9 to 
1987.4) and 1986 (95% Bayesian credibility intervals 1985.6 to 1988.4) respectively.  
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Figure 10: Maximum clade credibility (MCC) tree of the global EMRSA-15 population sampled between 1985 and 2015 
coloured by sampling location. Branch tips are constrained by sampling time and time scale is displayed along the bottom (x 
axis). Colour legend at top left of figure. Ciprofloxacin sensitive isolates are highlighted in a dotted box at the base of the tree.
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Loca+on	 Colour	
Birmingham		 	
UK		 	
Guernsey	 	
Europe	 	
Australia	 	
Singapore	 	
Hong	Kong	 	
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3.2.3 Global EMRSA-15 phylogeny  
 
 
Substantial clustering of genomes based on country of sampling was evident. Non-UK 
genomes resolved to similar positions on the MCC tree as detailed in the analysis by 
Holden et al (Holden et al., 2013) despite the inclusion of additional UK genomes.  
Clusters of German, Portuguese, Czech republic and Singaporean genomes were evident 
with each of these international isolate clusters (with the exception of Hong Kong) 
having isolates from the UK directly basal to their clusters (Figure 14) (Table 18). Of 
note, a single Guernsey sample was directly basal to the cluster of nine Portuguese 
genomes. Fourteen of the isolates from Hong Kong clustered together and arose from 
the Singaporean cluster (section 3.2.3.1). This was the only cluster of international 
isolates that did not have UK isolates located directly basal.   
 
Region specific clustering of isolates to specific branches of the MCC tree was also 
evident with the Birmingham and other UK source genomes. A large cluster of 
Birmingham genomes was evident at the distal end of the tree (section 3.2.3.3) with 
additional smaller clusters displayed throughout the tree (section 3.2.4).  
 Twelve clusters of UK genomes, excluding Birmingham sampled isolates, 
comprising between three and 11 genomes grouping to single branches of the MCC tree 
were evident. Four of these branches comprised solely of isolates from the West 
Midlands (Reuter et al 2016) each of which had sequenced Birmingham genomes 
directly basal to each cluster. Two branches of mixed West Midlands and Birmingham 
isolates were evident, while the remaining eight branches of mixed UK locations 
comprised of Holden et al 2013 and Reuter et al 2016 genomes only.  
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3.2.3.1 Hong Kong  
 
All 14 of the Hong Kong isolates clustered to a single branch of the MCC tree 
(Figure 10 and Figure 11) and showed evidence of hospital specific clustering. Eight 
temporally and geographically linked nasal screening isolates from neonatal wards at 
two hospitals (Appendix (Table 25)) clustered closely together with an average pairwise 
distance of 2 SNPs (range 0 to 4) suggesting these are highly related to each other.  Five 
blood culture isolates from four hospitals were located on the same branch but were 
more distantly related both to each other and the linked screening isolates and had an 
average SNP distance of 36 SNPs (range 32 to 37). The blood culture isolate closest to 
the node containing all of the linked nasal screening isolates was distinguishable by 22 
SNPs suggesting the blood culture isolates share a common ancestor but are more 
distantly related to the screening cluster. Overall, the average pairwise distance of all the 
14 Hong Kong isolates to each other was 22 SNPs. 
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Country 
Number of 
isolates in 
cluster 
Location of basal UK isolates 
(Collection) 
SNP distance to 
nearest common 
ancestor 
Germany 35 Norfolk (Holden et al 2013) 24 
Portugal  9 Guernsey  36 
Czech republic 5 
Shrewsbury, West Midlands 
(Reuter et al 2016) 
36 
Singapore 6 UK South East (Reuter et al 2016)  25 
 
Table 18: Clusters of internationally sourced isolates with the UK isolates basal to 
each.  
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The branch containing all of the Hong Kong isolates emerged in 2002 (95% 
Bayesian credibility intervals 2001.0 to 2003.9) from a group of six Singaporean 
isolates. The Singaporean isolates were from between 2004 and 2007 and had 
divergence dates ranging from 1999 to 2002 (total range 95% credibility intervals 
1998.1 to 2004.8). The SNP distance between the Hong Kong node and the closest 
Singaporean isolate was two SNPs therefore indicating that a transmission event from 
Singapore to Hong Kong between 1998 and 2004 was highly likely.  
 
3.2.3.2 Guernsey  
 
The 21 isolates from Guernsey demonstrated a mixed population of highly 
related and more sporadically distributed isolates.  
Ten of the 21 isolates from Guernsey (43%) clustered to a single branch on the 
tree that diverged in 1998 (95% Bayesian credibility intervals 1996.5 to 2000.7) (Figure 
10 and Figure 11). This cluster included seven of the twelve isolates sampled from the 
ITU at PEH, the only acute hospital trust on Guernsey, between 2006 to 2010 and had an 
average pairwise SNP distance of 7 SNPs (range 3 to 12). An additional three 
contemporaneous Guernsey isolates from 2014 to 2015 that were sampled from PEH 
inpatient wards (not ITU) also grouped to the branch but had had an average pairwise 
SNP distance of 87 SNPs (range 84 to 94) indicating they are less closely related to each 
other and to the ITU clustered isolates. The closest isolate to the branch containing the 
ten Guernsey isolates on the MCC tree (Figure 11) was a UK isolate sampled from 
London that was 23 SNPs from the Guernsey branch node.  
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The remaining 12 Guernsey sampled isolates did not cluster to the single branch 
described above. Five contemporaneously sampled isolates from PEH inpatient ward 
that were not linked in space and time grouped together to a single branch on the tree, 
with an average pairwise distance of 70 SNPs (range 6 to 102), next to two UK West 
Midlands (Coventry and Warwickshire) sampled isolates that were 24 SNPs from the 
nearest common ancestor. The remaining seven Guernsey isolates were sporadically 
distributed with UK genomes and showed no specific clustering with each other. This 
would indicate a population structure in Guernsey that comprises of a dominant local 
lineage alongside sporadic strains that are more related to UK mainland isolates.  
 
3.2.3.3 Birmingham isolates and their relationship to UK/Global phylogeny  
 
 
Out of the total 427 ciprofloxacin resistant genomes in the global phylogeny 94 
grouped to a large clade on a single branch at the distal end of the tree. This clade 
contained isolates sampled between 2002 and 2015 from all three Birmingham hospital 
trusts and two isolates from Coventry (West Midlands, UK) (Figure 10). All isolates 
within the cluster appeared to belong to a single EMRSA-15 sub-lineage, due to their 
evolution from a single branch of the tree, which diverged in approximately 1995 (95% 
Bayesian credibility intervals 1994.1 to 1997.5).  The average pairwise distance of all 
isolates in the clade was 72 SNPs, indicating a high degree of relatedness within the 
clade. This sub-lineage was subsequently named the BHM clade due to 98% of isolates 
within the clade being sampled from Birmingham and no genomes sampled from the 
rest of the UK or any other global sampling locations resolving to within the clade. 
Within the BHM clade there was evidence of further clustering with isolates being 
  
114 
 
distributed across two sub-lineages and evidence of localized evolution with 
epidemiologically linked isolates (section 3.2.4).  
The 97 Birmingham genomes that did not group to the BHM clade were 
distributed throughout the rest of the tree amongst the UK and international genomes 
however small scale clustering events occurred. Eight clusters of between three and 17 
Birmingham genomes that grouped to single branches were evident. The largest of 
cluster comprising of 17 genomes that were sampled between 2002 and 2015 grouped 
to a single branch that diverged in 1991 (95% Bayesian confidence intervals 1988.47 to 
1994.97) positioned at the centre of the tree and was the largest grouping of 
Birmingham isolates outwith the BHM clade. Of these eight Birmingham clusters 
(outside of the BHM clade), three had West Midlands and five had UK sampled isolates 
basal to the single branches containing each of the clusters.  
 
Thirty three Birmingham isolates (17%) were sporadically distributed 
throughout the tree and did not show major clustering or branching with other 
Birmingham isolates.  Nineteen of these isolates had a West Midlands genome as the 
closest related isolate, nine had a UK isolate and five had a European sampled isolate as 
the closest related isolate.  
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Figure 11: Branch of the MCC tree in Figure 6 containing the Hong Kong (pink), Singapore (yellow) and Guernsey cluster 
isolates (teal). Isolates from the UK are coloured dark blue and denoted with black arrows. 
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3.2.4 Birmingham Phylogenetic structure 
 
 
An MCC phylogenetic tree consisting only of isolates from Birmingham (n = 188) was 
created with BEAST and coloured by sampling hospital (Figure 12). There was no 
evidence of hospital specific phylogenetic structuring with isolates from all three 
hospitals being distributed throughout the tree. Six small clustering events occurring 
between 2010 and 2015 (ranging between four and 11 isolates) that were positioned at 
the end of long single branches were evident. Three of these clusters were from the 
hospital with the greatest number of isolates (HEFT), two were from QEHB and a sixth 
cluster was formed of isolates from all three hospitals. Where possible epidemiological 
data linked isolates in these clusters in space and time. This included six isolates 
sampled from a period of increased incidence (PII) occurring on a stroke unit at HEFT 
over a period of 35 days (cluster 5 in Figure 12) and four screening isolates from a 
neurosurgery ward over 18 days from QEHB (cluster 4 in Figure 12). Notably the cluster 
of 17 isolates (cluster 2 in Figure 12) was not only the largest cluster but was the only 
post-2010 cluster to contain isolates from all three hospitals therefore indicating 
possible transmission between the Birmingham hospitals. The topology of these closely 
related clusters at the end of long single branches post 2010 may be indicative of more 
localized evolution of EMRSA-15 since the reduction in MRSA burden between 2001 to 
present in the UK.  
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Figure 12: MCC tree of genomes from Birmingham hospitals only. Each branch tip is constrained by sampling date with the time 
scale displayed on the x axis. Branches are coloured by their sampling hospital and figure legend is displayed in the top left of 
the diagram. Clusters of isolates demonstrating localized evolution are displayed in dashed boxes. 
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The BHM clade contained 91 (52%) of the Birmingham sampled genomes and the 
constituency of the BHM clade changed with time. In 2002 only 17% of Birmingham 
genomes were found in this clade, whereas from 2003 onwards it constituted greater 
than 48% of sampled isolates for each year there were isolates available (no isolates 
were sourced from Birmingham between 2008 to 2012). Due to lack of isolates available 
from the QEHB or City Hospital pre dating 2012 the movement of the BHM strain 
between hospitals cannot be evaluated, however branches of QEHB or city isolates 
showed divergence dates in 2000 and 2002 respectively. These branches diverged from 
clusters of HEFT isolates suggesting spreading from HEFT to QEHB and CHB populations 
shortly after the strain emerged, indicating possible transmission from HEFT to QEHB 
and CHB during this time.  
 
3.2.4.1 SNP analysis of BHM clade isolates  
 
All of the BHM clade DNA sequences were scrutinized for SNPs and indels that were 
present in every BHM clade genome that may distinguish the clade from the rest of the 
EMRSA-15 population or may provide an evolutionary fitness advantage.  
Twelve SNPs and two indels were identified that differentiated the BHM clade to 
all other EMRSA-15 genomes (Table 19a and 19b). Seven of these SNPs were unlikely to 
impact on the fitness of the BHM clade due to three of them being synonymous 
mutations, three were intergenic and another was in a pseudogene that does not code 
for a functional protein. Five of the 12 SNPs were non-synonymous however two were in 
hypothetical proteins and are therefore difficult to infer any change to ecological fitness. 
The three remaining SNPs were in the genes for malate:quinone oxidoreductase 1 
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(mgo1), putative amino acid permease (pmh) and the DNA supercoiling gene 
topoisomerase IV subunit B (grlB). The amino acid change in mgo1 was from alanine to 
valine which are both nonpolar amino acids and therefore unlikely to change protein 
structure. The amino acid change in pmh was from arginine to glutamic acid, basic to 
acidic amino acids, and in grlB was from proline to serine, nonpolar to polar, suggesting 
both of these mutations could cause structural changes to the proteins they code for.  
 
An additional five isolates from MRSA bacteraemias in the West Midlands (two 
from Coventry and three from Shrewsbury) located directly basal to the BHM clade and 
had nine of the 12 identified SNPs including the five non-synonymous mutations. These 
SNPs were however included as distinguishing features of the BHM clade due to the 
sampling location and basal topology of these West Midlands genomes on the 
phylogenetic tree (Figure 13).  
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Figure 13: Enhanced region of the BHM clade and basal West Midlands isolates from the MCC tree in figure 5. The BHM clade is 
denoted in the dotted box. The evolution of the grlB mutation is depicted with a star and dotted line, with all isolates beyond 
this dotted cut off in the tree possessing the grlB mutation.
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Table 19a: SNPs that distinguish the BHM clade from the rest of the EMRSA-15 population. Genes located on the reverse DNA 
strand are in blue. * Protein is truncated and non-functional in EMRSA-15 due to non-sense mutation in gene (Holden et al 
2013). 
 
 
Position  Type Location Product ID (Genbank) Alternative Reference 
260331 Deletion CDS Putative PTS transport system, IIC component SAEMRSA15_02060 TA T 
2820060 Insertion CDS ABC transporter ATP-binding protein SAEMRSA15_26000 C CA 
 
Table 19b: Indels that distinguish the BHM clade from the rest of the EMRSA-15 population.
Position SNP Type 
Amino acid 
change Coding Sequence GenBank ID 
1184872 T to A Intergenic - - - 
1184877 C to T Intergenic - - - 
1334149 C to T Non-synonymous Pro 453 Ser topoisomerase IV subunit B (grlB) SAEMRSA15_12020 
1433441 G to A Pseudogene - ebh* SAEMRSA15_12970 
1679948 G to T Intergenic - - - 
2352714 G to A Synonymous - putative molybdenum transport system permease  SAEMRSA15_21760 
2442618 G to A Non-synonymous Ala 132 Val putative malate:quinone oxidoreductase 1 (mgo1) SAEMRSA15_22660 
2515404 G to A Non-synonymous Ala 50 Val hypothetical protein SAEMRSA15_23310 
2538962 G to A Non-synonymous Arg 323 Glu putative amino acid permease (pmh) SAEMRSA15_23500 
2732101 G to A Synonymous - sensor kinase protein SAEMRSA15_25280 
2758770 C to T Synonymous - hypothetical protein SAEMRSA15_25490 
2759407 G to A Non-synonymous Asp 300 Ile hypothetical protein SAEMRSA15_25490 
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3.2.4.2 Pan genomic analysis  
 
Nullarbor identified 328 genes present in all 91 BHM genomes, 69 of which were 
hypothetical. All of the remaining 259 genes were also identified in genomes out with 
the BHM clade, suggesting MGEs do not play a role in the success of the BHM lineage.  
 
3.3 Comparison of EMRSA-15 diversity using WGS and VNTR 
 
3.3.1 VNTR profiles  
 
 
 Forty two distinct VNTR profiles were identified from the 210 EMRSA-15 isolates. VNTR 
profile 1 2 0 3 17 – 2 was the most predominant (73 isolates, 34.8%) followed by 1 4 0 3 
17 – 2 (38 isolates, 13.3%) and 1 3 0 3 17 – 2 (25 isolates, 11.9%). Twenty-nine VNTR 
profiles were only represented by single isolates. 
 
 
 
3.3.2 Application of VNTR data to the Birmingham phylogeny  
 
VNTR data for loci 13 and 21 were applied to the Birmingham MCC phylogeny (Figure 
14). Locus 13 showed concordance with the MCC phylogeny in respect to the BHM clade. 
All isolates with 2 tandem repeats at loci 13 grouped to the BHM clade whereas isolates 
with 3,4 or 5 tandem repeats at locus L13 were distributed throughout the other 
branches of the tree. Therefore VNTR typing was able to identify the BHM clade with 
100% concordance at locus 13. Locus 21 showed more variable mapping in relation to 
the Birmingham phylogeny and was concordant with WGS for closely related or known 
epidemiologically linked isolates. The first reported EMRSA-15 genomes were also 
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included in the phylogenetic tree, however no VNTR data could be generated for these 
genomes due to only the public genomes and not isolates being available for analysis.  
 
In addition to the SNPs and indels in Table 19, all 91 isolates in the BHM clade 
were found to have a small unmapped region of 67 bases at the genomic location of 
VNTR locus 13 which was absent in all other genomes in the study, thereby further 
differentiating the BHM clade from the rest of the EMRSA-15 population.  
 
3.4 SNP and VNTR comparative analysis 
 
 
The 210 isolates that were WGS SNP typed and VNTR typed (Table 7) were analysed for 
relationships between SNPS, LVs and STRD. All versus all SNP distance was compared to 
the number of locus variants (LV) and STRD separately in Figure 15 and Figure 16 
respectively. All versus all SNP distance showed a range from zero to 196 SNPs between 
paired isolates. No isolates varied at more than two loci (LV of 2) and STRD values 
ranging from zero to 14.  
 The number of SNPs differentiating each LV showed similar ranges and each LV 
value showing similar distribution of isolates with bigger circles (more isolates) 
between 50 and 100 SNP discrimination (Figure 15). SNP and STRD comparison showed 
a small decrease in range of SNPs that differentiated increasing STRD, with an STRD of 
one ranging from 0 to 196 SNPs and an STRD of 14 ranging from 14 to 150 SNPs (Figure 
16).  
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Figure 14: Circularized MCC tree of Birmingham EMRSA-15 isolates with the number of tandem repeats at VNTR locus L13 
(inner ring) and locus L21 (outer ring) for each isolate concentrically displayed. Number of repeats are represented by 
different colours and described in the figure legend in the top right of diagram. The BHM clade is highlighted by a shaded 
box (left side of diagram). Branch lengths are not to scale. 
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Figure 15: Bubble chart of SNPs between locus variants (LV) amongst the 210 
WGS and VNTR typed EMRSA-15 isolates. Increasing bubble size represents 
increasing number of isolates. 
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Figure 16: Bubble chart of SNPs between STRDs amongst the 210 WGS and VNTR 
typed EMRSA-15 isolates. Increasing bubble size represents increasing number of 
isolates.
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3.5 The relationship between phylogenetic structure and fluoroquinolone use in 
Birmingham  
 
 
3.5.1 Antibiotic usage, occupied bed days and bacteraemia rate at HEFT 
3.5.1.1 Occupied Bed days 
 
The number of occupied bed days remained stable between 2001 and 2006 (SD 5431.18 
OBDs) then rose by 175583 OBDs (46% increase) from 383077 OBD to 558660 OBD in 
2007 due to the merger of Good Hope Hospital into the Heart of England Foundation 
trust (Figure 17). From 2007 to 2015 OBDs, continued to remain relatively stable (SD 
21653.58) over time.  
 
3.5.1.2 Antibiotic prescription at HEFT 
 
Antibiotic prescription data was evaluated as defined daily doses (DDD) rather than 
DDD/OBDs due to the lack of OBD data predating 2001 and a stable OBD rate (excluding 
the inclusion of Good Hope Hospital). Fluoroquinolones, macrolides and 3GCs each had 
different usage patterns across the 25-year timeframe from 1990 to 2015.  Between 
1998 and 2008 fluoroquinolone drugs were the most frequently used of the three 
classes of antibiotic, being replaced by macrolides from 2008 onwards, while 3GC usage 
remained at a low level between 1991 and 2015. Individual drug use within each class 
varied and generated a different proportion of each drug class total (Figures 18 to 21). 
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Figure 17: Occupied bed days (OBD) at Heart of England Foundation Trust 
between 2001 and 2015. * Rise in OBD in 2007 is attributed to the merger of Good 
Hope Hospital into the HEFT trust.
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Figure 18: Defined daily doses of fluoroquinolones (red), macrolides (blue) and 
third generation cephalosporins (green) between 1990 and 2015 at HEFT.  
 
Figure 19: Use of ciprofloxacin (red), levofloxacin (green) and ofloxacin (blue) at 
HEFT between 1990 and 2015. Total fluoroquinolone use is represented by a 
dashed black line.
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Figure 20: Use of ceftazidime (red), ceftriaxone(green) and cefotaxime (blue) at 
HEFT between 1990 and 2015. Total 3GC use is represented by a dashed black 
line. 
 
Figure 21: Use of clarithromycin (red) and erythromycin (blue) at HEFT between 
1990 and 2015. Total macrolide use is represented by a dashed black line.  
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3.5.1.2.1 Fluoroquinolones  
 
 Total fluoroquinolone antibiotic usage showed a variable rate between 1990 and 
2015 with rapid increase when the second generation drugs levofloxacin and ofloxacin 
became available (Figure 19).  
 In 1990 no quinolones were used in HEFT, with ciprofloxacin being introduced in 
1991, ofloxacin in 1998 and levofloxacin in 2002. Ciprofloxacin usage increased 
gradually from 1991 to 1998 and then further increased to peak usage at 44859 
DDD/year in 2006. Following 2006 there was a gradual decrease in ciprofloxacin usage 
until 2010. In contrast ofloxacin and levofloxacin usage increased sharply after their 
introduction to peak usage in 2002 and 2003 respectively. Changes in antibiotic 
prescribing policy were reflected in the fluoroquinolone antibiotic prescription data, 
with a switch from ofloxacin to levofloxacin in 2003 and reduced use of levofloxacin 
from 2004 to 2007. Between 2010 and 2015 total use of fluoroquinolones has gradually 
increased by an average of 3008 DDD/year due to increase in ciprofloxacin and 
levofloxacin (increasing annually by an average of 1485 and 1108 DD/year 
respectively). Ofloxacin use declined between 2010 and 2015 by an average of 694 
DDD/year to an all time low usage of 1446 DDD/year in 2015.  
  
3.5.1.2.2 Third generation cephalosporins 
 
Use of third generation cephalosporins remained at relatively constant low usage 
between 1990 and 2015 (minimum and maximum of 196 DDD/year and 13324 
DDD/year in 1991 and 2004 respectively) and had the least frequent usage of the three 
drug classes investigated (Figure 18 and Figure 20). Between 1990 and 2014 
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ceftazidime was the most frequently used cephalosporin. In 2015 ceftriaxone replaced 
ceftazidime as the most frequently used drug, having steadily increased in use since 
2003. Over the 25 years cefotaxime remained at low usage, with a reducing trend from 
2004 to 2015.  
 
3.5.1.2.3 Macrolides 
 
Macrolide usage increased annually from 225.5 DDD/year in 1991 to 90556 DDD/year 
in 2015 with an average increase of 3763 DD/year (Figure 21). This increase is mainly 
attributed to the annual increasing use of clarithromycin (average 3363 DDD/year) 
which rapidly increased in usage between 2005 and 2015, possible due to being part of 
the treatment algorithm for community acquired pneumonia.  
 
3.5.1.3 MRSA bacteraemias  
 
MRSA bacteraemia rate fluctuated over time and both mandatory and voluntary 
bacteraemias per year at HEFT are displayed in Figure 22. Voluntary data showed 
annual rates to primarily decreasing between 1998 and 1999, then increase again from 
1999. Mandatory reporting was introduced in 2001 and showed a further increase in 
MRSA rate to a peak of 140 MRSA bacteraemias per year in 2003 followed by a 
reduction then spike again in 2006. From 2006 onwards there was a notable decline in 
bacteraemia rate until 2010 where the rate plateaued until 2015 when the lowest MRSA 
rate was recorded at 13 bacteraemias per year.  
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Figure 22:Annual MRSA bacteraemia rate at HEFT. Mandatory reporting was 
introduced in 2001 and is displayed in red. Data from before 2001 was voluntarily 
reported and displayed in blue. 
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3.5.2 Impact of fluoroquinolone use on the EMRSA-15 phylogeny in Birmingham over 
time  
 
 
In order to further understand the evolution of EMRSA-15 in Birmingham the impact of 
fluoroquinolone use on the phylogenetic structure of the Birmingham MCC tree was 
investigated by pairing the time linked Birmingham phylogeny with HEFT annual 
fluoroquinolone data (Figures 22 and 23). Only fluoroquinolone prescription and not 
3GC or macrolide prescription was chosen for analysis due to a concordant pattern and 
a positive Pearson’s correlation of 0.65 and being obtained between annual MRSA 
bacteraemia and total fluoroquinolone usage at HEFT (Figure 23). Negative correlations 
of -0.32 and -0.84 were observed between bacteraemias and total use of third 
generation cephalosporins and macrolides respectively. 
 
The EMRSA-15 population in Birmingham demonstrated a linked relationship of 
increasing diversity with the increasing use of fluoroquinolones over the 25 year time 
period but has also established that the early evolution of EMRSA-15 occurred before 
fluoroquinolones were introduced at HEFT.  
 Figures 23 and 24 demonstrate that the early evolution of EMRSA-15 occurred 
before the introduction of ciprofloxacin in 1991. Our global MCC tree has demonstrated 
EMRSA-15 to have emerged in 1984 (Figure 10) which was seven years before 
ciprofloxacin was introduced at HEFT (Figure 23). Further evidence of pre-ciprofloxacin 
use evolution can be seen with major branches of the tree developing between 1985 and 
1990 (Figure 14), which continued to evolve post 1991, and account for a large 
proportion of the diversity within EMRSA-15 population in Birmingham.  
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Figure 23: Graph of total fluoroquinolone use (left y axis [blue]) and annual bacteraemias (right y axis [red]) at HEFT.  Key 
dates for EMRSA-15 evolution, new fluoroquinolone drug introduction and IPC screening policy have been annotated with 
coloured triangles and are detailed below the graph.
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Figure 24: Maximum clade credibility (MCC) tree of EMRSA-15 in Birmingham between 1985 and 2015 coloured by sampling 
hospital. Branch tips are constrained by sampling time and time scale is displayed along the bottom (x axis). Fluoroquinolone 
antibiotic use per year between 1990 and 2015 is displayed above the tree. Colour legend for antibiotic usage is located top left 
of figure and the colour legend for the MCC tree is located below with coloured boxes. The historical Birmingham isolate is 
denoted with a star. 
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Between 1991 and 1996 ciprofloxacin use increased from 0 to 9000 DDDs/year, 
increasing by approximately 2000 DDD/year. During this time the diversity of the 
EMRSA-15 population increased as demonstrated in 21 branching events occurring 
between 1991 and 1996 (including the emergence of the BHM lineage containing the 
grlB mutation) compared to 11 branching events before 1991 when ciprofloxacin was 
not being prescribed.  
 From 1996, when ofloxacin was introduced, to 2003, when fluoroquinolone 
usage peaked after the introduction of levofloxacin, there was a 4.5 fold increase in total 
ciprofloxacin usage and three fold increase in EMRSA-15 diversity with 59 branching 
events on the phylogenetic tree, 46 of which occurred within the BHM lineage, over this 
seven year period.  
 Between 2003 and 2010 fluoroquinolone use dropped to an all time low rate and 
branching of the tree was reduced to 21 events (18 within the BHM lineage). During this 
time local and national MRSA hospital infection rates were falling (from the introduction 
of IPC) which may also be accounting for the reduction in branching. 
 Post 2010 the fluoroquinolone rate plateaued and then fluctuated but showed no 
drastic change however 35 branching events occurred between 2010 and 2015 
suggesting localized evolutionary events.  As described in section 3.2.4 this may be 
reflecting the reduced MRSA burden (Figure 22) and increased number of outbreak or 
PII isolates that were included in our isolate collection during this time.  
The effect of IPC policies such as screening of hospital admissions (Figure 23), hand 
hygiene compliance may also have effected the phylogeny of EMRSA-15 in Birmingham, 
however analysis of these impacts are out with the scope of this study.  
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3.6 Desiccation tolerance of EMRSA-15  
 
3.6.1 Validation of desiccation chamber 
 
The desiccation assay was validated for coverslip sterility, temperature variability and 
humidity variability as these factors could affect the reliability of results.  
3.6.1.1 Sterilization of glass coverslips 
 
 
Quintuple glass coverslips that had been sterilized by either washing with absolute 
ethanol or UV irradiation at 450nm were incubated in BHI broth to test for sterilization 
efficiency. No growth in BHI broth was observed for any of the UV irradiated or ethanol 
washed coverslips or when 100μl inoculations of broth were plated onto CBA at 24 and 
48 hours incubation. Quintuple coverslips that had no sterilization applied to them each 
had cloudy BHI broth culture and a lawn of bacterial growth on CBA at 24 hours. A 
negative control of BHI broth with no coverslips showed no cloudiness or evidence of 
bacterial growth at 24 or 48 hours. From these data UV irradiation was chosen to be the 
method for sterilization of coverslips for the desiccation assay.  
 
3.6.1.2 Temperature and humidity control 
 
The temperature and RH of a single ward at HEFT was tested on three separate days at 
approximately the same time each day (circa 1pm).  Temperature remained stable at 
23.0oC and RH was seen to range from 36% to 46%. 
  
Temperature in the desiccation chamber varied little over the validation time ranging 
20oC to 23.4 oC (SD 0.77) with an average temperature of 21.2 oC (Table 18). The highest 
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temperature value of 23.4oC was recorded when direct sunlight was shining on the 
desiccation chamber. The desiccation chamber was then moved to avoid direct sunlight. 
This demonstrated the temperature in the lab was stable and additional temperature 
control of the desiccation assay would not be required.  
 
RH was recovered over the same validation period of eight hours each day for three days 
but showed greater variation than temperature and ranged from 26.2% to 43.4% (SD 
5.54) (Table 19) with an average of 36.8%.  
 
Maintenance of a stable RH was tested with the addition of a saturated calcium chloride 
solution in the desiccation chamber and recording of RH every hour over eight hours in 
a single day and overnight (+ 16 hours). The RH in the desiccation chamber with the 
addition of the calcium chloride solution showed a more stable RH range of 32.7% to 
33.2% (SD 0.14) compared to when no salt solution was added (Table 19). 
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Day 
Time 
9am 10am 11am 12pm 1pm 2pm 3pm 4pm 5pm 
1 20.0 20.1 20.4 20.4 20.4 20.7 20.7 20.7 20.5 
2 20.6 21.2 21.6 21.6 21.6 21.8 23.4 21.1 21.1 
3 21.5 21.6 21.5 21.4 21.7 21.8 21.4 21.5 21.4 
Table 20: Temperature record of desiccation box over three days. 
 
 
Condition 
Time 
9am 10am 11am 12pm 1pm 2pm 3pm 4pm 5pm 9am (+16h) 
No salt solution 39.6 39.3 35.6 38.1 37.4 34.8 31.9 30.4 32 32.7 
Saturated CaCl2 
solution 
39* 34 33.9 33.0 32.9 32.7 33 33.2 33 30.8 
Table 21: Validation of desiccation chamber RH and CaCl2 salt solutions. * CaCl2 solution was added at 9am. 
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3.6.2 Desiccation tolerance of EMRSA-15 strains suspended in water 
 
Bacterial counts for all isolates suspended in water decreased over time, and after 28 
days no viable bacteria could be detected (Figure 25 and 26).  
 No individual isolate demonstrated an overall ability to tolerate desiccation 
better compared to other isolates when suspended in water, with isolates that initially 
had a greater percentage survival in the first 240 hours showing poorer growth post 240 
hours and vice versa. Rapid reduction in enumerable bacteria was observed in all 11 
isolates at 12 hours post inoculation, however, this varied between isolates and ranged 
from 74.8% (HK_N5) to 15.7% (A901)(Figure 26). By 72 hours all isolates had dropped 
to below 3% survival and by 240 hours all isolates had dropped to below 1% survival. 
No growth was observed at 840 hours for any of the isolates; therefore the maximum 
detectable survival time for isolates suspended in water was 28 days.  
 
Area under the curve (AUC) values for each isolate were calculated from percentage 
survival graphs and detailed in Table 22. Isolate HK_N5 had the highest AUC and the 
flattest linear regression slope for all isolates in the water assay (Figure 27 and Table 
22). Isolate CT300 had the lowest AUC value the steepest linear regression slope when 
suspended in water. CT 300 also consistently had the lowest number of surviving 
bacteria at each time point of the assay, with the exception of 744 hours (where CT124 
had the lowest count).  
 The ciprofloxacin sensitive EMRSA-15 progenitor isolate CT124 showed similar 
desiccation tolerance to the EMRSA-15 isolates when suspended in water. CT124 had 
the second highest AUC values with percentage survival values in the upper quartile 
range of values until 336 hours when viable counts began to rapidly drop. At 672 hours 
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(the last time point bacteria were detected at) CT124 had the lowest percentage 
surviving bacteria. 
 BHM clade isolates displayed higher AUC values compared to non-BHM isolates 
when suspended in water, with the three BHM clade isolate (CT147, ECMM195, A120) 
AUC values ranging from 1627.90 to 2234.72 (average 1900.67) versus the three non-
BHM isolate (CT300, EMM513, A901) AUC values ranging from 1028 to 1689 (average 
1304.33).  
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Figure 25: Spiraled plates of water suspended EMRSA-15 control isolate from day 
1 to day 13. Plates after day 13 looked similar to the day 13 plate and are not 
shown. 
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Figure 26a: Percentage survival of each of the 11 isolates in the assay. Water suspension assays are in blue and BSA suspension 
assays are in red.
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Figure 26b: Percentage survival of each of the 11 isolates in the assay continued. Water suspension assays are in blue and BSA 
suspension assays are in red.
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Isolate 
Area under the curve 
Water BSA 
CT124 2262.26 14197.69 
CT300 1028.52 17126.56 
CT147 1627.80 15536.79 
HK_N5 2462.54 16254.12 
E15-C 1240.00 11929.56 
MSSA-476 1307.37 22530.17 
A120 2234.72 12646.99 
ECMM195 1841.27 16485.82 
EMM513 1689.73 9615.38 
KW-64 1916.37 13373.32 
A901 1196.97 16637.06 
 
Table 22: Area under the curve (AUC) values from Figure 26 for each isolate 
suspended in water or BSA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
147 
 
3.6.3 Effect of protein suspension menstrua on desiccation survival 
 
 
All bacterial isolates suspended in BSA had an statistically significant increased in 
tolerance to desiccation compared to being suspended in water at every time point of 
the assay with the exception of isolate EMM513 at 840 hours (Table 21). Heavy growth 
on agar plates was visible until 168 hours (Figure 27) and the percentage of surviving 
bacteria remained above 50% until 72 hours post inoculation in all isolates (Figure 26). 
The percentage survival of all strains was considerably higher at 12 hours desiccation 
compared to water suspended isolates with a mean of 82.8% survival (range 102% to 
64%); a two-fold increase in survival at this time point compared to water suspended 
isolates (mean 37.3%). All isolates also displayed between 5.7 and 17.2 fold increases in 
AUC values when suspended in BSA (Table 20) and all isolates suspended in BSA had 
linear regression lines with reduced slope gradient (Table 24) compared to water. Ten 
of the 11 isolates showed an increase in maximum survival time to greater than 35 days 
when suspended in BSA; a 25% increase in survival duration. Isolate CT300 showed a 
maximum survival time of 28 days, which was the same duration as when suspended in 
water.  
 
Unlike when suspended in water, the control isolate MSSA-476 showed the highest 
desiccation tolerance when suspended in BSA due to having the highest percentage 
survival of bacteria at every time point in the assay and the highest AUC value. MSSA-
476 had 3.5 fold more bacteria surviving than the EMRSA-15 isolate with the highest 
percentage survival (KW_64) at 840 hours (the last time point for bacteria to be 
detected) as well as the flattest slope gradient of all isolates in the assay.  
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Time 
Isolate 
CT124 CT300 CT147 HK-N5 EMRSA-15 MSSA-476 A120 ECMM195 EMM513 KW64 A901 
0 3.05E-09 5.99E-08 2.33E-08 2.00E-05 6.34E-10 6.89E-07 5.66E-04 1.11E-07 6.64E-11 9.04E-14 2.66E-08 
12 4.43E-07 8.88E-16 7.92E-10 1.52E-09 2.60E-15 2.61E-11 1.99E-04 4.80E-10 6.81E-12 1.78E-11 9.38E-18 
24 1.22E-12 5.65E-09 6.35E-12 1.13E-11 2.44E-11 2.43E-07 1.60E-11 7.59E-15 9.91E-09 2.60E-10 1.82E-09 
48 4.32E-13 2.69E-13 8.95E-13 7.88E-18 7.07E-11 2.10E-13 1.07E-12 3.76E-13 2.67E-10 9.89E-14 2.65E-15 
72 1.41E-13 2.69E-13 1.44E-16 1.38E-14 1.67E-14 3.44E-21 4.72E-09 3.71E-15 1.53E-14 1.25E-16 7.73E-16 
120 1.80E-15 6.40E-12 2.12E-14 5.64E-11 6.91E-10 3.89E-13 4.86E-06 3.29E-16 8.77E-11 1.25E-13 7.24E-15 
168 8.05E-13 1.67E-13 4.23E-06 1.51E-11 1.44E-10 7.00E-11 5.52E-05 1.26E-13 1.40E-13 1.90E-10 2.04E-16 
240 1.719E-12 6.68E-13 4.23E-07 5.07E-09 4.36E-08 9.95E-13 1.27E-07 2.57E-10 1.40E-10 9.00E-07 4.04E-12 
336 1.36E-11 8.59E-10 1.84E-11 6.58E-14 5.79E-10 1.84E-14 5.52E-05 1.72E-15 2.91E-08 1.02E-09 1.13E-13 
504 1.46E-06 1.10E-04 1.13E-07 3.22E-12 2.41E-04 2.86E-07 9.53E-11 9.20E-08 2.41E-05 3.29E-09 7.70E-09 
672 1.12E-02 8.86E-03 7.00E-07 1.24E-06 8.38E-06 1.14E-05 6.70E-10 3.63E-11 1.96E-04 7.92E-11 3.92E-09 
840 2.23E-02 - 1.83E-07 4.85E-03 1.03E-03 4.75E-14 5.47E-08 8.10E-06 7.60E-02 1.35E-07 1.55E-03 
 
Table 23: P-values of statistical significant difference between water and BSA suspensions for each isolate and every time point 
of the desiccation assay. Values in white are below 0.001 statistical significance, blue are below 0.05 statistical significance and 
values in red show no statistical significance.  
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 Isolate A901 displayed the highest desiccation tolerance amongst EMRSA-15 
isolates and isolate EMM513 displayed the lowest desiccation tolerance, instead of 
CT300 in the water assay, when suspended in BSA.  Isolate CT300 showed comparable 
tolerance to other EMRSA-15 isolates but was the only isolate to have no growth at day 
840 hours. 
 CT124 also showed similar desiccation tolerance to ciprofloxacin resistant 
isolates when suspended in BSA. CT124 again showed rapid reduction in viable counts 
after 336 hours and had the lowest percentage surviving bacteria at the end time point 
of 840 hours.  
 Both BHM and non BHM isolates had a greater range of AUC values when 
suspended in BSA (Figure 26 and Table 20) however unlike when suspended in water 
these ranges over overlapped each other. Non-BHM isolates demonstrated both the 
lowest (EMM513) and highest (A901) EMRSA-15 isolate AUC values when suspended in 
BSA (range 9614 to 16637). BHM clade isolates had a reduced range compared to non 
BHM isolates (range 12646 to 16584) however averages for both BHM and non BHM 
clades were similar (14889 and 13792 respectively).  
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Figure 27: Spiraled plates of BSA suspended EMRSA-15 control isolate from day 1 
to day 35. 
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Figure 28a: Linear regression of water (blue) and BSA (red) for each isolates in 
the desiccation assay (continued in pages 149 to 152) 
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Figure28b: Linear regression of water (blue) and BSA (red) for each isolates in the 
desiccation assay continued.  
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Figure 28c: Linear regression of water (blue) and BSA (red) for each isolates in the 
desiccation assay continued.  
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Figure 28d: Linear regression of water (blue) and BSA (red) for each isolates in 
the desiccation assay continued.  
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Isolate 
Regression line equation  
Water BSA 
CT124 y = 2E+09e
-0.02x y = 2E+09e-0.014x 
CT300 y = 5E+08e
-0.02x y = 2E+09e-0.014x 
CT147 y = 8E+08e
-0.018x y = 1E+09e-0.011x 
HK_N5 y = 2E+09e
-0.018x y = 2E+09e-0.012x 
E15-C y = 7E+08e
-0.02x y = 1E+09e-0.013x 
MSSA-476 y = 5E+08e
-0.015x y = 9E+08e-0.008x 
A120 y = 9E+08e
-0.017x y = 9E+08e-0.011x 
ECMM195 y = 1E+09e
-0.02x y = 1E+09e-0.011x 
EMM513 y = 8E+08e
-0.018x y = 8E+08e-0.013x 
KW-64 y = 1E+09e
-0.018x y = 1E+09e-0.01x 
A901 y = 5E+08e
-0.017x y = 1E+09e-0.011x 
 
Table 24: Slope rate of water and BSA for each isolate in the desiccation assay in 
the form y = c +b*x. 
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3.6.3.1 WGS linked analysis 
 
 
SNPs occurring in the core genome of each of the isolates in the assay were scrutinized 
for any possible markers for changes in desiccation tolerance. As detailed previously, all 
of the BHM clade isolates had a SNP in the grlB gene however this did not appear to 
cause any notable changes in desiccation tolerance. No other SNPs were detected in 
genes associated with desiccation tolerance or stress resistance with the exception of 
isolate CT300 which demonstrated a non-synonymous SNP in the crtN gene that 
comprises part of the staphyloxanthin operon. This guanine to adenine (G to A) SNP at 
position 2661949 caused a codon change from GCG to ACG resulting in an amino acid 
change from alanine to threonine. This amino acid change appears to have ablated 
staphyloxanthin activity and is supported phenotypically, as CT300 has pale white 
colonies when grown on ISO sensitest and CBA blood agar (compared to the classical 
golden yellow of S. aureus).   
  
157 
 
4 Discussion 
 
 
4.1 Discussion Introduction 
 
 
The follow section outlines the introduction of the thesis discussion, highlighting areas 
where this research has investigated novel areas. 
 MRSA has a highly clonal population structure consisting of distinct sequence 
types that are endemic or epidemic across different regions of the world. One such 
lineage is ST22 or EMRSA-15; a HA-MRSA clone that is dominant in the UK and is 
currently expanding across Europe, Australia (Coombs et al., 2011, Coombs et al., 2014) 
and into the Middle East (Udo et al., 2014, Udo et al., 2016). As EMRSA-15 continues to 
expand it is important to investigate both its evolutionary history and continuing 
epidemiology and evolution to understand how it has evolved in the past and how this 
will influence its continuing spread across the globe.   
 Previous studies have used WGS phylogenetic analyses to investigate the 
emergence and evolution of EMRSA-15 (Holden et al., 2013) and the national 
epidemiology of EMRSA-15 across the UK (Holden et al., 2013, Reuter et al., 2016). To 
date no study has extensively investigated the phylogeny of EMRSA-15 in the region it is 
proposed to have emerged in (Birmingham and the West Midlands). Here I have 
collected and whole genome sequenced 188 clinical and screening EMRSA-15 isolates 
from three Birmingham hospitals between c1985 and 2015 to give an intensive, long-
time spanning snapshot of the Birmingham EMRSA-15 population. This has not only 
expanded on previous study time frames but has included a single ciprofloxacin 
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sensitive ST22 isolates that was sampled from a West Midlands hospital during the mid 
1980s and is the first study to include any ST22 isolate from this time period. 
   
 The international spread of EMRSA-15 has also been demonstrated in WGS 
studies. EMRSA-15 has been exported from the UK to Germany, Portugal, the Czech 
Republic and Singapore followed by clonal expansion within these countries (Holden et 
al., 2013, Aanensen et al., 2016, Hsu et al., 2015).  
 By combining Birmingham sequenced isolates with 23 and 14 sequenced isolates 
from Guernsey and Hong Kong respectively (the first inclusion of isolates from these 
two location in a phylogenetic analysis) alongside 227 publically available UK and 
international genomes from the Holden and Reuter papers (Holden et al., 2013) (Reuter 
et al., 2016) I have generated a time linked MCC phylogeny of 437 EMRSA-15 genomes. 
At the time of writing this is the largest number of EMRSA-15 isolates used to generate a 
MCC tree and is the longest time spanning Bayesian phylogenetic study of UK and 
internationally sourced EMRSA-15 isolates (1985 to 2015).  
 
 Evidence for the clinical use of fluoroquinolones and the evolution of MRSA has 
been detailed in previous literature. Holden and colleagues have suggested clinical trials 
of ciprofloxacin in the West Midlands led to the emergence of the ciprofloxacin resistant 
EMRSA-15 lineage (Holden et al., 2013) while studies examining MRSA bacteraemia rate 
and fluoroquinolone usage have shown correlation between increasing fluoroquinolone 
use and increasing MRSA infection rate (Charbonneau et al., 2006, Parienti et al., 2011). 
 The data presented here is the first to extensively interlink fluoroquinolone 
prescription data with a phylogenetic reconstruction of EMRSA-15 over time.. This has 
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allowed a comparison of how fluoroquinolone usage and phylogenetic diversity in a 
single hospital has changed over a 25 year period identifying changes in 
flouoroquinolone use that may affect the phylogenetic structure of EMRSA-15 in 
Birmingham.  
 
 In addition to fluoroquinolone resistance, EMRSA-15 has phenotypic 
characteristics that make it a well adapted hospital pathogen. MRSA has been shown to 
survive in the hospital environment on specific surfaces such as bed rails, linen or 
medical equipment, therefore providing an environmental reservoir for infection. As 
such, increased tolerance to desiccation has important implications for EMRSA-15 in the 
clinical setting, where the bacteria are exposed to harsh environmental conditions that 
cause drying or desiccation, and plays a key role in MRSA persistence in the hospital 
environment (Chemaly et al., 2014). To date no study has examined the desiccation 
tolerance of sub strains of EMRSA-15 with differing ciprofloxacin resistance or strains 
sampled from different geological and climatological niches. Here EMRSA-15 sub 
lineages have been identified from our phylogenetic analysis along with EMRSA-15 
isolates sampled from Hong Kong and Kuwait to compare their desiccation tolerance to 
each other in a controlled laboratory environment.    
 
4.2 Pipeline validation 
 
 
As WGS technology has expanded the scope of bioinformatics programmes available to 
analyse the produced data has expanded with it. This has led to a myriad of publicly 
available programmes and pipelines, Each of these programmes have unique features 
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but ultimately perform similar functions. Unlike with other scientific disciplines, public 
forums play an important role in the review and development of programmes as well as 
how to implement them along with any caveats or faults. When used in conjunction with 
published literature this can provide a high degree of review/confidence in the selected 
programme.  
 This study has constructed a unique pipeline to trim then map Illumina paired 
end reads to the EMRSA-15 reference genome HO 5096 0412 (Koser et al., 2012b), 
determine SNPs in the core genome of each isolate and remove recombinant SNPs to 
generate an aligned fasta file for application to BEAST. When compared to four WGS 
studies investigating EMRSA-15 epidemiology the pipeline produced here was unique 
but found to employ similar protocols for phylogenetic tree building and the use of 
BEAST (Table 16)(Holden et al., 2013, Reuter et al., 2016, Hsu et al., 2015, Aanensen et 
al., 2016). 
 All pipelines, including the one described here mapped trimmed reads to the 
reference genome HO 5096 0412, that was part of a UK neonatal ward outbreak and was 
published in 2012 (Koser et al., 2012b). This is due to it being the only the fully 
annotated EMRSA-15 reference genome available and therefore the only suitable 
genome for SNP analysis of EMRSA-15 genomes.  
 Each study showed a range of average read coverages produced from their 
respective sequencing platforms,  however debate arises around what level of coverage 
is required for WGS analyses. Appropriate coverage depth of sequenced reads is 
dependent on the analysis being performed and mapping based approaches require less 
coverage than de-novo assembly. Most coverage considerations come from mammalian 
genomic studies, 15x for homozygous SNP determination and 33x for heterozygous SNP 
  
161 
 
determination, as they were the first to investigate NGS SNP typing applications (Wang 
et al., 2008, Ahn et al., 2009). These values have been lower in subsequent years as 
sequencer read length has increased, therefore reducing the need for higher coverage 
depth. Furthermore eukaryote genomics require higher coverage due to multiple 
chromosomes and diploid genomes, with coverage of single choromosomal bacteria 
being downscaled (Ekblom and Wolf, 2014, Sims et al., 2014). Studies with eukaryotic 
genomes have also demonstrated a trade of between increasing sample size and reduced 
sequence coverage, where the error rate from low read coverage is mitigated from data 
provided by the other samples in the population (Le and Durbin, 2011) (Li et al., 2011).  
 The average coverage in this study was 60.10x which is comparable to other 
MRSA (Reuter et al., 2016) (Driebe et al., 2015) or bacterial studies (Koser et al., 2014, 
Cairns et al., 2015). Here we have used Qualimap with a 1000bp sliding window to 
assess coverage of each isolates across the HO 5096 0412 reference.  This has given 
more accurate sequence coverage values for each isolates and ensured complete 
coverage across the reference genome for give accurate and reliable SNP determination.   
 
 
Only SNPs from the core genome, the ubiquitous set of genes that are present in all 
genomes of the study, were used to build evolutionary phylogenetic trees with SNPs 
arising in MGEs (including the SCCmec element, prophages, plasmids and pathogenicity 
islands (Lindsay et al., 2012)) and repetitive regions being excluded. This method has 
been applied in all EMRSA-15 phylogenetic studies (Holden et al., 2013, Reuter et al., 
2016, Hsu et al., 2015, Aanensen et al., 2016) due to the need to build phylogenies on 
reliable SNPs and exclude those in MGEs and repetitive regions which may give 
misleading analyses. Therefore the core genome provides the most consistent set of 
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SNPs for evolutionary reconstruction (Planet et al., 2016), but can lose additional 
phylogenetic information that would be present in the MGE genes.  
 
4.2.1 Homologous recombination  
 
 
The impact of homologous recombination on the evolution of bacteria has been well 
documented (Feil and Spratt, 2001) and can effect the accuracy of phylogenetic 
reconstructions due to a single recombination event being able to introduce multiple 
polymorphisms, therefore confounding the ability to accurately measure the rate of 
nucleotide substitutions arising by point mutation. Furthermore recombination 
occurring between two isolates in a dataset may make them appear to be more closely 
related than they actually are and can reduce the accuracy of phylogenetic signal 
(Croucher et al., 2013, Posada and Crandall, 2002). Therefore it is prudent to identify 
and remove recombinant SNPs from phylogenetic analyses. This study used the Gubbins 
tool (Croucher et al., 2015) to identify blocks of recombination arising in each of the 437 
genomes. Gubbins is similar to other recombination determining programmes such as 
ClonalFrame (Didelot et al., 2010) or BRATNextGen (Marttinen et al., 2011) which 
identify regions of high density SNPs occurring in the genome. Gubbins has the 
advantage however of converging on results significantly faster than other programmes 
(Croucher et al., 2015) and is tailored for use with clonal populations. A drawback of 
using SNP density methodology for recombination determination is that SNPs naturally 
arising in high-density regions or those occurring from sequencing error cannot be 
distinguished from those arising by recombination, allowing a margin of error in 
recombinant SNP determination. This is likely to be minimal in this dataset due to the 
  
163 
 
large sampling population and the low error rate reported for Gubbins (Croucher et al., 
2015).  
 The number of recombinant SNPs in my dataset was low (3.15% of determined 
SNPs). This value is similar to those observed in other EMRSA-15 studies (Holden et al., 
2013) but is higher than in ST239, which has been seen to range from 0.88% (Harris et 
al., 2010) to 1.1% of core genome SNPs (Hsu et al., 2015).  This could be due to ST239 
and ST22 being endemic to different regions of the globe and are therefore under 
different evolutionary selection pressures (climate environment, hospital environment, 
antibiotic regimes). Another possible reason is the sampling population examined in 
each study. Inclusion of a greater number of diverse isolates will give more 
representation across lineages compared to studies that have included a large number 
of highly related or virulent isolates (Didelot and Maiden, 2010). This study presented 
here has both included a larger number of isolates and both clinical and screening 
isolates  and therefore may give a more accurate representation of recombination. While 
specific rates between MRSA lineages may vary, low rates of recombination are 
consistently  reported in MRSA. This indicates recombination within MRSA lineages is 
detectable but occurs infrequently, demonstrating the highly clonal nature of MRSA 
sequence types (Planet et al., 2016, Kuhn et al., 2006).  
 
 
4.2.2 Bayesian phylogenetics 
 
Several methods of phylogenetic tree construction are available, all of which display 
data in different ways. One of these methods is to use Bayesian analysis with Marcov 
Chain Monte Carlo (MCMC) statistical modeling with the Bayesian Evolutionary Analysis 
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Sampling (BEAST) platform to create maximum clade credibility (MCC) trees. Bayesian 
methods are becoming increasingly used due to the availability of large SNP datasets to 
infer accurate timelines of bacterial evolution. Grey et al (2011) were the first authors to 
use Bayesian inference to understand MRSA epidemiology by applying publically 
available SNP data from the Harris et al 2010 global ST239 study to the BEAST platform 
(Gray et al., 2011) to demonstrate the temporal evolution and global transmission of 
ST239. This method is considerably more complex than more standard methodologies 
such as ML or NJ trees (Huelsenbeck et al., 2001), but has the added value that it allows 
the temporal divergence of isolates to be determined, therefore providing a greater 
understanding of how a species or strain has evolved over time. This is particularly 
appropriate for the current study outlined here, where the aim was to investigate the 
evolution of a single lineage over time and determine when the strain emerged. This 
information would not be able to be gained from ML or NJ phylogenetic techniques.   
 Before data is applied to BEAST it is important to evaluate if a robust ML 
phylogeny has been created. Bootstrapping remains one of the most common methods 
for demonstrating the robustness of a phylogenetic tree since it was first applied to 
phylogenetics in 1985 (Felsenstein, 1985) and is a measure of how often the tree 
topology is recreated when randomly generated many times over (ideally 500 times or 
above). The tree generated in this study had high bootstrap values (mode 100) which 
indicated a robust phylogeny had been generated from the WGS data before it was 
applied to BEAST.  
 
BEAST is a complex programme to operate and it has several caveats that need to be 
considered. Firstly, the extensive choice of parameters, models and priors require 
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significant understanding to be implemented appropriately due to accurate inference 
relying on suitable model selection and calibrations (along with informative sequence 
data). The selection of an appropriate molecular clock for the dataset is critical and 
involves determining a balance between the complexity of the model and the fit of the 
dataset to the model. This can lead to a “trial and error” approach to generate the 
desired outcome and variation between different studies but can also result in 
misleading divergence time estimates if a poor model is chosen. Due to the exact 
calibrations of BEAST not being defined in published literature direct comparisons in 
BEAST methodology are not possible however it should be noted that differences in 
molecular clock or population models can infer differences in the MCC tree.   
 A variety of molecular clocks have become available as molecular evolutionary 
studies have expanded over the past 20 years. The most basic clock is the strict 
molecular clock (or global molecular clock) which assumes that the rate of evolution is 
the same for every branch of the tree. In contrast the relaxed molecular clock assumes 
heterogeneity in the rate along branches of the tree and allows different substitution 
rates on each branch (Ho and Duchêne, 2014).  Gray and colleagues (Gray et al., 2011)  
used a combination of clock and population models to demonstrate how different model 
combinations can give different tMRCA values (ranging 21 years) and the superiority of 
the relaxed molecular clock compared to the strict molecular clock for tMRCA 
determination.  
The Path-O-Gen programme provided by BEAST can analyse ML trees to determine if a 
strict molecular clock would be appropriate for the dataset by measuring the root to tip 
distance of each isolate against time. The dataset of 437 genomes applied to Path-O-Gen 
in this study showed an increasing accumulation of sequence variation over the 25 year 
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sampling timeframe with only 26 isolates (5.9%) displaying marked variation away 
from the linear regression line.  This small number of outliers is indicative of a clonal 
population of isolates that have evolved at a similar rate, demonstrating linear specific 
evolution and that a relaxed clock model should be applied in BEAST. 
 Statistical methods can also be employed to determine the most appropriate 
model for a dataset, the most common of which is Bayes factor test (BFT) (Drummond 
and Rambaut, 2007, Jeffreys, 1935, Kass and Raftery, 1995). BFT calculates marginal 
likelihoods of each model therefore allowing a pairwise comparison of models and 
selection. However this in itself has the caveat of the model with the best fit to the 
dataset may not be the best fit for the biology of the organism being studied. BFT was 
used here to determine that a relaxed clock model with a constant population model 
was the most appropriate model for my dataset. This was confirmed with high ESS 
values from trace files and a hairy caterpillar trace that indicated a robust model had 
been chosen for my analysis.  
 
Another caveat of implementing BEAST is it is highly computationally demanding and 
can take weeks to months to complete a 10,000,000 chain run depending on the size of 
the dataset. Furthermore each genome sequence added to the analysis increasing the 
time for completion. Many laboratories may not have the computational capabilities to 
accommodate this analysis, however the increasing demand for bioinformatics has led 
to several freely accessible cloud based infrastructures to be developed 
(http://www.climb.ac.uk) which can help alleviate this problem. Due to the high number 
of genomes applied to the BEAST platform in this study, analysis time for each BEAST 
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run was approximately 2 months, however the use of cloud based infrastructure allowed 
these runs to be completed in parallel, drastically reducing analysis time.  
 For accurate BEAST divergence dating a good representation of isolates across 
time is required. This is due to reduced accurate where there are large gaps in the 
timeframe of isolate sampling. For example a period of 10 years with no sampled 
isolates means that there is no molecular data to estimate evolutionary change over this 
10 year time period. By including a large number of isolates over a lengthy timespan this 
inaccuracy has been reduced and strengthened the phylogenetic reconstruction. 
Unfortunately no studies, including this one, have many EMRSA-15 isolates sampled 
between 1980 and 2001 included in analyses. This is because EMRSA-15 isolates from 
this time period being extremely difficult to source due to two main reasons. Firstly 
isolates from the 1980s would need to have been stored for over 30 years and 
collections may have been lost due to poor archiving and maintenance of collections. 
Secondly the MRSA infection rate was relatively low in the UK until the mid 1990s 
(Figure 1) and was not considered a public health threat until the late 1990s and early 
2000s (Duerden et al., 2015).  Indeed as the number of MRSA bacteraemias began to rise 
in the 1990s and governments around the world introduced national policies to tackle 
the threat of MRSA, isolates were stored in much greater number for reference and 
research purposes which is demonstrated by the large availability of MRSA isolates from 
2001 onwards in this study and other MRSA evolutionary studies (Reuter et al., 2016) 
(Holden et al., 2013). 
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4.3 Global phylogeny  
 
The public health threat of the continued expansion of EMRSA-15 has been widely 
acknowledged and as such there is a need to investigate the epidemiology of the global 
EMRSA-15 population. A previous study by Holden and colleagues whole genome 
sequenced 193 EMRSA-15 isolates sampled between 1991 and 2008 and employed 
Bayesian phylogenetics and phylogeographics (determining spatial and temporal 
patterns of population structure using genetic variation (Avise et al., 1987)) to suggest 
EMRSA-15 evolved in the West Midlands (UK) in the mid 1980s after acquiring 
ciprofloxacin resistance. 
 The data presented here has expanded on this knowledge base by analyzing 437 
EMRSA-15 genomes that included over 200 isolates from Birmingham and a single ST22 
isolate from the region that pre-dates the emergence of EMRSA-15. To date this is the 
largest WGS study of EMRSA-15 that has longitudinally investigated a single region and 
contextualized in a national and international setting.  
 The selection of isolates for inclusion in a phylogenetic study is arguably one of 
the most important facets of the study due to impact of sample biasing (Planet et al., 
2016, Pearson et al., 2009). Unlike previous EMRSA-15 evolutionary studies that have 
used only clinical isolate collections (Reuter et al., 2016) or collections of isolates that 
may be biased towards outbreak sampling  (Holden et al., 2013), the collection analysed 
here included 152 screening isolates (34.7% of total genomes analysed). By including a 
large number of screening isolates alongside clinical and internationally sourced isolates 
I have generated a more representative cross sectional understanding of the EMRSA-15 
population over this time period and reduce the biasing that may be introduced by 
analyzing only isolates that have caused clinical infection.  
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4.3.1 Evolutionary rate  
 
Investigating the rate of evolution of bacteria is important to be able to understand how 
isolates have evolved over time. By knowing the rate at which a strain has evolved one 
can infer the number of SNPs that have arisen between isolates since they shared a 
common ancestor. By using BEAST I have been able to determine the evolutionary rate 
of the EMRSA-15 population analysed in this study to be 1.38 x106 substitutions per site 
per year or the equivalent to approximately 5 mutations across the genome per year. 
This value is within the 95% confidence intervals described by Holden et al in 2013 
(Holden et al., 2013) who demonstrated a rate of 1.30 x106 substitutions per site per 
year and Hsu et al in 2015 who demonstrated a rate of 1.4 x106 substitutions per site 
per year from a Singaporean collection of EMRSA-15 (Hsu et al., 2015). The inclusion of 
a large number of the Holden et al 2013 isolates in this analysis may bias the rate result, 
however the BEAST analysis that only included Birmingham sampled isolates had a 
similar rate of 1.36 x106. This concordant collection of evidence would indicate that 
EMRSA-15 has a steady evolutionary rate across different geographical areas, 
Birmingham versus Singapore for example, but also that it appears to evolve slower 
than other MRSA lineages. ST239 has been reported to evolve at a rate of 2.2 x106  to 3.3 
x106 substitutions per site per year ((Harris et al., 2010, Hsu et al., 2015, Castillo-
Ramírez et al., 2012)) and EMRSA-16 has been reported at 1.42 × 106 substitutions per 
site per year (McAdam et al., 2012) which is more similar to the rate of EMRSA-15. The 
reasons for this potential difference in evolutionary rate between lineages is similar to 
the reasons described for homologous recombination (section 4.2.1). Different 
methodologies have different accuracies, for example Bayesian inference with BEAST 
(Hsu et al., 2015, Holden et al., 2013, McAdam et al., 2012) is more accurate than root to 
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tip and sampling date linear regression analysis (Harris et al., 2010) (Young et al., 2012). 
The isolates included in a study will also influence rate determination. Evolutionary rate 
is not fixed in time and space, with environment specific selection pressures, such as 
colonization versus blood stream infection, or evolutionary bottlenecks changing the 
mutation rate. Therefore determining mutation rate from isolates that have only been 
sampled from a single sub-lineage, outbreak or clinical infections may give different 
results compared to those from a more varied sampling source collection. Here I have 
included clinical, screening and globally sourced EMRSA-15 isolates and have a greater 
total of isolates analysed, therefore may give a more accurate rate of the EMRSA-15 
population by reducing sample bias.  
   
4.3.2 The evolution of ciprofloxacin resistance and the EMRSA-15 lineage 
 
 
 The historical ciprofloxacin sensitive isolates from CHB sampled in c1985 was 
not only related to the other UK ciprofloxacin sensitive genomes, due to it’s basal 
positioning on the tree, but was also highly related to the first reported historical 
EMRSA-15 genomes sampled in 1991 to 1993 from Birmingham. These historical 
Birmingham EMRSA-15 isolates were 50 SNPs from the CHB historical isolate which is 
consistent with the SNP accumulation rate discussed in section 4.3.1 over a six year time 
period. Furthermore the historical CHB progenitor isolate was sampled in a hospital that 
carried out the first ciprofloxacin trials in the West Midlands (Crump et al., 1983) 
indicating the ST22 progenitor population was in present in a hospital where 
ciprofloxacin was being trialed.  This combination of topology and SNP distance is 
indicative that a hospital associated ciprofloxacin sensitive ST22 population (lacking the 
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Ser80Phe mutation in grlA and Ser84Leu in gyrA mutation) that was highly related to 
the emergent  EMRSA-15 was circulating in the West Midlands. This would therefore 
indicate that ciprofloxacin resistance did emerge in the West Midlands rather than be 
imported from elsewhere in the UK (and subsequently transmitted onward from 
Birmingham). 
 To date this is the first report of the whole genome sequencing and phylogenetic 
analysis of a hospital sampled ciprofloxacin sensitive ST22 isolate that predated 1991. It 
is therefore a key isolate in the determination of EMRSA-15 evolution by providing 
genetic information from the time EMRSA-15 emerged and allows a more robust 
phylogenetic trees to be built. The addition of more ciprofloxacin sensitive or resistant 
ST22 isolates sampled before 1991, ideally from other UK or international locales, to 
this phylogeny would further enhance my findings by giving more precise estimates of 
the time EMRSA-15 evolved. As stated in section 4.2.2 isolates from this time period are 
rare and no isolates from elsewhere in the UK from this time could be sourced in either 
this study or the study by Holden and colleagues (Holden et al., 2013). Therefore, 
theories of simultaneous evolution of EMRSA-15 in other UK locales or the importation 
of the ST22 progenitor population from elsewhere in the UK before ciprofloxacin trials 
began cannot be excluded.  
 
The emergence of ciprofloxacin resistant ST22 (EMRSA-15) was dated as approximately 
1984 in this study. This date is two years earlier than was proposed by Holden et al 
however 95% HPD intervals for both this divergence date and the Holden and 
colleagues date overlap, indicating relative concordance. This difference in divergence 
dating may be accounted for by the increased number of isolates in my phylogeny and 
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the inclusion of the ciprofloxacin sensitive ST22 isolate from Birmingham providing 
increased time divergence dating accuracy at this time point on the MCC tree.   
 The possible earlier evolution of ciprofloxacin resistance in ST22 has an impact 
on current theories of EMRSA-15 evolution. Holden and colleagues propose that 
ciprofloxacin trials occurring in the West Midlands (UK) region may have been the 
selection pressure for the evolution of ciprofloxacin resistance based on three published 
ciprofloxacin trials in 1983 (Crump et al., 1983) and 1986 (Silverman et al., 1986) (Finch 
et al., 1986) coinciding with a ciprofloxacin resistance emergence date of 1986. Only the 
trial by Crump et al in 1983 pre-dates my EMRSA-15 emergence time point of 1984 and 
was a trial conducted on only six patients at CHB (then known as Dudley Road Hospital) 
but interestingly occurred in the hospital the EMRSA-15 progenitor isolate was sampled 
from. It is possible that ciprofloxacin use was limited in clinical trials before 1986 and a 
resistant phenotype could have emerged in 1984 but did not spread until 
fluoroquinolone use became more frequent in clinical trials in 1986 that included larger 
numbers of patients (26 patients (Silverman et al., 1986) and 52 patients (Finch et al., 
1986)). Furthermore significant early branching of the MCC phylogenetic tree is evident 
from circa 1985 to 1986 and may be accounted for by the increasing use of pre-licenced 
ciprofloxacin.  It should however be noted that time divergence dating uncertainty 
increases the further back in time the phylogeny goes and neither the data presented 
here or in the Holden et al 2013 paper are exact dates for the emergence of EMRSA-15.  
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4.4 Global phylogenetic structure  
 
EMRSA-15 continues to spread internationally and is currently the fastest growing HA-
MRSA lineage in Europe (Grundmann et al., 2014) and has become a healthcare threat in 
the Middle East (Udo et al., 2016, Udo et al., 2006, Goudarzi et al., 2016) and Australasia 
(Hsu et al., 2007b, Coombs et al., 2014, Groves et al., 2016, Hsu et al., 2005).  
 The inclusion of EMRSA-15 genomes from new international sources being 
analysed alongside previously WGS phylogenies is required to monitor the continuing 
expansion of the strain. By including the isolates from Hong Kong, Guernsey and the UK 
with genomes from ten additional countries I have created the largest global phylogeny 
of EMRSA-15 to date. 
 
 The global phylogenetic reconstruction presented here is highly concordant with the 
Holden et al paper (Holden et al., 2013), where the international genomes were sourced, 
and demonstrates genomes from specific countries clustering distinctly together 
indicating importation and clonal expansion. Three recent whole genome studies that 
used ML (Aanensen et al., 2016) and MCC (Holden et al., 2013, Hsu et al., 2015) 
phylogenetic trees have demonstrated exportation of EMRSA-15 from the UK followed 
by clonal expansion to become the dominant clone within healthcare systems that 
previously had no significant ST22 MRSA burden. This is corroborated in my analysis 
where UK isolates that were less than 40 SNP distant were directly basal to each cluster 
of German, Portugese and Singaporean isolates in the MCC phylogeny. In contrast to 
Aanensen and colleagues a Guernsey isolate was basal to the Portuguese cluster (36 SNP 
distance) instead of a UK mainland isolate (over 100 SNPs (Aanensen et al., 2016). This 
could potentially suggest Guernsey as an exportation source to Portugal rather than 
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directly from the UK, however the sampling bias of limited number of isolates from both 
Guernsey and Portugal in this analysis means complex routes of importation of EMRSA-
15 to Portugal may have occurred.  
 
Both the Guernsey and Hong Kong isolates demonstrated geographically restricted 
clustering (Hong Kong isolates are discussed in the section below). Guernsey is a small 
British island dominion in the English Channel where EMRSA-15 is also the dominant 
MRSA clone. The phylogenetic structuring of EMRSA-15 in Guernsey showed a localized 
EMRSA-15 population predominating alongside EMRSA-15 isolates that were more 
related to those of the UK mainland. This echoes the findings of Birmingham, where a 
distinct Guernsey clone is circulating alongside a more genetically diverse population of 
EMRSA-15 that are related to other UK circulating strains. Movement of patients and 
healthcare workers between Guernsey and the UK mainland is common. Therefore the 
distinct Guernsey clone may have been imported from the UK and then clonally 
expanded in the Guernsey healthcare system at a similar time to when EMRSA-15 was 
expanding across the rest of the UK (c1996 from this analysis). Additional sporadic 
introductions of EMRSA-15 from the UK may also account for the UK related clones in 
the population. Some biasing is however present in the Guernsey collection due to seven 
of the ten isolates in the Guernsey branch of the phylogenetic tree being from an ITU 
outbreak. However three non ITU isolates also clustered to this branch suggesting it is a 
real phenomenon.  
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4.4.1 Transmission of EMRSA-15 in East Asia 
 
 The 14 isolates from Hong Kong showed evidence of region specific clustering 
following a single importation event. Unlike other countries the importation of EMRSA-
15 to Hong Kong appears to be from Singapore and not directly from the UK. Unlike in 
the UK, ST239 is the dominant MRSA lineage across Asia (Ko et al., 2005, Feil et al., 2008, 
Chen and Huang, 2014) including Hong Kong and formerly in Singapore up to the mid 
2000s.  Between 2003 and 2015 there was a notable increase in ST22 MRSA strains 
being isolated from clinical specimens in Singapore where EMRSA-15 in now the 
dominant lineage (Hsu et al., 2005, Hsu et al., 2015, Hsu et al., 2007b).  Using BEAST on a 
collection of 87 isolates from four Singaporean hospitals, Hsu and colleagues 
demonstrated that this replacement of ST239 with ST22 likely occurred from an 
importation event from the UK in 2001, which is supported by my analysis. The BEAST 
analysis presented here indicates that approximately one year after this importation to 
the Singaporean healthcare system there was an exportation event to Hong Kong. This 
transmission event is strengthened by evidence of only two SNPs differentiating the 
Singaporean and Hong Kong clusters of the MCC tree.  
 This is the first report of UK, Singapore and Hong Kong EMRSA-15 isolates being 
analysed together and highlights how movement of strains between healthcare systems 
can occur across large geographical areas. A similar phenomenon has been 
demonstrated with ST239 being imported to London (UK) where it caused an outbreak 
of invasive infections in ITU (Edgeworth et al., 2007) but failed to become established in 
the healthcare system. This exportation was subsequently found to have likely been 
imported from Singapore using a BEAST analysis (Hsu et al., 2015). Unlike in Singapore 
EMRSA-15 has not become established as the dominant lineage in Hong Kong (where 
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ST239 remains the dominant clone) despite having been introduced to the respective 
healthcare systems at a similar time (2001 and 2002 [Figure 10]). Due to the high 
degree of genetic similarity between the Hong Kong and Singaporean isolates it is 
prudent to suggest differing healthcare practices between Singapore and Hong Kong 
rather than genetic mutation and adaptation are the reason for the poor success of 
EMRSA-15 in Hong Kong. Regional differences in ST239 spa type have been 
demonstrated in China (Chen et al., 2014) with isolates from Hong Kong being more 
related to “Asian clade” ST239 spa type t037 compared to those from Beijing which are 
more related to “Turkish clade” ST239 spa type t030. Shang and colleagues have shown 
that spa type t037 grew slower and had a reduced viable count in a murine kidney 
infection model compared to t030 (Shang et al., 2015) showing differences in infectivity 
between the ST239 spa types.  Therefore it is possible the ST239 population in Hong 
Kong is not as easily outcompeted in the healthcare niche as those in Singapore, 
however no spa tying data is available from Singapore, therefore making comparisons 
difficult.   
  Increased sampling from Asian countries and continued public access to WGS 
data will increase the understanding of MRSA movement across Asia as a whole, where 
genome studies are largely limited to countries such as Singapore, Japan or China (Kong 
et al., 2016).  
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4.4.2 Birmingham Phylogeny  
 
Analysis of the global and Birmingham phylogenetic trees has demonstrated a distinct 
EMRSA-15 population across the large Birmingham UK conurbation.  
 The Birmingham EMRSA-15 population structure comprised of a dominant, 
localized, highly clonal lineage (BHM clade) alongside a more diverse population of 
isolates that were more related to other UK strains. Reuter et al (2016) demonstrated 
similar geographical structuring of EMRSA-15 in the UK on a national scale. Using an 
extensive collection of bacteraemia isolates they were able to demonstrate the 
emergence of region specific sub clones but had only 16 isolates from Birmingham (all 
from CHB) in their West Midlands sample population (Reuter et al., 2016, Holden et al., 
2013). Furthermore BSAC submitting centres may not accurately represent hospitals in 
each referral region. For example a single hospital centre submitted isolates to BSAC 
from the “South Central” region and centres submitting from the “North Central” region 
being localized to the east coast (Newcastle) (Reuter et al., 2016).  
 Here I have performed a higher resolution analysis by extensively sampling across 
Birmingham and applied Bayesian inference to generate this phylogeny. Furthermore I 
have also included the publically available genomes of the West Midlands isolates from 
the Reuter study to further contextualize the Birmingham EMRSA-15 population in the 
West Midlands region.   
 The BHM lineage was highly localized to Birmingham but contained two isolates 
sampled from Coventry (West Midlands, UK) and a single isolates from Shrewsbury 
(West Midlands, UK), which may have been exportations from one of the three 
Birmingham hospitals. As stated above Reuther and colleagues demonstrated a similar 
phenomenon in their regional sampling framework. Due to the authors not using a 
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BEAST analysis, which would be difficult to achieve with over 700 isolates, dating the 
divergence of their regional specific sub-clones its not possible, however it is feasible 
they may have emerged at a similar time to the BHM clade (c1995) (Reuter et al., 2016).  
  
The BHM clade dominated the Birmingham healthcare system, comprising 
approximately half of the total Birmingham sampled isolates and constituted over 50% 
of isolates sampled in 2003, 2005 to 2008 and 2014 to 2015. Bayesian inference 
estimated the divergence date of the BHM clade to be circa 1995 and less than 10 years 
after it emerged there appears to have been a cladal shift towards BHM dominance in 
the Birmingham MRSA population. Due to the lack of isolates sampled before 2001 from 
Birmingham an importation of the BHM clade from elsewhere in the UK cannot be 
excluded, however the lack of proximal clustering of any of the UK isolates near the BHM 
clade would suggest this is unlikely.  
 A phylogenetic study using ML methodology of 76 ST239 isolates prospectively 
sampled over three months in a single hospital in Thailand (Tong et al., 2015a) showed 
that there was significant diversity in the HA-MRSA population over time. Three major 
ST239 sub-clades were present that were each distinguishable by over 100 SNPs, with 
no single stable clone being maintained within the hospital. In contrast my findings 
show that a single, highly clonal EMRSA-15 sub-strain has emerged and been 
maintained in the Birmingham hospital population for 20 years; the first description of a 
clone being maintained for such a period of time. This indicates the BHM clone is well 
adapted to the Birmingham healthcare system and lack of transmission out with the 
Birmingham conurbation may be due to care in Birmingham is predominantly provided 
by the three hospitals analysed here with patients being transferred between HEFT, 
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QEHB, and CHB. Similar patient demographics may also account for the regional clones 
described by Reuter and colleagues 2016.  
 
 Delineation of the sampling hospital of each of the Birmingham isolates showed 
isolates linked in space and time to cluster, as has frequently been demonstrated in WGS 
studies (Harris et al., 2013, Koser et al., 2012b). However there was a lack of hospital 
specific structuring, with isolates from all three hospitals being distributed throughout 
the tree. Hsu et al 2015 demonstrated a similar phenomenon in Singapore across four 
hospitals in a single healthcare system over a 10 year time period for ST239 and ST22 
(Hsu et al., 2015) and studies in the USA using over 300 sterile site infection isolates 
from four hospitals (Long et al., 2014) and 30 clinical isolates from seven hospitals 
(Prosperi et al., 2013) have demonstrated similar results. The concordance of this study 
with these reports that used both Bayesian and ML phylogenetics with multiple hospital 
sites and long temporal sampling would indicate that transmission between hospitals 
across restricted geographical areas is frequent and that a shared patient population is 
present in the region. 
 
4.4.3 Evaluation of WGS and VNTR typing 
 
VNTR typing and WGS examine different regions of the genome, the accessory and core 
genome respectively, however to date no published study has investigated the 
relationship between the two techniques in MRSA.  
 The clonal nature of HA-MRSA lineages means that VNTR typing, and other 
genotyping techniques, have a reduced ability to discriminate between isolates within a 
single HA-MRSA lineage. This is demonstrated here with EMRSA-15, where in all 210 
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isolates no variability in repeat number was observed at five of the seven loci. The 
variation in repeat number only occurs at loci 13 and 21, and therefore decreases the 
STRD that is observed. A Similar reduction in typing discriminatory power within 
defined bacterial lineages has been demonstrated with M. tuberculosis and the globally 
distributed Beijing clone where 12 or 15 loci typing schemes cannot differentiate 
between clusters within the lineage (Kremer et al., 2005, Kato-Maeda et al., 2011).  
Increasing the number of VNTR loci used in M. tuberculosis typing to 24 has however 
increased the discriminatory power of VNTR within the Beijing clone, where 24 loci 
could identify twice as many clusters of the M. tuberculosis Beijing clone compared to 
the 12 locus set (Jiao et al., 2008).  
  
 To further investigate the discriminatory power of VNTR typing within the 
EMRSA-15 lineage, changes in LV and STRD between paired isolates were compared to 
more discriminatory SNP distances.  Similar ranges of between 0 and 196 SNPs were 
demonstrated between zero, one and two locus variants between isolates. This would 
indicate a restricted range of SNPs differentiate EMRSA-15 isolates and further clarifies 
the high degree of clonality within the EMRSA-15 lineage. Some extent of this variation 
in SNPs between isolates may be accounted for by the cloud of diversity that has been 
demonstrated in S. aureus whereby individuals may be carrying heterogeneous 
populations of the bacterium. Different colonies from a single MRSA screening swab 
have been reported to differ from each other by up to 40 SNPs (Harris et al., 2013, 
Paterson et al., 2015), meaning each isolate in our study could be plus or minus 40 SNPs 
from the SNP difference values calculated. 
  
181 
 
 Walker and colleagues have shown a similar result when comparing VNTR and 
SNPs with M. tuberculosis using a 24 locus scheme, where LVs of zero to two showed a 
range of zero to 200 SNPs between paired isolates. The authors also demonstrated that 
with increasing LV the range of SNPs remained constant but had higher upper and lower 
boundaries (LV of 10 ranging from 200 to 2000 SNPs for example) (Walker et al., 2013). 
Somewhat conversely, Eyre et al also demonstrated increasing SNP difference with 
increasing LV using a seven locus system on over 300 Clostridium difficile isolates. The 
authors also showed that LV of zero and one between paired isolates only varied by up 
to 5 SNPs; a greatly reduced range compared to S. aureus or M. tuberculosis. This may be 
due to the biology of the organism, however C. difficile evolves faster than M. tuberculosis 
(1.5 SNPs per year (Didelot et al., 2012) versus 0.5 SNPs per year (Walker et al., 2013) 
respectively) but slower than S aureus, suggesting the difference may be in the 
discriminatory power of the C. difficile VNTR loci rather than a reduced mutation rate.  
 Both the Walker and Eyre studies have included isolates from different lineages 
in their respective bacteria and have demonstrated greater range of LV and STRD within 
the species. Here only a single highly clonal MRSA lineage was examined and accounts 
for the reduced variability in my VNTR data. VNTR discriminatory power may differ 
between MRSA lineages, as is seen with M. tuberculosis (Kato-Maeda et al., 2011).  MRSA 
ST239 is more a more diverse lineage compared to EMRSA-15 (Gray et al., 2011, Hsu et 
al., 2015) and therefore ST239 may have greater LV, STRD and SNP pairwise differences 
within the lineage.  
 
 VNTR typing data was also applied to my WGS phylogeny to determine how it 
reflected the Birmingham EMRSA-15 population structure. The mapping of the only 
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variable VNTR loci L13 and L21 to the WGS phylogeny showed a highly concordant 
EMRSA-15 population structure.  Locus L13 was able to discriminating BHM and non 
BHM isolates with 100% concordance which further highlights the clonality of the BHM 
clade. Ahlstrom and colleagues investigated the epidemiology of 134 isolates of the 
veterinary pathogen Mycobacterium avium using a similar method (Ahlstrom et al., 
2015). The authors applied six polymorphic loci to their WGS phylogeny but found more 
limited clade-related mapping with VNTR repeat number. VNTR loci have been shown to 
have different allelic diversity and therefore different discriminatory power (Supply et 
al., 2000, Supply et al., 2006) which could mean the loci being investigated by Ahlstrom 
and colleagues are not variable enough to identify clones within Mycobacterium avium 
population (Ahlstrom et al., 2015).  Interestingly locus L21 is more variable than L13, 
due to smaller sized tandem repeats (Hardy et al., 2006b) but was less concordant than 
L13 to the WGS phylogeny. This may be due to the genomic region of L13 having SNPs 
that would have been used to generate the phylogenetic tree.  
 
 
 
4.5 The impact of fluoroquinolone usage on the Birmingham EMRSA-15 phylogeny  
 
4.5.1 Fluoroquinolone use at HEFT  
 
 
Both the Birmingham EMRSA-15 phylogeny and the use of fluoroquinolones at HEFT 
showed similar patterns that changed over the 25 period they were compared for.  
 Ciprofloxacin appears to have been introduced relatively late (1991) to HEFT, 
four years after it was licensed, however after 1991 ciprofloxacin use showed a similar 
trend to national usage with a steady increase between 1991 and 1996 (Livermore et al., 
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2002). Total fluoroquinolone use increased sharply after 1996 when ofloxaxin was 
introduced and this drug was largely replaced with levofloxacin in 2003 due to the poor 
antibacterial efficacy of ofloxacin compared to levofloxacin (Davis and Bryson, 1994, 
Une et al., 1988, George and Morrissey, 1997). This period of increase has been reported 
in other UK hospitals and has been followed by post 2003 reduction in use of 
fluoroquinolones both at HEFT and nationally (Aldeyab et al., 2008, Sarma et al., 2015) 
(Ashiru-Oredope et al., 2012) (Cooke et al., 2015) to help combat Clostridium difficile 
infection in UK hospitals. Post 2012 fluoroquinolone use at HEFT is also concordant with 
national data from the ESPAUR report (Public Health England, 2015) which states 
reduction in fluoroquinolone use has plateaued but levofloxacin usage is rising slowly. 
Therefore my data appears to be largely concordant with hospital prescribing patterns 
in the rest of the UK and is not demonstrating region or hospital specific biasing (an 
acute hospital trust for example). However several limitations should also be 
considered. Firstly ambiguity can arise around antibiotic usage data due to issues with 
how the data is collected and analysed. Antibiotics procured by wards may not all be 
administered therefore giving higher values for antibiotic usage than may actually be 
occurring but is likely to have a limited impact on annual data. National and local DDD 
values for drugs may also differ and can change over time, giving higher or lower DDDs 
than may have actually been used. This may partially account for the rapid spike in 
levofloxacin usage at HEFT in 2003 (Figure 19).   
  OBD data pre dating 2001 could be sourced, meaning antibiotic prescription data 
was determined as DDD and not DDD/OBD. The stable post 2001 OBD rate indicates 
very limited fluctuation in the in patient population at HEFT, suggesting the OBD rate 
prior to 2001 would have been similar to that seen between 2001 and 2006 (before the 
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merger with Good Hope Hospital). Antibiotic prescription data could only be sourced 
from a single hospital trust in Birmingham and QEHB and CHB may have had different 
prescribing policies and antibiotic usage over the 25 year time period. Antibiotic 
prescribing policy and stewardship is specific to each hospital trust in England and often 
reflects their specialism or function (Public Health England, 2015). For example QEHB is 
a trauma specialist trust and is likely to use more empirical prescribing of antibiotics 
compared to HEFT or CHB.  
 
4.5.2 Antibiotic usage and phylogenetic comparison  
 
 
The impact of antibiotic usage on the evolution of bacteria is now well established and 
the use of fluoroquinolone, third generation cephalosporin and macrolide antibiotics 
have been associated with the evolution of resistant MRSA lineages and increased risk of 
MRSA colonization (Charbonneau et al., 2006) (Parienti et al., 2011) (Tacconelli et al., 
2008).  Resistance to fluoroquinolones has been proposed to facilitate the expansion of 
MRSA clones including EMRSA-15 but to date, no study has combined antibiotic usage 
over time with a time linked phylogenetic tree from a localized area or healthcare 
system. 
 Ciprofloxacin usage at HEFT started 1991 however both the phylogeny presented 
here and the Holden and colleagues data (Holden et al., 2013) have shown that the 
emergence of EMRSA-15 and it’s immediate evolution, the major branching of the tree 
between 1985 and 1990 (Figure 10), occurred prior to the introduction of ciprofloxacin 
into the HEFT trust in 1991. As discussed in section 4.3.2 the use of ciprofloxacin in 
clinical trials in the West Midlands may have resulted in this primary evolution and 
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major branching of the MCC tree between 1984 and 1990, but the ciprofloxacin usage at 
this time was in a minimal number of patients.  
 The gradual increase of ciprofloxacin between 1991 to 1997 followed by the 
more rapid increase in total fluoroquinolone use when ofloxacin was introduced in 1997 
(causing a 4.5 fold increase in total fluoroquinolone use by 2002) coincided with the 
continual branching and expansion of the EMRSA-15 population in the Birmingham 
healthcare system. During this ten year time period the Birmingham EMRSA-15 
population diversified more than any other time period in my analysis and may have 
been facilitated by increasing use of fluoroquinolones. From 1991 to 1997 the national 
EMRSA-15 population, bacteraemia rate and the national rate of fluoroquinolone use 
were also increasing (Livermore et al., 2002) (Johnson et al., 2001) (Ellington et al., 
2010). Therefore the expansion of EMRSA-15 in Birmingham coincides with the 
expansion of EMRSA-15 across the UK, as would be expected.  
  The evolution of the BHM clade (c1995) also occurred within this initial ten year 
period of ciprofloxacin use. Bayesian confidence intervals of the BHM clade emergence 
date overlap with the introduction of ofloxacin in 1997, indicating the possible selection 
pressure of increased ciprofloxacin and ofloxacin use may have precipitated the 
evolution of the BHM clade. Furthermore the BHM clade genomes contain a Pro453Ser 
mutation in the DNA supercoiling gene grlB, a mutation that is not frequently reported 
but has been showed to cause reduced MICs to ofloxacin (Takahashi et al., 1998) in 
bacteria with gyrA Ser84Leu and grlA Ser80Phe mutations. While no literature 
performing a similar analysis could be sourced this theory of mutation, selection 
pressure and expansion echoes that of the primary EMRSA-15 evolution described by 
Holden and colleagues (Holden et al., 2013). Similar to the increasing use of 
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ciprofloxacin and the evolution of ERMSA-15 in the late 1980s and early 1990s, 
ofloxacin use doubled annually between 1997 and 2003 allowing the BHM clade to 
expand and become established (comprising over 50% of Birmingham sampled isolates 
in 2003) before ofloxacin use was curtailed.  
 A further possible explanation for the dominance of the BHM clade is increased 
fitness from the alteration of DNA supercoiling gene structure. Mutations in DNA 
supercoiling genes have been demonstrated to cause a global fitness increase in Gram 
negative Salmonella Typhi and Campylobacter jejuni (Baker et al., 2013, Han et al., 2012). 
Therefore the grlB mutation in conjunction with the increasing fluoroquinolone usage 
when the clade emerged could have provided the BHM clade with a selective advantage 
over other EMRSA-15 strains, however this would require significant further study to be 
confirmed (see future work section). 
 
Although my analysis has demonstrated a possible role of fluoroquinolone use in the 
evolution of EMRSA-15 the evolutionary impacts of IPC are difficult to quantify or assess 
(Lawes et al., 2015). Screening of patient admissions (elective and emergency) are 
believed to have drastically reduced the MRSA burden in hospitals (Elgohari et al., 
2016). Reduced branching of the MCC tree was demonstrated from 2003 to 2010 when 
MRSA bacteriaemia rate was reducing, coinciding with a reduction in fluoroquinolone 
and a wide spectrum of IPC initiatives. Therefore it is likely a combination of enhanced 
IPC, screening and reduced fluoroquinolone use inducing the reduction in MRSA 
diversity.  
 Contrary to this pattern of reduced diversity with reducing fluoroquinolone 
usage, there was an increase in branching of the MCC tree from 2010 to 2015 when 
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fluoroquinolone use had plateaued. This is likely reflecting the increased number of 
outbreak and PII sampled isolates in my collection from this time, demonstrating small 
scale evolution occurring over restricted periods of time.  
 
1.1 Desiccation tolerance of EMRSA-15 
 
 
S. aureus is known to persist in the environment and one of the key factors contributing 
to environmental survival is tolerance to desiccation. Previous studies have examined 
desiccation tolerance between different MRSA sequence types or strains (Knight et al., 
2012, Baldan et al., 2015, Duckworth and Jordens, 1990) however to date no previous 
study has compared EMRSA-15 sub-strains to each other or those from different 
geographical and climatological environments. 
 
4.5.3 Desiccation assay  
 
1.1.1.1 Methodology and control of desiccation chamber 
 
 
The environmental conditions of a desiccation assay play an important role in 
generating results however few studies have actively controlled the environment the 
bacteria are being desiccated in. Here I adopted a similar methodology to that of Jawad 
and colleagues (Jawad et al., 1996) and used a closed system with a controlled 
atmospheric RH in order to control environmental variables as much as possible to give 
robust results. Previous studies have shown that bacterial death rate is linked to RH and 
that RH is linked to temperature (Jawad et al., 1996, Lidwell and Lowbury, 1950), 
indicating assays where RH and temperature are not controlled may produce variably 
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inaccurate results. Furthermore changing RH or temperature may in turn be affected by 
seasonal climate changes or differences between geographical locations of laboratories 
or even the availability of air conditioning (Rountree, 1963, Pettit and Lowbury, 1968).  
Validation of the desiccation chamber in my study showed there was a constant 
temperature but a variable relative humidity in an air-conditioned and temperature 
controlled laboratory; demonstrating the need for a controlled RH in the desiccation 
assay. Another variable that is likely to fluctuate is light intensity, which was not 
controlled in this experiment, however previous studies have shown no effect on 
desiccation in light or dark conditions (Beard-Pegler et al., 1988).  In reality the 
environment in the hospital would not be fixed, with daily fluctuations in light, 
temperature and humidity as was demonstrated when humidity and temperature 
readings were taken from a ward at HEFT. Furthermore assessing desiccation is difficult 
to evaluate without being affected by other stress responses such as starvation which 
are likely to induce the general SOS response, making a perfect model system difficult to 
achieve.  
 
 Only two studies have investigated the desiccation tolerance of EMRSA-15, both 
of which shared similar methodology. Studies by Baldan et al (Baldan et al., 2015) and 
Knight et al (Knight et al., 2012) used 200μl innocula of bacteria suspended in BHI broth 
plated onto empty sterile petri dishes and left in an open environment to desiccate. This 
may give higher bacterial recovery values due to the nutritious and protective 
environment provided by the BHI broth and may also be affected by dust or particulate 
matter landing on the petri dish from the open environment. By washing bacterial cells 
before desiccation and sealing them inside the desiccation chamber my results should 
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have controlled for these variables. These studies also set experiment end points at 120 
hours (5 days) (Knight et al., 2012) 168 hours (7 days) (Baldan et al., 2015) whereas this 
study has continued to 35 days when bacteria were no longer recoverable; providing a 
greater understanding of the survival of EMRSA-15 over longer periods of time.  
 
 
4.5.4 Isolate susceptibility to desiccation 
 
 
Bacterial counts for each isolate varied over time, with each isolate showing dips and 
spikes in enumerated bacteria at each time point and no isolate showing a directly linear 
reduction in count over time. Previous studies have shown similar variability in 
bacterial counts over time both in S. aureus (Knight et al., 2012, Baldan et al., 2015, 
Jawad et al., 1996) and other species (Jawad et al., 1996) and is likely due to variation in 
the number of bacteria inoculated onto coverslips and the inherent inaccuracy of 
counting bacteria. Clumping of S. aureus during washing could mean an uneven number 
of bacteria were inoculated onto each coverslip (variation in number of bacteria on each 
coverslip was present) or clumping when eluting from coverslips or application to plates 
via capillaries in the spiral plater could also give increased counts on plates. Clumped 
bacteria may survive desiccation better due to a reduced net loss of water, giving higher 
survival rates at a time point after a previously lower count from an enumerated 
coverslip with no clumped bacteria. Furthermore human error in pipetting, spiral 
plating or counting of bacterial colonies can also add variation to results.  
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Of the ten EMRSA-15 isolates analysed the Hong Kong isolate HK_N5 showed the highest 
tolerance to desiccation and CT300 the lowest tolerance when suspended in water. 
From our phylogenetic analysis the Hong Kong isolate is the most genetically distant 
isolate compared to the other EMRSA-15 isolates in the assay and has possible 
undergone selective evolution in the Singapore and Hong Kong healthcare environments 
it has passed through (section 3.2.3). It is possible that the strain has evolved to have a 
higher tolerance of desiccation but no genetic evidence could be found for this in the 
WGS analysis however epigenetic changes to the transcriptome could account for the 
increased tolerance and were not investigated here.   
 
When suspended in water the BHM isolates showed slightly higher desiccation tolerance 
(higher range of AUC values and reduced slope gradients) compared to non-BHM 
isolates however this was ablated when suspended in BSA where AUC values and linear 
regression gradients overlapped. This would suggest that desiccation tolerance is not 
heightened in the BHM clade and is unlikely to be a reason for the strains success in 
Birmingham. Increasing the number of BHM and non BHM isolates may give further 
distinction to these results.  
 
The poor desiccation tolerance of isolates CT300 is likely due to its impaired ability to 
produce staphyloxanthin. This was evident from the lack of pigmentation of the 
bacterial colonies and WGS data that showed a SNP in the ctrN gene comprising part of 
the ctrNOPQM operon that codes for the production of staphyloxanthin (Pelz et al., 
2005). Staphyloxanthin is known to be an important cellular mechanism for desiccation 
tolerance due to it protecting from oxidative stress along with neutrophil killing in host 
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infection (Liu and Nizet, 2009, Pelz et al., 2005). Two successful MRSA lineages also lack 
the production of staphyloxanthin. Firstly an early branching CA-MRSA lineage in clonal 
complex 75 that lacks staphyloxanthin has been reported to be the dominant MRSA 
lineage among indigenous Australian communities (McDonald et al., 2006, Holt et al., 
2011). This strain has a predilection for skin and soft tissue infection and is rarely 
identified in hospitals (Brennan et al., 2013) which  Tong et al 2013  suggest is due to 
the strain being less fit for the hospital environment compared to staphyloxanthin 
producing strains. On the other hand EMRSA-16 is a successful HA-MRSA lineage found 
mainly in Southern England that emerged at a similar time to EMRSA-15, and is also 
ciprofloxacin resistant, which has a nonsense mutation in ctrM to give non-pigmented 
colonies (McAdam et al., 2012). EMRSA-16 is not found in the community and McAdam 
et al 2012 (McAdam et al., 2012) account this to the lack of staphyloxanthin (along with 
other virulence factors such as hla and agr) giving the strain reduced virulence and an 
inability to infect healthy individuals outside of the hospital. Both of these examples 
demonstrate staphyloxanthin lacking strains have reduced fitness compared to 
staphyloxanthin producing strains (such as EMRSA-15) but suggest the pigment is not 
essential for maintenance in either the community or the hospital setting which in turn 
may indicate desiccation tolerance has a minor role in strain fitness.  
 
 
 
 
4.5.5 Effect of protein suspension media  
 
To date no study has examined the desiccation tolerance of EMRSA-15 when suspended 
in BSA. A statistically significant increase in the desiccation tolerance of all S. aureus 
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strains was shown when bacteria were suspended in BSA. A solution of 3% w/v was 
chosen due to this being the percentage of protein present in “dirty environmental 
conditions” in an attempt to emulate an unclean hospital environment (Tuladhar et al., 
2012, Kawamura-Sato et al., 2008). These finding has been echoed in previous literature 
in both S. aureus (Chaibenjawong and Foster, 2010) and A. baumanii (Jawad et al., 1996) 
where a significant increase in long term survival and a reduced death rate of both 
organisms was observed. The exact reasoning behind the increased desiccation 
tolerance remains poorly understood, however the protein may form a coating around 
the bacteria, preventing loss of water from the cell and reducing UV damage (Fraud et 
al., 2001).  
 The increase in desiccation tolerance over the first 24 hours of the experiment 
and increased duration of survival has implications in the hospital environment and 
suggests the bacteria can survive longer in the dirty hospital environment. 
Contamination of hospital environments is known to cause an increased risk of infection 
with MRSA (and other HA pathogens) (Chemaly et al., 2014, Otter et al., 2011) and 
transmission from environment to patient is a known route of MRSA infection (Tajeddin 
et al., 2016, Boyce, 2007). Hospital wards contaminated with proteins from blood, faeces 
or skin particles may therefore act an extended reservoir of viable bacteria to be 
transmitted. Furthermore BSA has been shown to provide protection to biocide agents 
(Fraud et al., 2001, Simões et al., 2006) and a combination of desiccation and biocide 
tolerance provided by organic proteins in the environment may allow MRSA to 
withstand standard hospital cleaning practices. Recent changes in hospital cleaning 
practices due to the inefficiency of cleaning regimes mean more modern “no-touch” 
cleaning technologies such as UV irradiation and gaseous hydrogen peroxide are being 
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employed to decontaminate wards and side rooms. Studies combining desiccation 
tolerance with UV irradiation or hydrogen peroxide exposure may give further insight 
into MRSA desiccation tolerance in the moden hospital environment (Carling and 
Bartley, 2010, Boyce, 2016).  
 
Interestingly all of the EMRSA-15 isolates showed poorer desiccation tolerance than the 
MSSA control strain in BSA but not when suspended in water.  Previous studies have 
investigated the desiccation tolerance of S. aureus with the gain or loss of resistance to 
antibiotics other than fluoroquinlones (Chaibenjawong and Foster, 2010, Beard-Pegler 
et al., 1988, Duckworth and Jordens, 1990). Lacey et al 1972 (Lacey, 1972) 
demonstrated no effect on desiccation tolerance with the loss or gain of antibiotic 
resistance to methicillin, penicillin or tetracycline, however their desiccation exposure 
time was only 6 hours (an end time point before the first sampling at 12 hours in our 
study), and similarly Duckworth and Jordens et al 1990 (Duckworth and Jordens, 1990) 
demonstrated that isolates with increased number of resistances tolerated desiccation 
similar to those with fewer resistances. None of these studies included EMRSA-15 
isolates and conversely studies investigating desiccation tolerance of EMRSA-15 have 
not included MSSA isolates. The data presented here suggests EMRSA-15 is poorer at 
surviving desiccation that MSSA in a dirty environment, however the lack of other MRSA 
STs in the study and only a single MSSA control isolate (no screening or clinical MSSA 
isolates) means these result may be biased.  
 
 
4.5.6 Effect of ciprofloxacin resistance 
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Antibiotic resistance is thought to play an important role in the overall fitness of HA-
MRSA in the hospital environment due to the high usage of a myriad of antibiotics in this 
ecological niche.  
 By including the historical CHB isolate (CT124) from the progenitor population of 
EMRSA-15 I have been able to compare the effect of the gyrA and grlA mutations on the 
EMRSA-15 lineages tolerance to desiccation. Overall, the CT124 isolates had comparable 
desiccation tolerance compared to the ciprofloxacin resistant isolates, having the second 
highest AUC values in water but the lowest number of bacteria surviving 576 hours 
(with the exception of CT300) as well as median range values when suspended in BSA 
but was again the poorest surviving strain post 408 hours. Mutation in gyrA in 
Salmonella enterica has been shown to cause a change in transcription leading to 
increased expression of stress response pathways (Webber et al., 2013), indicating DNA 
supercoiling gene alteration (and therefore fluoroquinolone resistance) can affect the 
overall fitness of the bacteria, however there has been no similar study in Gram positive 
organisms. My study suggests fluoroquinolone resistance appears to have given a small 
increase in desiccation tolerance, which is controlled by stress response, indicating 
possible fitness advantage from the change in DNA supercoiling gene structure that 
induces fluoroquinolone resistance. The poorer desiccation tolerance of the 
staphyloxanthin lacking CT300 isolate would however suggest cellular environmental 
tolerance mechanisms provide a greater degree of protection than potential increased 
stress response activity provided by fluoroquinolone resistance. Repetition of the 
desiccation assay with targeted point mutation in grlA and gyrA mutants of isolate 
CT124 may demonstrate this increased tolerance more appropriately along with 
additional ciprofloxacin sensitive ST22 isolates.  
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1.2 Conclusions 
 
By constructing a bespoke bioinformatics pipeline and applying Bayesian phylogenetics 
to 437 globally sampled EMRSA-15 genomes I have expanded the current knowledge 
base of EMRSA-15 evolution and epidemiology by determining several key findings.  
 The identification, sequencing and phylogenetic analysis of a single isolate 
sampled from c1985 has shown that a hospital associated ciprofloxacin sensitive ST22 
population (lacking the Ser80Phe mutation in grlA and Ser84Leu in gyrA mutation) that 
was highly related to current EMRSA-15 was circulating in the West Midlands during the 
proposed period fluoroquinolone resistant ST22 (EMRSA-15) emerged. This would 
indicate an EMRSA-15 progenitor population was present in the West Midlands during 
the mid 1980s; the same time that my Bayesian analysis indicates EMRSA-15 first 
emerged (c1984). Therefore I have been able to support the hypothesis suggested by 
Holden and colleagues that EMRSA-15 emerged in the West Midlands but have arrived 
at an emergence date two years prior to the respective authors proposal of 1986.  
  
 Geographically restricted clones of EMRSA-15 in Birmingham, Guernsey and 
Hong Kong were demonstrated from the global phylogeny.  
 Using a time linked MCC phylogenetic tree I have identified a clonal, highly 
localized and dominant EMRSA-15 clone (BHM clone) that emerged in the mid 1990s 
which was present in the three largest hospitals in Birmingham. Further WGS analysis 
has shown the BHM clone to have a unique SNP in the grlB (topoisomerase IV subunit B) 
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gene which may give the clone a selective advantage in the Birmingham healthcare 
system.  
 Guernsey and Hong Kong both represent island populations of EMRSA-15 and 
demonstrated localized evolution in their respective geographical regions. The 
population in Guernsey demonstrated a highly localized strain was present alongside 
EMRSA-15 strains related to the UK mainland. This is likely due to an importation of 
EMRSA-15 from the UK followed by clonal expansion, alongside continuous sporadic 
importations from UK health workers and patients trafficking between Guernsey and 
the UK. 
 In Hong Kong ST239 dominates and EMRSA-15 is a minority clone. Here I have 
shown that a group of related EMRSA-15 isolates across four Hong Kong hospitals have 
a single ancestral origin from Singapore, demonstrating transmission of EMRSA-15 
within Hong Kong but also between Asian countries. This further highlights that global 
population movements can promote the spread of pathogens. The combination of 
Birmingham, Guernsey and Hong Kong epidemiology presented here along with 
evidence of UK localization of EMRSA-15 sub strains demonstrated by Reuter and 
colleagues is indicative of patient and healthcare worker movement being highly 
influential in local, national and international EMRSA-15 population structuring.  
  
All versus all pairwise comparison of the 210 EMRSA-15 isolates that were VNTR typed 
and whole genome sequenced showed a limited range in LV, STRD and SNPs between 
isolates in this collection. This reinforces the highly clonal nature of EMRSA-15. Mapping 
of two polymorphic VNTR loci to the MCC phylogeny showed, VNTR and WGS (Bayesian 
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analysis) to be concordant for the Birmingham EMRSA-15 population with VNTR typing 
discriminating the BHM clade with 100% concordance at a single locus. 
 
By performing a unique comparative analysis of the Birmingham MCC phylogeny with 
antibiotic prescription data from HEFT I have demonstrated a relationship between 
increasing fluoroquinolone use and evolution of EMRSA-15. Increasing ciprofloxacin use 
and the introduction of ofloxacin in the 1990s coincided with the emergence and 
expansion of the BHM clade containing a Pro456Ser grlB mutation. This increase in 
fluoroquinolone use may have provided a selection pressure for the evolution and 
expansion of the EMRSA-15 sub lineage. This demonstrates the introduction of new drug 
classes may influence localized EMRSA-15 population structures and therefore change 
the dynamic of hospital MRSA burden.  
 
Finally using carefully controlled methodology I have demonstrated a significant 
increase in EMRSA-15 desiccation tolerance when isolates were suspended in protein 
media emulating dirty hospital environmental conditions. This would suggest that 
EMRSA-15 can survive longer in dirty hospital environments, therefore allowing 
surfaces to act as reservoirs for infection over increased periods of time. Examination of 
multiple EMRSA-15 sub-lineage isolates has shown limited difference in desiccation 
tolerance between BHM and non-BHM isolates when suspended in water but not in BSA. 
This would suggest changes in osmotic stress tolerance may give increased desiccation 
tolerance in BHM isolates (due to the reduction in osmotic stress tolerance when 
suspended in BSA).  
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1.3 Future Work  
 
 
 To further analyse the impact of the grlB mutation on the fitness of the BHM 
clade by: 
o Generating Pro453Ser grlB point mutations in ciprofloxacin sensitive 
progenitor isolates and determine impacts on MIC to fluoroquinolones. 
o Using fitness experiments such as co-culture growth assays, pH tolerance 
or fatty acid resistance to identify any further physiological characteristics 
that may provide the BHM clade with a selective advantage.  
 
 To investigate any possible differences in biocide tolerance, triclosan and 
chlorhexidine between sub-strains of EMRSA-15 including the presence or 
absence of qac genes and changes in MIC or minimum bactericidal concentrations 
(MBC).  
 
 To use the Oxford Nanopore minION sequencer to sequence the MGE and VNTR 
long repeat regions, that were excluded from the analysis presented here, to link 
mini satellite regions to possible phenotypic characteristic changes and 
determine the repertoire of MGEs circulating in the Birmingham EMRSA-15 
population.  
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5 Appendices  
 
 
 
Table 25: Isolates and associated metadata that were whole genome sequenced and included in the study. Entries colour red 
have been identified as the BHM clone.  
Isolate 
Identifier 
Country Hospital 
Trust 
Collection Screening 
or clinical 
sample 
Sampling 
Date 
VNTR profile  L1 L13 L15 L16 L21 L5 L7 Sequence 
type 
Ciprofloxacin 
resistance 
Coverage 
A11 UK HEFT HEFT ITU Screening 04/02/2002 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 15.43 
A33 UK HEFT HEFT ITU Screening 11/02/2002 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 15.76 
A120 UK HEFT HEFT ITU Screening 27/02/2002 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 22.45 
A174 UK HEFT HEFT ITU Screening 13/03/2002 1 4 0 3 13 - 2 1 4 0 3 13 - 2 22 R 15.08 
A193 UK HEFT HEFT ITU Screening 15/03/2002 1 4 0 3 17 - 2  1 4 0 3 17 - 2 22 R 15.71 
A221 UK HEFT HEFT ITU Screening 25/03/2002 1 4 0 3 13 - 2 1 4 0 3 13 - 2 22 R 15.79 
A280 UK HEFT HEFT ITU Screening 29/04/2002 1 4 0 3 13 - 2 1 4 0 3 13 - 2 22 R 19.60 
A328 UK HEFT HEFT ITU Screening 24/05/2002 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 17.97 
A442 UK HEFT HEFT ITU Screening 14/08/2002 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 16.12 
A453 UK HEFT HEFT ITU Screening 30/08/2002 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 17.84 
A510 UK HEFT HEFT ITU Screening 27/09/2002 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.69 
A540 UK HEFT HEFT ITU Screening 30/09/2002 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 20.73 
A556 UK HEFT HEFT ITU Screening 02/07/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 16.51 
A640 UK HEFT HEFT ITU Screening 06/08/2003 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 19.40 
A714 UK HEFT HEFT ITU Screening 20/08/2003 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 24.30 
A746 UK HEFT HEFT ITU Screening 20/08/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 17.89 
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A780 UK HEFT HEFT ITU Screening 01/09/2003 1 4 0 3 16 - 2  1 4 0 3 17 - 2 22 R 16.97 
A782 UK HEFT HEFT ITU Screening 01/09/2003 1 3 0 3 16 - 2 1 3 0 3 16 - 2 22 R 15.34 
A811 UK HEFT HEFT ITU Screening 05/09/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 18.83 
A817 UK HEFT HEFT ITU Screening 12/09/2003 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 16.44 
A878 UK HEFT HEFT ITU Screening 01/10/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.96 
A901 UK HEFT HEFT ITU Screening 08/10/2003 1 3 0 3 16 - 2 1 2 0 3 18 - 2 22 R 15.97 
A958 UK HEFT HEFT ITU Screening 31/10/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.58 
A1052 UK HEFT HEFT ITU Screening 12/11/2003 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 17.60 
A1043 UK HEFT HEFT ITU Screening 14/11/2003 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.16 
A1039 UK HEFT HEFT ITU Screening 17/11/2003 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 19.41 
A1093 UK HEFT HEFT ITU Screening 05/12/2003 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.87 
A1099 UK HEFT HEFT ITU Screening 05/12/2003 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 15.33 
A1103 UK HEFT HEFT ITU Screening 05/12/2003 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 15.64 
A1173 UK HEFT HEFT ITU Screening 02/01/2004 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 15.98 
A1247 UK HEFT HEFT ITU Screening 23/01/2004 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.90 
A1257 UK HEFT HEFT ITU Screening 02/02/2004 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 26.12 
A1263 UK HEFT HEFT ITU Screening 04/02/2004 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 17.50 
A1298 UK HEFT HEFT ITU Screening 18/02/2004 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.14 
A1316 UK HEFT HEFT ITU Screening 20/02/2004 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 20.12 
A1323 UK HEFT HEFT ITU Screening 23/02/2004 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.56 
R198 UK PEH Guernsey Unknown 06/06/2005 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 44.28 
EMM4 UK HEFT HEFT surgical Screening 13/11/2005 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 25.11 
EMT8 UK HEFT HEFT surgical Screening 19/11/2005 1 4 0 3 14 - 2 1 4 0 3 14 - 2 22 R 194.00 
EMT10 UK HEFT HEFT surgical Screening 22/11/2005 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 83.78 
EMM23 UK HEFT HEFT surgical Screening 01/12/2005 1 2 0 3 10 - 2 1 2 0 3 10 - 2 22 R 26.75 
EMM38 UK HEFT HEFT surgical Screening 12/12/2005 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.71 
EMM63 UK HEFT HEFT surgical Screening 22/12/2005 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 27.50 
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EMM88 UK HEFT HEFT surgical Screening 14/01/2006 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 97.59 
EMM138 UK HEFT HEFT surgical Screening 30/01/2006 1 2 0 3 18 - 2 1 2 0 3 18 - 2 22 R 111.24 
EMM139 UK HEFT HEFT surgical Screening 06/02/2006 1 2 0 3 19 - 2 1 2 0 3 18 - 2 22 R 70.89 
EMM144 UK HEFT HEFT surgical Screening 08/02/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 108.22 
EMM146 UK HEFT HEFT contemporary Screening 08/02/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 116.00 
EMM265 UK HEFT HEFT surgical Screening 27/03/2006 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 71.01 
EMT154 UK HEFT HEFT surgical Screening 09/04/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 57.06 
EMM302 UK HEFT HEFT surgical Screening 12/04/2006 1 2 0 2 13 - 2 1 2 0 2 13 - 2 22 R 16.37 
EMM320 UK HEFT HEFT surgical Screening 14/04/2006 1 2 0 3 12 - 2 1 2 0 3 12 - 2 22 R 182.00 
EMT194 UK HEFT HEFT surgical Screening 01/05/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 17.53 
EMM419 UK HEFT HEFT contemporary Screening 22/05/2006 1 5 0 3 12 - 2 1 5 0 3 12 - 2 22 R 53.54 
EMM418 UK HEFT HEFT surgical Screening 25/05/2006 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 57.13 
EMM443 UK HEFT HEFT surgical Screening 02/06/2006 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 421.78 
EMM451 UK HEFT HEFT surgical Screening 06/06/2006 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 170.62 
EMM450 UK HEFT HEFT surgical Screening 10/06/2006 1 2 0 3 14 - 2 1 2 0 3 14 - 2 22 R 107.23 
EMM513 UK HEFT HEFT surgical Screening 25/06/2006 1 1 0 3 17 - 2 1 1 0 3 17 - 2 22 R 45.95 
EMM573 UK HEFT HEFT surgical Screening 15/07/2006 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 129.41 
EMT309 UK HEFT HEFT surgical Screening 22/08/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 51.10 
EMT311 UK HEFT HEFT surgical Screening 22/08/2006 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 27.76 
ECMM082 UK HEFT HEFT surgical Screening 04/10/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 170.64 
ECMM102 UK HEFT HEFT surgical Screening 19/10/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 23.79 
ECMM116 UK HEFT HEFT surgical Screening 04/11/2006 1 4 0 2 17 - 2 1 4 0 2 17 - 2 22 R 17.90 
ECMM195 UK HEFT HEFT surgical Screening 16/12/2006 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 192.87 
ECMM265 UK HEFT HEFT surgical Screening 12/02/2007 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 41.06 
R012 UK PEH Guernsey Screening 28/03/2007 1 3 0 3 16 - 2 1 3 0 3 16 - 2 22 R 26.06 
ECMM349 UK HEFT HEFT surgical Screening 27/04/2007 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 46.32 
R245 UK PEH Guernsey Unknown 17/07/2010 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 15.04 
R874 UK HEFT HEFT contemporary Screening 06/06/2012 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 105.08 
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CT273 UK PEH Guernsey Clinical 13/09/2012 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 32.09 
CT275 UK PEH Guernsey Clinical 07/01/2013 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 26.10 
R841 UK HEFT HEFT contemporary Screening 20/03/2013 1 2 0 3 15 2 2 1 4 0 3 15 2 2 22 R 103.31 
R853 UK HEFT HEFT contemporary Screening 08/05/2013 1 2 0 3 21 - 2 1 2 0 3 21 - 2 22 R 103.75 
R862 UK HEFT HEFT contemporary Screening 20/05/2013 1 2 0 3 19 - 2 1 4 0 3 19 - 2 22 R 83.36 
R863 UK HEFT HEFT contemporary Screening 20/05/2013 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 93.98 
R869 UK HEFT HEFT contemporary Screening 21/05/2013 1 2 0 3 18 - 2 1 2 0 3 18 - 2 22 R 78.17 
CT268 UK PEH Guernsey Screening 24/06/2013 1 5 0 3 18 - 2 1 5 0 3 18 - 2 22 R 23.40 
R885 UK HEFT HEFT contemporary Screening 29/06/2013 1 4 0 4 14 - 2 1 4 0 4 14 - 2 22 R 112.97 
R890 UK HEFT HEFT contemporary Screening 25/07/2013 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 111.20 
R891 UK HEFT HEFT contemporary Screening 25/07/2013 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 107.25 
CT276 UK PEH Guernsey Clinical 22/09/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 23.11 
CT139 UK HEFT HEFT contemporary Clinical 10/10/2013 1 2 0 3 14 - 2 1 2 0 3 14 - 2 22 R 17.41 
CT140 UK HEFT HEFT contemporary Clinical 15/10/2013 1 2 0 3 14 - 2 1 2 0 3 14 - 2 22 R 16.28 
CT145 UK HEFT HEFT contemporary Screening 28/10/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 16.63 
CT146 UK HEFT HEFT contemporary Screening 31/10/2013 1 2 0 2 18 - 2 1 2 0 2 18 - 2 22 R 16.43 
CT143 UK HEFT HEFT contemporary Clinical 03/11/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 20.68 
CT147 UK HEFT HEFT contemporary Clinical 04/11/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 22.90 
CT148 UK HEFT HEFT contemporary Clinical 07/11/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 23.31 
CT149 UK HEFT HEFT contemporary Clinical 10/11/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.79 
CT204 UK CHB CHB Contemporary Screening 18/11/2013 1 3 0 3 16 - 2 1 3 0 3 16 - 2 22 R 22.46 
CT200 UK QEHB QEHB Contemporary Screening 19/11/2013 1 5 0 3 18 - 2 1 5 0 3 18 - 2 22 R 22.18 
CT209 UK CHB CHB Contemporary Clinical 27/11/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.17 
CT211 UK CHB CHB Contemporary Screening 01/12/2013 1 4 0 3 17 - 2 1 2 0 3 17 - 2 22 R 20.19 
CT154 UK HEFT HEFT contemporary Clinical 03/12/2013 1 3 0 3 20 - 2 1 3 0 3 20 - 2 22 R 27.18 
CT210 UK CHB CHB Contemporary Clinical 04/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 20.53 
CT207 UK CHB CHB Contemporary Screening 05/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 18.68 
CT206 UK CHB CHB Contemporary Clinical 06/12/2013 1 2 0 3 14 - 2 1 2 0 3 14 - 2 22 R 17.02 
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CT199 UK QEHB QEHB Contemporary Screening 07/12/2013 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 25.81 
CT155 UK HEFT HEFT contemporary Screening 09/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.00 
CT213 UK CHB CHB Contemporary Screening 10/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 17.63 
CT202 UK QEHB QEHB Contemporary Screening 11/12/2013 1 3 0 3 14 - 2 1 3 0 3 14 - 2 22 R 15.75 
CT158 UK HEFT HEFT contemporary Screening 12/12/2013 1 4 0 3 17 - 2 1 2 0 3 17 - 2 22 R 18.57 
CT156 UK HEFT HEFT contemporary Screening 13/12/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.62 
CT165 UK HEFT HEFT contemporary Screening 13/12/2013 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.81 
CT166 UK HEFT HEFT contemporary Screening 15/12/2013 1 4 0 3 15 - 2 1 4 0 3 15 - 2 22 R 16.88 
CT212 UK CHB CHB Contemporary Clinical 18/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 50.40 
CT168 UK HEFT HEFT contemporary Clinical 19/12/2013 1 3 0 2 15 - 2 1 3 0 2 15 - 2 22 R 19.73 
CT180 UK QEHB QEHB Contemporary Screening 19/12/2013 1 2 0 3 18 - 2 1 2 0 3 18 - 2 22 R 52.24 
CT169 UK HEFT HEFT contemporary Screening 20/12/2013 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 17.70 
CT170 UK HEFT HEFT contemporary Screening 24/12/2013 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 18.52 
CT135 UK HEFT HEFT contemporary Screening 28/12/2013 1 2 0 3 12 - 2 1 2 0 3 12 - 2 22 R 15.71 
CT136 UK HEFT HEFT contemporary Screening 30/12/2013 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 18.06 
CT159 UK HEFT HEFT contemporary Screening 31/12/2013 1 2 0 3 20 - 2 1 2 0 3 18 - 2 22 R 18.57 
CT171 UK HEFT HEFT contemporary Screening 01/01/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.30 
CT141 UK HEFT HEFT contemporary Screening 05/01/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 15.13 
CT160 UK HEFT HEFT contemporary Screening 06/01/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 23.36 
CT161 UK HEFT HEFT contemporary Screening 07/01/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 16.03 
CT163 UK HEFT HEFT contemporary Screening 13/01/2014 1 2 0 2 15 - 2 1 2 0 2 15 - 2 22 R 15.72 
CT164 UK HEFT HEFT contemporary Screening 14/01/2014 1 3 0 3 15 - 2 1 3 0 3 15 - 2 22 R 21.33 
CT181 UK QEHB QEHB Contemporary Clinical 24/01/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 46.34 
CT190 UK QEHB QEHB Contemporary Clinical 30/01/2014 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 19.93 
CT182 UK QEHB QEHB Contemporary Screening 01/02/2014 1 2 0 3 13 - 2 1 3 0 3 13 - 2 22 R 18.83 
CT183 UK QEHB QEHB Contemporary Screening 01/02/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.24 
CT175 UK QEHB QEHB Contemporary Screening 04/02/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 23.52 
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CT196 UK QEHB QEHB Contemporary Screening 11/02/2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 15.49 
CT218 UK CHB CHB Contemporary Screening 12/02/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 53.25 
R979 UK HEFT HEFT contemporary Screening 13/02/2014 1 2 0 3 17 2 2 1 2 0 3 17 2 2 22 R 107.11 
CT219 UK CHB CHB Contemporary Screening 13/02/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 26.81 
CT220 UK CHB CHB Contemporary Screening 13/02/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 18.85 
CT203 UK QEHB QEHB Contemporary Screening 15/02/2014 1 2 0 3 10 - 2 1 2 0 3 10 - 2 22 R 19.09 
CT230 UK CHB CHB Contemporary Screening 18/02/2014 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 20.87 
CT227 UK CHB CHB Contemporary Screening 20/02/2014 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 23.00 
CT225 UK CHB CHB Contemporary Screening 22/02/2014 1 4 0 3 10 - 2 1 4 0 3 10 - 2 22 R 21.34 
CT229 UK CHB CHB Contemporary Screening 25/02/2014 1 4 0 3 10 - 2 1 4 0 3 10 - 2 22 R 99.69 
CT236 UK CHB CHB Contemporary Screening 09/03/2014 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 19.81 
CT244 UK CHB CHB Contemporary Screening 15/03/2014 1 2 0 3 11 - 2 1 4 2 3 11 - 2 22 R 15.18 
R1032 UK HEFT HEFT contemporary Screening 10/04/2014 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 373.32 
R988 UK HEFT HEFT contemporary Clinical 15/04/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 117.54 
CT286 UK QEHB QEHB Contemporary Clinical 04/05/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 47.62 
CT287 UK QEHB QEHB Contemporary Screening 06/06/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 40.12 
CT279 UK PEH Guernsey Clinical 24/06/2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 15.31 
CT288 UK QEHB QEHB Contemporary Clinical 25/06/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 36.79 
R1011 UK HEFT HEFT contemporary Screening 08/07/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 293.58 
R1012 UK HEFT HEFT contemporary Screening 10/07/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 264.03 
CT289 UK QEHB QEHB Contemporary Clinical 11/07/2014 1 2 0 3 14 - 2 1 2 0 3 14 - 2 22 R 16.67 
R1013 UK HEFT HEFT contemporary Screening 18/07/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 374.65 
R1029 UK HEFT HEFT contemporary Screening 24/07/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 316.05 
R1028 UK HEFT HEFT contemporary Screening 28/07/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 270.34 
R1039 UK HEFT HEFT contemporary Screening 23/08/2014 1 3 0 3 12 - 2 1 3 0 3 12 - 2 22 R 428.79 
R1043 UK HEFT HEFT contemporary Clinical 04/09/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 336.41 
CT291 UK QEHB QEHB Contemporary Screening 22/09/2014 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 15.37 
CT292 UK QEHB QEHB Contemporary Screening 25/09/2014 1 3 0 3 15 - 2 1 3 0 3 15 - 2 22 R 33.73 
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CT284 UK PEH Guernsey Clinical 29/09/2014 1 2 0 3 18 - 2 1 4 0 3 18 - 2 22 R 23.25 
CT293 UK QEHB QEHB Contemporary Clinical 16/10/2014 1 2 0 3 17 - 2 1 2       - 2 22 R 17.98 
R1075 UK HEFT HEFT contemporary Screening 21/10/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 392.31 
R1074 UK HEFT HEFT contemporary Clinical 25/10/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 251.79 
R1080 UK HEFT HEFT contemporary Screening 24/11/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 100.03 
R1081 UK HEFT HEFT contemporary Screening 17/12/2014 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 119.81 
R1126 UK HEFT HEFT contemporary Clinical 30/12/2014 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 131.33 
R1127 UK HEFT HEFT contemporary Screening 02/01/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 141.05 
R1130 UK HEFT HEFT contemporary Clinical 09/01/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 146.41 
R1128 UK HEFT HEFT contemporary Clinical 15/01/2015 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 115.10 
R1129 UK HEFT HEFT contemporary Clinical 15/01/2015 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 115.00 
CT294 UK QEHB QEHB Contemporary Clinical 08/02/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 23.67 
CT295 UK QEHB QEHB Contemporary Screening 12/03/2015 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 39.48 
CT296 UK QEHB QEHB Contemporary Screening 12/03/2015 1 2 0 3 14 - 2 1 3 0 3 14 - 2 22 R 23.39 
CT297 UK QEHB QEHB Contemporary Screening 14/03/2015 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 46.09 
CT298 UK QEHB QEHB Contemporary Clinical 16/03/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 32.29 
CT299 UK QEHB QEHB Contemporary Clinical 25/03/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.98 
CT300 UK QEHB QEHB Contemporary Clinical 25/03/2015 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 18.23 
CT301 UK QEHB QEHB Contemporary Clinical 31/03/2015 1 4 0 3 15 - 2 1 4 0 3 15 - 2 22 R 17.67 
CT302 UK QEHB QEHB Contemporary Screening 04/04/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 30.79 
CT303 UK QEHB QEHB Contemporary Clinical 04/04/2015 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 27.80 
CT304 UK QEHB QEHB Contemporary Clinical 06/04/2015 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 51.02 
CT305 UK QEHB QEHB Contemporary Screening 08/04/2015 1 2 0 3 15 - 2 1 2 0 3 15 - 2 22 R 28.52 
CT306 UK QEHB QEHB Contemporary Screening 11/04/2015 1 4 0 3 15 - 2 1 4 0 3 15 - 2 22 R 26.65 
CT307 UK QEHB QEHB Contemporary Screening 14/04/2015 1 4 0 3 15 - 2 1 4 0 3 15 - 2 22 R 40.27 
CT308 UK QEHB QEHB Contemporary Screening 17/04/2015 1 4 0 3 17 4 2 1 2 0 3 17 4 2 22 R 16.90 
CT309 UK QEHB QEHB Contemporary Clinical 19/04/2015 1 5 0 3 17 - 2 1 5 0 3 17 - 2 22 R 25.83 
CT282 UK PEH Guernsey Clinical 18/05/2015 1 2 0 3 18 3 2 1 4 0 3 18 3 2 22 R 30.21 
CT267 UK PEH Guernsey Clinical 20/05/2015 1 4 0 3 14 - 2 1 4 0 3 14 - 2 22 R 17.91 
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CT272 UK PEH Guernsey Clinical 21/05/2015 1 3 0 3 18 - 2 1 3 0 3 18 - 2 22 R 21.87 
CT177 UK QEHB QEHB Contemporary Unknown - 1 2 0 3 17 - 2 1 2 0 3 17 - 2 22 R 15.31 
CT195 UK QEHB QEHB Contemporary Unknown - 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 18.96 
ECMM322 UK HEFT HEFT contemporary Screening 02/04/2007 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 31.07 
R267 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 16 - 2 1 4 0 3 16 - 2 22 R 18.65 
R306 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 17 2 2 1 4 0 3 17 2 2 22 R 23.76 
R307 UK PEH Guernsey Unknown 2010-2011 1 3 0 3 17 2 2 1 3 0 3 17 2 2 22 R 33.59 
R415 UK PEH Guernsey Unknown 2010-2011 1 3 0 3 17 - 2 1 3 0 3 17 - 2 22 R 32.17 
R005 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 45.08 
R034 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 34.71 
R200 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 27.92 
R239 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 15.49 
R240 UK PEH Guernsey Unknown 2010-2011 1 4 0 3 17 - 2 1 4 0 3 17 - 2 22 R 23.39 
ECMM341 UK HEFT HEFT contemporary Screening 21/04/2007 1 2 0 3 16 - 2 1 2 0 3 16 - 2 22 R 66.65 
CT124 UK CHB CHB Contemporary Unknown c1985 1 4 0 3 16 2 2  1 4 0 3 16 2 2 22 S 20.68 
HK_w17 Hong Kong HK1 Hong Kong Clinical 2010 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 132.57 
HK_w32 Hong Kong HK1 Hong Kong Clinical 2010 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 111.06 
HK_w16 Hong Kong HK4 Hong Kong Clinical 2010 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 105.43 
HK_w129 Hong Kong HK1 Hong Kong Clinical 2011 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 105.56 
HK_N02 Hong Kong HK2 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 100.52 
HK_N03 Hong Kong HK2 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 121.96 
HK_N04 Hong Kong HK2 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 94.55 
HK_N05 Hong Kong HK2 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 176.12 
HK_N12 Hong Kong HK1 Hong Kong Screening 2014 1 4 0 3 17 - 2 1 4 0   17 - 2 22 R 138.29 
HK_N13 Hong Kong HK1 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 98.22 
HK_N16 Hong Kong HK1 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 95.30 
HK_N17 Hong Kong HK1 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 118.73 
HK_N01 Hong Kong HK2 Hong Kong Screening 2014 1 4 0 3 18 - 2 1 4 0 3 18 - 2 22 R 124.44 
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  Number of colonies in region  
 =cfu/ml 
Volume of region in mls 
  e.g. 31 + 31 colonies (in two opposing quadrants) 
0.0015ml deposition volume  
 
  31 + 31 
 = 4.1x10^4 cfu/ml 
0.0015 
  * NEEDS TO BE WORKED BACK UP TO ORIGINAL VOLUME 
  > Orignially had 20μl spot that was diluted in 2mls 
 = 20ul in 2000μl  
  = 1 in 100 dilution  
 
  > then took 500 μl of diluent and mixed with 3.5ml of water 
 = 500μl in 3500μl  
  = 1 in 8 dilution 
 
  Total dulution ratio = 1 in 800 
  = x cfu values from spiral plater by 800 
  4.1x10^4 x 800 = 3.3x10^7 cfu/ml 
 
Figure 29: Example calculation of colony counts 
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Figure 30: Scatter plot of residual value distance from the strict molecular clock 
line with a histogram of isolate proportion in grey. Residual values falling beyond 
+/- 2E-3 are coloured green. 
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